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Hepatitis	  C	  virus	  (HCV)	  infection	  is	  a	  major	  cause	  of	  global	  morbidity,	  causing	  chronic	  
liver	  injury	  that	  can	  progress	  to	  cirrhosis	  and	  hepatocellular	  carcinoma.	  The	  liver	  is	  a	  
large	   and	   complex	   organ	   containing	   multiple	   cell	   types,	   including	   hepatocytes,	  
sinusoidal	   endothelial	   cells	   (LSEC),	   stellate	   cells,	   Kupffer	   cells	   and	   biliary	   epithelial	  
cells.	  Hepatocytes	  are	  the	  major	  reservoir	  supporting	  HCV	  replication,	  however,	  the	  
role	   of	   non-­‐parenchymal	   cells	   in	   the	   viral	   lifecycle	   remain	   largely	   unexplored.	  
Endothelial	  cell	  hepatocyte	  co-­‐cultures	  were	  established	  to	  study	  the	  role	  of	  LSEC	  in	  
HCV	   biology.	   	   Vascular	   endothelial	   growth	   factor	   (VEGF-­‐A)	   regulated	   transcripts	  
were	  profiled	  by	  microarray	  to	  identify	  factors	  modulating	  HCV	  replication.	  	  
The	   initial	   studies	   indicated	   that	   rather	   than	   transmitting	   HCV	   to	   permissive	  
hepatocytes	   LSEC	   were	   protective	   in	   HCV	   infection.	   Co-­‐culture	   of	   epithelial	   and	  
endothelial	  cell	  showed	  that	  LSEC	  limit	  hepatocyte	  permissivity	  to	  HCV	  infection	  via	  
cell	   contact-­‐dependent	  mechanisms	   and	   by	   the	   expression	   of	   soluble	  mediator(s)	  
that	  are	  regulated	  by	  VEGF-­‐A.	  Transcript	  analysis	  identified	  LSEC	  expression	  of	  bone	  
morphogenetic	   protein	   4	   (BMP4),	   a	   novel	   proviral	   molecule	   that	   is	   negatively	  
regulated	   by	   VEGF-­‐A	   via	   a	   VEGF	   receptor-­‐2	   (VEGFR-­‐2)	  MAPK	   dependent	   pathway.	  
Consistent	  with	  the	  in	  vitro	  data	  I	  observed	  increased	  BMP4	  expression	  and	  reduced	  
VEGFR-­‐2	  activation	  in	  inflamed	  liver	  tissue.	  	  
These	  studies	  show	  a	  novel	   role	   for	  LSEC	  and	  BMP4	   in	  HCV	   infection	  and	  highlight	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  abbreviations	  	  
BMP	   bone	  morphogenetic	  protein	  
BSA	   bovine	  serum	  albumin	  
CHO	   Chinese	  hamster	  ovary	  
CM	  	   conditioned	  medium	  
FGF	   fibroblast	  growth	  factor	  
HCV	   hepatitis	  C	  virus	  
HGF	   hepatocyte	  growth	  factor	  
IgG	   immunogolbulin	  G	  
IL	   interleukin	  
LPS	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LSEC	   liver	  sinusoidal	  endothelial	  cells	  
NS	   non-­‐structural	  
PBS	   phosphate	  buffered	  saline	  
PlGF	   placental	  growth	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VEGF	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Chapter	  1	  	   Introduction	  
	  
1.1	   General	  introduction	  
	  
The	   liver	   is	   a	   large	   and	   complex	   organ	   that	   has	   fundamental	   roles	   both	   in	   the	  
development	  and	  normal	  function	  of	  vertebrate	  organisms.	  	  These	  functions	  of	  the	  
liver	  are	  frequently	  taken	  for	  granted	  but	  the	  occurrence	  of	   liver	  failure	  provides	  a	  
daily	   insight	   for	  physicians	   caring	   for	  patients	  with	   this	   condition.	   	  Although	  acute	  
liver	   failure	   is	   rare	   it	   provides	   an	   illustration	   of	   the	   functions	   of	   the	   liver,	   namely	  
gluconeogenesis,	   clearance	   of	   toxic	  metabolites,	   conjugation	   of	   bile	   pigments	   and	  
drugs,	  and	  synthesis	  of	  plasma	  proteins.	  	  	  
	  
Chronic	  liver	  disease	  has	  by	  definition	  a	  more	  insidious	  onset	  and	  is	  characterised	  by	  
fatigue	   and	  malaise	   in	   its	   early	   stages.	   	   Repetitive	   liver	   injury	   of	   any	   cause,	  most	  
commonly	   alcohol,	   but	   also	   fatty	   liver,	   autoimmunity,	   and	   chronic	   viral	   infection	  
establishes	  chronic	   inflammation	   in	  the	   liver.	   	  As	  a	  consequence	  of	  on-­‐going	   injury	  
and	   inflammation	   there	   is	   a	   wound	   healing	   response	   that	   is	   characterised	   by	   the	  
generation	  of	   fibrosis.	   	  An	  accumulation	  of	   fibrosis	   in	   liver	  disease	   is	   common	  and	  
when	  severe	  is	  termed	  cirrhosis.	  	  As	  disease	  becomes	  more	  advanced	  and	  cirrhosis	  is	  
established,	   features	   of	   liver	   failure	   develop,	   most	   frequently	   jaundice	   and	   fluid	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retention.	  	  Catastrophic	  bleeding	  events	  and	  infections	  are	  also	  common.	  	  Cirrhosis	  
itself	  is	  also	  a	  risk	  factor	  for	  the	  development	  of	  primary	  liver	  cancer	  (hepatocellular	  
carcinoma,	   HCC).	   	   At	   this	   stage	   of	   disease	   there	   is	   no	   medical	   treatment	   that	   is	  
effective	   and	   rather	   liver	   transplantation	   is	   considered.	   	   Transplantation	   is	   an	  
imperfect	   treatment	   and	   improving	   medical	   treatments	   for	   patients	   with	   liver	  
disease	  is	  likely	  to	  reduce	  the	  need	  for	  transplantation	  in	  the	  future.	  	  Moreover	  due	  
to	   the	   inherent	   limitations	   of	   transplantation	   and	   the	   availability	   of	   donor	   organs	  
many	  patients	   die	   from	   liver	   disease.	   	  Most	   strikingly,	   1	   in	   9	   deaths	   in	   individuals	  
aged	  between	  40	  and	  49	  is	  due	  to	  liver	  disease	  (Fig.	  1-­‐1).	  	  Furthermore	  liver	  disease	  
is,	   in	   contrast	   to	  heart	  disease,	   stroke,	   and	   cancer,	   the	  only	  major	   cause	  of	   death	  
that	  continues	  to	  increase	  in	  prevalence.	  	  Thus	  there	  are	  many	  major	  unmet	  needs	  
for	  patients	  with	   liver	  disease	   that	   if	   adequately	  addressed	  would	  benefit	  patients	  
and	  society.	  
	  








Figure	  1-­‐1.	  	  The	  proportion	  of	  deaths	  attributable	  to	  liver	  disease	  by	  age.	  	  	  
The	  proportion	  of	  deaths	   in	  England	  attributed	  to	   liver	  disease	  as	   recorded	  by	   the	  
Office	  for	  National	  Statistics	  (National	  End	  of	  Life	  Care	  Intelligence	  Network,	  2012).	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Hepatitis	  C	  virus	  (HCV)	  infection	  is	  common	  (Shepard	  et	  al.,	  2005),	  and	  is	  a	   leading	  
reason	  for	  liver	  transplantation	  in	  the	  UK	  and	  the	  rest	  of	  the	  western	  world	  (Brown,	  
2005).	   	   	   	  Until	   recently	   the	  only	  available	   treatment	   for	   this	   chronic	   viral	   infection	  
was	   combination	   therapy	  with	   pegylated	   interferon-­‐α	   and	   ribavirin,	   a	   non-­‐specific	  
antiviral	   drug	   with	   uncertain	   mechanism	   of	   action.	   	   The	   last	   year	   has	   seen	   the	  
licensing	  of	  the	  first	  class	  of	  specific	  targeted	  antiviral	  therapies	  for	  HCV.	  	  These	  have	  
increased	  response	  rates	  but	  come	  at	  the	  expense	  of	  increased	  adverse	  effects	  since	  
they	  are	  given	  in	  combination	  with	  interferon	  and	  ribavirin	  as	  triple	  therapy	  (Rowe	  
and	  Mutimer,	   2011).	   	  Many	   other	   specific	   therapies	   are	   in	   development	   that	  will	  
further	  increase	  response	  rates	  and	  likely	  reduce	  both	  the	  frequency	  and	  severity	  of	  
adverse	   events	   (Poordad	   and	  Dieterich,	   2012).	   	   These	  developments	   are	  welcome	  
and	  will,	  if	  treatment	  is	  widely	  used,	  change	  the	  outlook	  for	  many	  patients	  with	  HCV	  
(Rowe	   et	   al.,	   2012).	   	   The	   next	   great	   need	   in	   this	   disease	   is	   the	   identification	   of	  
therapeutic	  targets	  that	  modulate	  established	  fibrosis,	  or	  cirrhosis,	  or	  that	  decrease	  
the	  risk	  of	  cancer	  that	  remains	  even	  after	  viral	  eradication.	  	  These	  strategies	  would	  
likely	   also	   be	   applicable	   for	   patients	   with	   liver	   diseases	   of	   all	   aetiologies	   since	  
fibrosis	  progression	  and	  development	  of	   liver	  cancer	   is	  a	  common	  pathway	   in	   liver	  
disease.	  
	  
A	  detailed	  understanding	  of	  the	  pathogenesis	  of	  liver	  injury	  that	  is	  mediated	  by	  HCV	  
is	  one	  path	   to	  uncovering	  novel	   therapeutic	   targets	   in	   liver	  disease.	   	   In	   this	   thesis	  
aspects	  of	  the	  viral	  lifecycle	  and	  the	  influence	  of	  “bystander”	  endothelial	  cells	  in	  the	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liver	  will	  be	  discussed.	   	  Ultimately	  a	  novel	  pathway	  active	   in	   liver	  disease	  that	  HCV	  
may	  have	  adapted	  to	  exploit	  will	  be	  described.	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1.2	   Anatomy	  and	  function	  of	  the	  liver	  
	  
Gross	  anatomy	  
The	  liver	  is	  the	  largest	  solid	  organ	  in	  the	  body	  and	  weighs	  between	  1200	  and	  1500g.	  	  
It	  performs	  many	  varied	  functions	  that	  are	  required	  for	  survival	  and	  without	  which	  
death	  ensues	   rapidly.	   	  Hidden	   from	  the	   trauma	  of	  everyday	   life	  by	   the	   ribs	  on	   the	  
right	  side	  of	  the	  abdomen,	  anatomically	  the	  liver	  is	  divided	  into	  two	  lobes.	  	  The	  right	  
lobe	  is	  much	  larger	  than	  the	  left	  and	  these	  are	  separated	  by	  the	  falciform	  ligament	  
(actually	   a	   fold	   of	   peritoneum)	   anteriorly,	   and	   by	   the	   ligamentum	   teres	   inferiorly.	  	  
These	   structures	   act	   as	   physical	   support	   for	   the	   liver	   that,	   together	   with	   intra-­‐
abdominal	  pressure	  from	  the	  normal	  tone	  of	  the	  abdominal	  wall,	  holds	  the	  liver	   in	  
position.	  	  	  
	  
The	   liver	   is	  perfused	  with	  a	  dual	  blood	  supply.	   	  80%	  of	   inflow	  comes	  directly	   from	  
the	  gut	  in	  portal	  circulation;	  the	  remaining	  20%	  of	  supply	  is	  from	  the	  hepatic	  artery	  
that	   brings	   freshly	   oxygenated	   blood	   from	   the	   heart	   via	   the	   coeliac	   axis.	   	   Both	  
vessels	  enter	  the	  liver	  at	  the	  porta	  hepatis	  before	  dividing	  into	  branches	  and	  being	  
distributed	   by	   the	   sinusoidal	   networks.	   	   This	  mixed	   blood	   is	   then	   collected	   in	   the	  
central	   vein	  where	   drainage	   is	   subsequently	   into	   the	   hepatic	   veins	   and	   ultimately	  
into	   the	   inferior	   vena	   cava	   just	   inferior	   to	   the	   entry	   to	   the	   right	   atrium.	  	  
Understanding	   of	   this	   vascular	   supply	   has	   allowed	   functional	   classification	   of	   liver	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anatomy.	   	   This	   classification	   described	   by	   Couinaud	   (Coinaud,	   1957)	   defines	   8	  
segments	   (Fig.	   1-­‐2)	   that	   are	   functionally	   distinct	   since	   there	   are	   no	   macroscopic	  
vascular	   anastomoses	   (although	   blood	   may	   mix	   at	   the	   sinusoidal	   level).	   	   The	  
classification	   allows	   for	   rational	   surgical	   treatment	   planning	   when	   considering	  
resection	  of	  hepatic	  lesions,	  including	  primary	  liver	  cancers	  that	  are	  associated	  with	  
chronic	  liver	  disease	  (Bismuth,	  1982).	  







Figure	  1-­‐2.	  	  The	  functional	  anatomy	  of	  the	  liver.	  	  	  
The	   blood	   supply	   from	   the	   portal	   vein	   branches	   are	   shown	   in	   light	   blue	   and	   the	  
drainage	  into	  the	  hepatic	  veins	  in	  indicated	  in	  dark	  blue	  (Lefkowitch,	  2011).	  	  
	  




The	   major	   cell	   type	   populating	   the	   liver	   is	   the	   hepatocyte.	   	   These	   cells	   occupy	  
approximately	  80%	  of	  liver	  volume	  (Blouin	  et	  al.,	  1977)	  and	  are	  responsible	  for	  many	  
of	   the	  essential	   functions	  of	   the	   liver.	   	   These	  parenchymal	   cells	  have	  multiple	  and	  
complex	   interactions	   with	   non-­‐parenchymal	   cells,	   namely	   liver	   sinusoidal	  
endothelial	   cells	   (LSEC),	   biliary	   epithelial	   cells,	   Kuppfer	   cells	   (liver	   resident	  
macrophages),	   and	   hepatic	   stellate	   cells.	   	   The	   hepatocytes	   form	   single	   cell	   thick	  
chords	  bound	  together	  by	  tight	  junction	  proteins.	  	  These	  separate	  the	  apical	  surface	  
that	  forms	  the	  border	  of	  the	  canalicular	  structures	  from	  the	  basolateral	  surface	  that	  
faces	   the	   sinusoidal	   lumen	   (Fig.	   1-­‐3A).	   	   The	   canaliculi	   resulting	   from	   this	   cellular	  
polarity	   are	   responsible	   for	   draining	   bile	   (the	  major	   exocrine	   product	   of	   the	   liver)	  
into	  the	  bile	  ducts	  that	  are	  located	  in	  a	  triad	  with	  the	  hepatic	  artery	  and	  portal	  vein.	  	  
These	  triads	  are	  arranged	   in	  a	  hexagonal	  distribution,	  each	  hexagon	  surrounding	  a	  
central	  vein.	  	  Blood	  entering	  these	  hexagonal	  structures,	  termed	  lobules	  thus	  flows	  
from	   the	   portal	   vein	   and	   hepatic	   artery	   inflow	   to	   the	   central	   vein	   and	   bile	   is	  
collected	  in	  the	  opposite	  direction	  (Fig.	  1-­‐3B).	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Figure	  1-­‐3.	  	  The	  liver	  architecture.	  	  	  
False	  colour	  scanning	  electron	  micrograph	  of	  a	  freeze	  fracture	  through	  mouse	  liver.	  	  
Hepatocytes	  are	  coloured	  green,	  and	   liver	  sinusoidal	  endothelial	  cells	  are	  coloured	  
pink.	   	   Canalicular	   structures	   are	   seen	   running	   through	   the	   chords	   of	   hepatocytes.	  	  
Image	  courtesy	  of	  the	  Wellcome	  Trust	  image	  library	  (A).	  	  Schematic	  diagram	  of	  the	  
liver	  lobule	  or	  acinus	  (Adams	  and	  Eksteen,	  2006)	  (B).	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There	   are	   important	   differences	   in	   hepatocellular	   function	   between	   hepatocytes	  
depending	   on	   their	   location	   in	   the	   liver	   lobule.	   	   Those	   positioned	   closest	   to	   the	  
portal	   triad	  –	   zone	  one	  –	  have	  different	   functions	   to	   those	  positioned	  adjacent	   to	  
the	   central	   veins	   –	   zone	   three.	   	   These	   differences	   are	   related	   to	   differences	   in	  
lobular	  oxygenation	  (Jungermann	  and	  Kietzmann,	  2000),	  with	  higher	  oxygen	  delivery	  
to	  zone	  one	  than	  to	  zone	  3,	  and,	  as	  has	  recently	  been	  described,	  are	  also	  dependent	  
on	   signals	   relayed	   by	   the	  Wnt/βcatenin	   system	   (Burke	   et	   al.,	   2009).	   	   For	   instance	  
drug	   metabolising	   cytochrome	   P450	   enzymes	   are	   more	   abundant	   in	   zone	   three.	  	  
These	   hepatocytes	   also	   have	   reduced	   glutathione	   concentration	   rendering	   these	  
cells	   more	   susceptible	   to	   drug	   related	   injury.	   	   Indeed	   these	   drug	   reactions	   are	  
typified	   by	   centrilobular	   hepatocyte	   injury	   when	   liver	   biopsies	   are	   taken	   from	  
affected	   patients.	   	   Similarly	   the	   commonly	   used	   mouse	   model	   of	   carbon	  
tetrachloride	  causes	  a	  similar	  injury	  for	  the	  same	  reasons	  (Friedman,	  2010).	  
	  
The	  understanding	  of	  the	  development	  of	  this	  complex	  arrangement	  of	  multiple	  cell	  
types	   is	   critical	   in	   understanding	   the	   response	   of	   the	   organ	   to	   liver	   injury.	   	   The	  
molecular	  cues	  that	  are	  required	  during	  development	  are	  also	  likely	  to	  be	  activated	  
in	  the	  regenerating	  liver	  after	  partial	  liver	  resection.	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1.3	   Development	  of	  the	  liver	  
	  
Due	   to	   the	   size	   of	   the	   liver	   and	   the	   relative	   accessibility	   of	   tissue	   samples	   the	  
development	  of	  the	  liver	  is	  well	  characterised	  (Lemaigre,	  2009,	  Si-­‐Tayeb	  et	  al.,	  2010).	  	  
Initial	  formation	  of	  the	  liver	  bud,	  and	  specification	  of	  primitive	  hepatoblasts	  that	  go	  
on	  to	  form	  both	  hepatocytes	  and	  biliary	  epithelial	  cells	  occurs	  early	  in	  development	  
and	  requires	  multiple	  signals	  that	  are	  co-­‐ordinated	  in	  both	  space	  and	  time.	  
	  
Hepatoblasts	   have	   their	   origins	   initially	   in	   the	   definitive	   endoderm	   that	   is	  
established	  during	  gastrulation.	  	  This	  lies	  in	  close	  proximity	  to	  the	  developing	  heart	  
that	  provides	  the	  first	  instructive	  signals	  in	  specification	  to	  a	  hepatoblast	  fate.	  	  These	  
signals	  were	  described	  to	  be	  members	  of	   the	   fibroblast	  growth	   factor	   (FGF)	   family	  
(Deutsch	   et	   al.,	   2001).	   	   Although	  many	   FGF	   family	  members	   are	   expressed	   in	   the	  
developing	  heart	  there	  is	  significant	  redundancy	  since	  genetic	  manipulation	  of	  each	  
of	  these	  factors	  has	  little	  effect	  (Miller	  et	  al.,	  2000).	  	  Following	  initial	  specification	  a	  
second	   signal	   is	   required	   from	   the	   developing	   septum	   transversum	  mesenchyme.	  	  
Bone	   morphogenetic	   protein	   4	   (BMP4)	   is	   highly	   expressed	   in	   the	   septum	  
transversum	  mesenchymal	   cells,	   as	   is	   its	   regulator	   the	   transcription	   factor	   GATA4	  
(Nemer	  and	  Nemer,	  2003).	   	  Genetic	  deletion	  of	  either	  of	  these	  factors	  significantly	  
delays	  both	  hepatoblast	  specification,	  and	  also	  the	  early	  migration	  of	  the	   liver	  bud	  
into	   the	   septum	   transversum	  mesenchyme	   (Watt	   et	   al.,	   2007,	   Rossi	   et	   al.,	   2001).	  	  
Interestingly	  both	  GATA4	  and	  BMP4	  are	  expressed	  in	  other	  cell	  types	  at	  the	  time	  of	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specification	  but	  it	  is	  the	  signals	  derived	  from	  the	  septum	  transversum	  mesenchyme	  
that	  are	  critical	  for	  liver	  development.	  	  These	  findings	  are	  supported	  by	  the	  findings	  
that	   both	  GATA4	   and	   BMP4	   are	   indispensible	   for	   liver	   bud	   formation	   in	   zebrafish	  
(Shin	  et	  al.,	  2007).	  
	  
Following	  specification	  there	  is	  a	  proliferation	  of	  hepatoblasts	  as	  they	  bud	  into	  the	  
adjacent	  stroma.	  	  This	  process	  is	  related	  to	  the	  provision	  of	  stimulatory	  signals	  from	  
endothelial	   cells	   within	   the	   stroma	   (Lammert	   et	   al.,	   2001,	   Lammert	   et	   al.,	   2003,	  
Matsumoto	  et	  al.,	  2001).	   	  The	  soluble	  signals	  that	  are	  secreted	  by	  endothelial	  cells	  
have	  not	  been	  identified	  to	  date.	  	  However	  it	  is	  interesting	  that	  liver	  endothelial	  cells	  
have	  been	  reported	  to	  drive	  hepatocyte	  proliferation	  after	  liver	  resection	  in	  mouse	  
models	  through	  expression	  of	  hepatocyte	  growth	  factor	  and	  other	  factors	  (LeCouter	  
et	   al.,	   2003,	   Ding	   et	   al.,	   2010).	   	   This	   migration	   into	   the	   stroma	   and	   subsequent	  
formation	  of	  the	  liver	  bud	  is	  associated	  with	  a	  change	  in	  transcriptional	  networks	  in	  
the	  hepatoblasts.	   	  There	  is	  expression	  of	  the	  homeobox	  transcription	  factors	  Hhex,	  
and	  Prox1,	  as	  well	  as	  Hnf6,	  and	  OC-­‐2	  (Zaret	  and	  Grompe,	  2008).	  
	  
The	   on-­‐going	   development	   of	   the	   liver	   is	   supported	   by	   the	   generation	   of	   the	  
sinusoidal	  networks	  that	  distribute	  blood	  across	  the	  liver.	  	  The	  sinusoidal	  endothelial	  
cells	   develop	   from	   the	   endothelial	   cells	   within	   the	   septum	   transversum	  
mesenchyme	  (Gouysse	  et	  al.,	  2002).	   	  As	  development	  progresses	  these	  endothelial	  
cells	  differentiate	  into	  the	  mature	  sinusoidal	  endothelial	  cell	  phenotype.	  	  The	  signals	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that	   are	   required	   for	   this	   process	   are	   not	  well	   established	   but	   it	   is	   apparent	   that	  
there	  are	  contemporaneous	  changes	   in	  the	  supporting	  matrix	  suggesting	  that	  such	  
cues	  may	  be	  important	  (Couvelard	  et	  al.,	  1996).	  	  Another	  possibility	  is	  a	  role	  for	  Wnt	  
signalling	   (Zeng	  et	  al.,	  2007,	  Klein	  et	  al.,	  2008,	  Matsumoto	  et	  al.,	  2008):	  Wnt2	  has	  
been	  shown	  to	  increase	  the	  proliferation	  of	  rat	  sinusoidal	  endothelial	  cells,	  and	  that	  
when	  Wnt2	  levels	  were	  depleted	  there	  was	  a	  reduction	  in	  the	  expression	  of	  vascular	  
endothelial	  growth	  factor	  receptor	  2	  (VEGFR-­‐2)	  (Klein	  et	  al.,	  2008)	  that	  is	  responsible	  
for	  mediating	  the	  mitogenic	  activity	  of	  that	  growth	  factor	  (Quinn	  et	  al.,	  1993,	  Olsson	  
et	  al.,	  2006).	  
	  
The	   final	   important	   step	   in	   establishing	   the	   liver	   lobule	   is	   in	   the	   development	   of	  
hepatocellular	   polarity.	   	   In	   chick	   embryo	   studies	   the	   first	   signs	   of	   polarity	   –	   the	  
detection	  of	  apically	  expressed	  proteins	  –	  occurs	  soon	  after	  the	  development	  of	  the	  
liver	   bud,	   but	   fully	   mature	   structures	   are	   not	   seen	   until	   after	   birth	   (Gallin	   and	  
Sanders,	   1992).	   	   The	   mediators	   implicated	   in	   the	   development	   of	   polarity	   have	  
largely	   been	   extrapolated	   from	   other	   polarised	   cell	   systems	   (Nelson,	   2003,	  Wang	  
and	  Boyer,	  2004)	  however	  two	  mechanisms	  that	  pertain	  to	  hepatocyte	  polarity	  have	  
been	  identified	  in	  human	  cell	  systems.	  	  Firstly,	  signals	  through	  the	  interleukin	  (IL)	  6	  
receptor	   unit	   gp130	   drives	   bile	   canalicular	   formation	   in	   the	   hepatoma	   cell	   line	  
HepG2	  (van	  der	  Wouden	  et	  al.,	  2002).	  	  Oncostatin	  M,	  an	  IL6	  related	  cytokine,	  is	  also	  
implicated	  in	  the	  early	  stages	  of	  liver	  development,	  including	  in	  the	  differentiation	  of	  
hepatoblasts	  to	  hepatocytes	  (Kamiya	  et	  al.,	  1999).	  	  Secondly,	  the	  extracellular	  matrix	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component	   fibronectin	   has	   also	   been	   shown	   to	   stimulate	   the	   development	   of	  
hepatocellular	   polarity	   (Herrema	   et	   al.,	   2006).	   	   Interestingly,	   given	   the	   close	  
relationships	  between	  developing	  hepatocytes	  and	  endothelial	   cells	   in	   the	  nascent	  
sinusoids	  a	  direct	  cellular	   interaction	  has	  been	  described	  in	  zebrafish	  (Sakaguchi	  et	  
al.,	   2008).	   	   Using	   previously	   identified	   mutants	   a	   role	   for	   endothelial	   cell-­‐cell	  
junction	   proteins	   valentine	   (human	   homolog,	   cerebral	   cavernomous	  malformation	  
(CCM)	  2),	  and	  heart	  of	  glass	  (human	  homolog	  HEG1)	  a	  binding	  partner	  for	  valentine	  
was	   identified	   as	   regulators	   of	   hepatocellular	   polarity.	   	   Incorporation	   of	   cells	  
overexpressing	   heart	   of	   glass	   modified	   the	   polarisation	   of	   surrounding	   cells	  
suggesting	  direct	  regulation	  by	  this	  protein	  in	  the	  liver.	  	  These	  studies	  indicate	  that	  
the	   regulation	   of	   hepatocellular	   polarity	   is	   complex	   requiring	  multiple	   signals	   that	  
have	  likely	  not	  been	  completely	  elucidated.	  	  	  
	  
A	  fundamental	  role	  for	  endothelial	  cells	  is	  therefore	  established	  at	  several	  stages	  of	  
development	   of	   the	   liver	   suggesting	   that	   these	   cells	   are	   critical	   in	   the	   organ’s	  
response	  to	  injury.	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1.4	   Liver	  sinusoidal	  endothelial	  cell	  biology	  
	  
Liver	  sinusoidal	  endothelial	  cells	  (LSEC)	  provide	  the	  physical	  distribution	  system	  for	  
blood	  entering	  the	  hepatic	  lobule.	  	  Whilst	  hepatocytes	  make	  up	  the	  majority	  of	  liver	  
volume	  LSEC	  comprise	  some	  40%	  of	  the	  remaining	  non-­‐parenchymal	  cells,	  or	  3%	  of	  
the	   total	   liver	   volume	   (Blouin	   et	   al.,	   1977).	   	   The	   initial	   identification	   of	   LSEC	   as	   a	  
unique	   microvascular	   cell	   type	   dates	   from	   the	   development	   of	   high	   resolution	  
electron	  microscopy	   techniques.	   	   Indeed	   the	   first	  description	  of	   LSEC	   fenestration,	  
the	   characteristic	   feature	  of	   this	   cell	   type,	  was	   from	  Wisse	   in	   1970	   (Wisse,	   1970).	  	  
Since	  that	  time	  the	  study	  of	  LSEC	  has	  expanded	  from	  those	  investigators	  interested	  
in	   pure	   endothelial	   cell	   biology	   to	   investigators	   interested	   in	   immunology,	  
pharmacology,	  virology,	  and	  the	  contribution	  of	  endothelium	  to	  metabolism.	  
	  
Ultrastructural	  characteristics	  of	  LSEC	  in	  vivo	  
The	   identity	   of	   LSEC	   remains	   a	   controversial	   topic.	   	   In	   vivo	   LSEC	   are	   best	  
characterised	  by	   the	  presence	  of	   fenestrations.	   	  These	   fenestrations	  are	  organised	  
into	  sieve	  plates	  that	  are	  critical	  for	  normal	  endothelial	  cell	  function.	  	  In	  human	  LSEC	  
the	  endothelial	  fenestrae	  measure	  150-­‐175nm	  in	  diameter	  and	  occur	  at	  a	  frequency	  
of	  9-­‐13	  per	  μm2.	  	  Thus	  these	  fenestrae	  occupy	  approximately	  7%	  of	  the	  endothelial	  
cell	   surface	   (Wisse	   et	   al.,	   1985)	   (Fig.	   1-­‐4).	   	   Further	   important	   ultrastructural	  
	  	  
17	  
characteristics	   that	   are	   functionally	   significant	   are	   the	   presence	   of	   numerous	  







Figure	  1-­‐4	  Sinusoidal	  endothelial	  cell	  fenestrations	  are	  organised	  into	  sieve	  plates.	  
Scanning	  electron	  micrograph	  of	  rat	  liver	  highlighting	  endothelial	  cell	  fenestrations.	  	  
Scale	  bar,	  1μm	  (Braet	  and	  Wisse,	  2002).	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These	  ultrastructural	  findings	   indicated	  the	  prominent	  roles	  of	  LSEC	   in	  vivo.	   	  Firstly	  
the	  organisation	  of	  sieve	  plates	  suggested	  the	  function	  of	  LSEC	  as	  a	  dynamic	  filter	  for	  
substances	  absorbed	  from	  the	  gut	  and	  delivered	  to	  the	  liver	  in	  the	  portal	  circulation.	  	  
Secondly	   the	   presence	   of	  multiple	   endocytic	   vesicles	   indicated	   the	   high	   endocytic	  
capacity	   LSEC	  and	  a	   critical	   functional	   role	   in	   clearing	  waste	  macromolecules	   from	  
the	  circulation.	  	  	  
	  
It	  is	  important	  to	  note	  that	  these	  ultrastructural	  studies	  also	  indicated	  the	  presence	  
of	  only	  a	  minimal	  basement	  membrane	  supporting	  LSEC	   in	   the	  normal	   liver	   (Braet	  
and	  Wisse,	   2002).	   	   This	   finding	   is	   in	   keeping	  with	   the	   functions	  of	   LSEC	   suggested	  
above	   since	   the	   absence	   of	   a	   significant	   quantity	   of	   basement	  will	   allow	   the	   free	  
passage	  of	  substances	  through	  the	  dynamic	  filter	  of	  the	  sieve	  plates.	  
	  
Molecular	  characteristics	  of	  LSEC	  
To	   further	   dissect	   the	   function	   of	   LSEC	   it	   was	   important	   to	   reliably	   identify	   cells	  
isolated	  from	  whole	  liver.	  	  However	  a	  number	  of	  different	  markers	  have	  been	  used	  
for	   this	   purpose	   that	   are	   not	   consistent	   between	   species,	   or	   indeed	   between	  
investigators.	  	  In	  vivo,	  LSEC	  express	  a	  different	  repertoire	  of	  surface	  markers	  to	  other	  
microvascular	  and	   large	  vessel	  endothelia.	   	   For	   instance	  LSEC	  are	  characteristically	  
CD31	   low	  and	  expression	   is	   typically	   intracellular	   in	  normal	   conditions,	   in	   contrast	  
vascular	  endothelium	  shows	  high	  level	  CD31	  expression	  (Lalor	  et	  al.,	  2006).	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The	   specialised	   function	   of	   LSEC	   suggests	   the	   presence	   of	   specific	   phenotypic	  
protein	   expression.	   	   Indeed	   several	   receptors	   expressed	   by	   LSEC	   have	   been	  
suggested	   as	   phenotypic	   markers	   of	   this	   cell	   type	   (Lalor	   et	   al.,	   2006).	   	   These	  
receptors	   relate	   specifically	   to	   scavenger	   function	   and	   interestingly	   often	   show	  
overlapping	   expression	   with	   lymph	   node	   endothelium.	   	   Those	   receptors	  
characterised	   to	   have	   predominant	   LSEC	   (and	   lymph	   node)	   expression	   include	  
stabilin-­‐1,	  and	  -­‐2	   (Hansen	  et	  al.,	  2005,	  Politz	  et	  al.,	  2002);	  liver/lymph	  node	  specific	  
ICAM-­‐3-­‐grabbing	   nonintegrin	   (L-­‐SIGN)	   (Bashirova	   et	   al.,	   2001)	   and	   the	   related	  
molecule	  liver	  and	  lymph	  node	  sinusoidal	  endothelial	  cell	  c-­‐type	  lectin	  (LSECtin)	  (Liu	  
et	  al.,	  2004);	  and	  lymphatic	  vessel	  endothelial	  hyaluronan	  receptor	  (LYVE-­‐1)	  (Mouta	  
Carreira	   et	   al.,	   2001).	   	   These	   receptors	   have	   an	   important	   role	   in	   the	   scavenger	  
functions	   of	   LSEC,	   and	   provide	   an	   important	   insight	   into	   the	   phenotypic	  
characterisation	  of	  isolated	  cells	  in	  vitro.	  
	  
Functional	  characteristics	  of	  LSEC	  
The	  phenotypic	   characteristics	  of	   LSEC	  have,	   as	  described,	   given	  major	   clues	  as	   to	  
the	   identity	  of	   the	   functions	  of	   LSEC.	   	   Broadly	   these	  have	  been	   characterised	   into	  
filtration	   and	   scavenger	   activity.	   	   However	   it	   is	   now	   recognised	   that	   LSEC	   have	  
additional	  functions	  that	  relate	  to	  immune	  function	  of	  the	  liver	  and	  the	  tolerance	  to	  
repetitive	   immune	  stimulation	  by	  bacterial	  products	  carried	   in	  portal	  blood	  (Knolle	  





The	   role	   of	   fenestrations	   in	   the	   “liver	   sieve”	   has	   been	   carefully	   elucidated	   largely	  
using	  lipoprotein	  components.	   	  These	  range	  in	  size	  from	  50-­‐100nm	  in	  diameter	  for	  
chylomicron	  remnants	  to	  100-­‐1000nm	  in	  diameter	  for	  intact	  chylomicrons.	  	  Isolated	  
hepatocytes	   are	   unable	   to	   distinguish	   between	   these	   lipoproteins	   in	   vitro	   (Floren,	  
1984),	  but	  in	  the	  liver	  only	  the	  chylomicron	  remnants	  are	  taken	  up	  by	  hepatocytes.	  	  
Furthermore,	   intact	   chylomicrons	   were	   identified	   only	   in	   the	   sinusoidal	   lumen	  
whereas	  chylomicron	  remnants	  were	  identified	  in	  the	  space	  of	  Disse,	  the	  anatomical	  
space	  between	  the	  sinusoidal	  endothelium	  and	  underlying	  hepatocytes	  (Fraser	  et	  al.,	  
1978).	  	  These	  findings	  are	  further	  supported	  by	  additional	  studies	  with	  molecules	  of	  
differing	   physical	   properties.	   	   For	   example	   nonliposomal	   doxorubicin	   (a	  
chemotherapeutic	   agent)	   is	   taken	   up	   by	   hepatocytes	   whereas	   the	   liposomal	  
formulation	   is	   excluded	   from	   the	   space	   of	   Disse	   (Hilmer	   et	   al.,	   2004).	   	   It	   is	  
noteworthy	   that	   this	   change	   in	   pharmacokinetics	   leads	   to	   an	   increase	   in	   systemic	  
drug	  exposure	  of	  the	  liposomal	  compound	  of	  >300-­‐fold,	  and	  a	  decrease	  in	  clearance	  
of	  >250-­‐fold	  highlighting	   the	   importance	  of	   the	  action	  of	   the	   liver	   sieve	   in	  hepatic	  
drug	   clearance.	   	   These	   findings	   support	   a	  model	  where	   small	   particles	   <100nm	   in	  
diameter	  readily	  pass	  through	  LSEC	  fenestrations	  in	  a	  sieving	  process.	  
	  
Scavenger	  functions	  
The	  scavenger	  functions	  of	  LSEC	  have	  been	  well	  defined	   in	  studies	  using	  rats	  using	  
an	   array	   of	   macromolecules	   and	   other	   potentially	   hazardous	   components	   of	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connective	   tissue.	   	   The	   endocytic	   receptors	   in	   rat	   have	   been	   defined	   in	   five	  
functional	  groups:	  
1. Collagen	  α-­‐chain	  receptor	  (COLLAR)	  has	  specificity	  for	  free	  α-­‐chains	  of	  type	  I	  
to	  V,	  and	   IX	  collagen	  but	  not	  native	  triple	  helical	  collagen	  and	  this	  receptor	  
has	  been	  identified	  exclusively	  in	  LSEC	  (Smedsrod	  et	  al.,	  1985a).	  
2. Hyaluronan	   receptor	   (HAR)	   is	   responsible	   for	   clearance	   of	   circulating	  
hyaluronan	  (Eriksson	  et	  al.,	  1983).	  	  This	  receptor	  that	  has	  been	  purified	  and	  
characterised	  to	  be	  a	  high	  affinity	  receptor	  for	  hyaluronan	   	   (McCourt	  et	  al.,	  
1999),	  as	  well	  as	  a	  number	  of	  other	  ligands	  including	  chondroitin	  (Smedsrod	  
et	   al.,	   1985b).	   	   The	   receptor	  efficiently	   clears	  hyaluronan	   from	   the	  plasma.	  	  
Hyaluronan	  has	  a	  plasma	  half-­‐life	  of	  less	  than	  one	  minute	  and	  large	  amounts	  
of	   protein	   (10-­‐100mg	   in	   humans)	   are	   cleared	   from	   the	   plasma	   each	   day	  
(Engstrom-­‐Laurent	  and	  Hallgren,	  1985).	  
3. The	   immunoglobulin	   G	   Fc	   receptor	   (that	   is	   expressed	   on	   both	   LSEC	   and	  
Kuppfer	   cells)	   has	   been	   shown	   to	   eliminate	   circulating	   immune	   complexes	  
from	  the	  bloodstream	  (Lovdal	  et	  al.,	  2000).	  
4. Mannose	  receptor	  activity	  has	  been	  shown	  to	  be	  extremely	  rapid,	  indeed	  the	  
cell	  surface	  half	   life	  of	  the	  receptor	   is	  estimated	  at	  10	  seconds	  (Magnusson	  
and	  Berg,	   1989).	   	   The	   receptor	   recognises	   the	   terminal	   non-­‐reducing	   sugar	  
residue	   of	   the	   oligosaccharide	   (fucose,	   mannose	   or	   N-­‐acetyl-­‐glucosamine)	  
moiety	   of	   glycoproteins	   (Ashwell	   and	   Harford,	   1982).	   	   Interestingly	   the	  
mannose	   receptor	   has	   also	   been	   implicated	   in	   the	   sorting	   of	   antigens	   for	  
cross	  presentation	  to	  CD8	  T	  cells	  (Burgdorf	  et	  al.,	  2007),	  a	  pathway	  that	  has	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been	  identified	  as	  a	  mechanism	  of	  tolerance	  development	  in	  the	  liver	  (Diehl	  
et	  al.,	  2008).	  
5. The	  scavenger	  receptor	   family	   is	  a	  growing	  group	  of	  receptors	  that	  clears	  a	  
larger	   number	   of	   macromolecules	   from	   circulation	   including	  
glycosaminoglycans,	   hyaluronic	   acid	   and	   chondroitin	   (Harris	   et	   al.,	   2007).	  	  
The	   most	   well	   characterised	   human	   receptors	   in	   this	   family	   are	   stabilin-­‐1	  
(also	   termed	   CLEVER-­‐1	   and	   FEEL-­‐1),	   and	   stabilin-­‐2	   (FEEL-­‐2)	   (Hansen	   et	   al.,	  
2005,	   Politz	   et	   al.,	   2002).	   	   The	   functional	   significance	   of	   these	   receptors	   is	  
highlighted	   by	   the	   recent	   report	   of	   glomerulofibrotic	   injury	   in	  mice	   lacking	  
expression	   of	   both	   stabilin-­‐1,	   and	   stabilin-­‐2	   (Schledzewski	   et	   al.,	   2011).	  	  
Mechanistically	   this	   fibrotic	   injury	   was	   related	   to	   failed	   clearance	   of	  
transforming	  growth	  factor	  β	  (TGF-­‐β)	  family	  member	  growth	  differentiation	  
factor	   15	   (GDF-­‐15).	   	   This	   finding	   underscores	   the	   importance	   of	   scavenger	  
activity	  for	  the	  function	  of	  the	  whole	  organism,	  and	  not	  just	  in	  liver	  function.	  
	  
Immune	  functions	  
The	   liver	   is	   a	   tolerogenic	   organ	   (Crispe,	   2009,	   Protzer	   et	   al.,	   2012).	   	   When	  
considering	   normal	   liver	   function,	   tolerance	   is	   expected.	   	   Multiple	   antigens,	  
including	   food	   antigens,	  microbial	   products,	   and	   those	   from	   injured	   gut	   epithelial	  
cells	   are	   constantly	   delivered	   to	   the	   liver	   in	   portal	   blood.	   	   Continuous	   immune	  
responses	   to	   these	   antigens	  would	  be	  deleterious	   and	   therefore	  mechanisms	   that	  
dampen	  immune	  responses	  in	  the	  liver	  have	  developed.	  	  Two	  particular	  tolerogenic	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mechanisms	  involve	  LSEC	  directly.	  	  The	  first	  of	  these	  relates	  to	  tolerance	  to	  bacterial	  
products.	   	   Lipopolysaccharide	   (LPS)	   is	  a	  common	  component	  of	  bacterial	   cell	  walls	  
and	   this	   potently	   stimulates	   immune	   responses	   through	   activation	   of	   the	   pattern	  
recognition	  receptor	  toll-­‐like	  receptor	  4	  (TLR4).	  	  However,	  proinflammatory	  bacterial	  
products	   including	   LPS	  are	   constantly	  delivered	   to	   the	   liver	   and	  are	   cleared	   in	   the	  
absence	   of	   an	   inflammatory	   response.	   	   Studies	   of	   isolated	  murine	   LSEC	   indicated	  
that	  repetitive	  stimulation	  of	  these	  cells	  with	  LPS	  rapidly	  lead	  to	  the	  development	  of	  
a	   refractory	   state	   where	   activation	   of	   signalling	   downstream	   of	   TLR4	   was	   not	  
sustained	   but,	   importantly,	   clearance	   was	   maintained	   (Uhrig	   et	   al.,	   2005).	   	   The	  
second	  of	  these	  relates	  to	  the	  unusual	  antigen	  presentation	  function	  of	  LSEC	  (Knolle	  
et	  al.,	  1998,	  Lohse	  et	  al.,	  1996).	  	  Many	  cell	  populations	  in	  the	  liver	  have	  the	  ability	  to	  
present	  antigen	  and	  in	  the	  case	  of	  LSEC	  this	  usually	  results	  in	  tolerogenic	  activation	  
of	  T	  cells	  (Diehl	  et	  al.,	  2008,	  Knolle	  et	  al.,	  1998,	  Knolle	  et	  al.,	  1999,	  von	  Oppen	  et	  al.,	  
2008).	   	   Indeed	  this	   tolerogenic	  activation	  may	  be	  one	  reason	  why	  the	   liver	   is	   such	  
fertile	  ground	  for	  chronic	  viral	  infection	  (Protzer	  et	  al.,	  2012).	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1.5	   Regulation	  of	  LSEC	  phenotype	  
	  
The	  many	  and	  varied	  distinct	   functions	  of	   LSEC	   suggest	   the	  need	   for	  maintenance	  
signals	   that	   are	   not	   required	   by	   other	   endothelial	   cells.	   	   In	   keeping	   with	   this	  
hypothesis	  LSEC	  dedifferentiate	  when	  cultured	   in	  vitro	  as	  evidenced	  by	  a	  rapid	  loss	  
of	  fenestrations	  and	  sieve	  plates	  (DeLeve	  et	  al.,	  2004,	  Elvevold	  et	  al.,	  2008).	  	  In	  vitro	  
studies	   have	   been	  hampered	   by	   the	   lack	   of	   an	   agreed	  well-­‐defined	  molecule	   that	  
defines	   normal	   sinusoidal	   endothelial	   cell	   phenotype.	   	   Indeed	   the	   phenotypic	  
markers	   described	   above	   have	   not	   been	   studied	   in	   relation	   to	   regulation	   of	   LSEC	  
phenotype.	  
	  
Regulation	  of	  endothelial	  cell	  function	  in	  general	  has	  been	  variously	  described	  to	  be	  
dependent	  on	  interactions	  with	  paracrine	  signalling	  systems,	  heterotypic	  cell	  types,	  
and	  basement	  membrane	  components.	  	  In	  the	  case	  of	  LSEC,	  in	  vivo	  these	  cells	  are	  in	  
close	   proximity	   to	   hepatocytes	   as	   well	   as	   hepatic	   stellate	   cells	   that	   are,	   amongst	  
many	  other	  functions,	  considered	  to	  be	  the	  pericyte	  in	  the	  liver.	  	  It	  is	  likely	  therefore	  
that	   these	   cell	   types	   provide	   signals	   to	   LSEC	   to	   maintain	   fenestration,	   and	   other	  
aspects	  of	  normal	  cellular	  function.	  	  Co-­‐cultivation	  of	  hepatocytes	  with	  LSEC	  in	  vitro	  
has	  been	  associated	  with	   the	  maintenance	  of	  a	  microvascular	  phenotype	  although	  
initially	   the	  mechanism	  defining	   this	   process	  was	  not	  well	   understood	   (Modis	   and	  
Martinez-­‐Hernandez,	   1991).	   	   It	   was	   shortly	   after	   this	   report	   that	   alterations	   in	  
vascular	   endothelial	   growth	   factor	   (VEGF)	   signalling	   were	   noted	   to	   have	   marked	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effects	   on	   LSEC	   function	   in	   vitro	   (Yamane	   et	   al.,	   1994,	   Mochida	   et	   al.,	   1998).	  	  
Furthermore	   VEGF-­‐/-­‐	   mice	   show	   delayed	   liver	   development	   and	   an	   abnormal	  
sinusoidal	   network	   further	   illustrating	   the	   importance	   of	   this	   growth	   factor	   in	  
sinusoidal	   endothelial	   cell	   biology	   (Gerber	   et	   al.,	   1999).	   	   Taken	   together	   these	  
studies	   highlighted	   a	   likely	   role	   for	   VEGF-­‐A	   signalling	   in	   the	  maintenance	   of	   LSEC	  
phenotype.	  
	  
A	  clear	  role	  for	  VEGF-­‐A	  signalling	  in	  the	  normal	  liver	  has	  been	  further	  defined	  both	  in	  
vivo,	  and	  in	  vitro.	  	  VEGF-­‐A	  expression	  in	  the	  liver	  is	  detectable	  in	  hepatocytes	  but	  not	  
in	   LSEC	   (Yamane	   et	   al.,	   1994,	   Maharaj	   et	   al.,	   2006).	   	   LSEC	   however	   express	   the	  
cognate	   receptors	   for	   this	   growth	   factor	   whereas	   expression	   of	   the	   receptors	   is	  
undetectable	   on	   hepatocytes	   (Yamane	   et	   al.,	   1994,	   Ding	   et	   al.,	   2010,	   Cao	   et	   al.,	  
2010).	   	  This	  pattern	  of	  ligand	  receptor	  expression	  indicates	  the	  likely	  presence	  of	  a	  
paracrine	  signalling	  system	  involving	  the	  closely	  opposed	  hepatocytes	  and	  sinusoidal	  
endothelial	  cells	  of	  the	  lobule.	  
	  
The	  defining	  role	  of	  VEGF-­‐A	  regulation	  of	  LSEC	  function	  was	  provided	  by	  an	  elegant	  
in	   vivo	   study	   from	   Carpenter	   and	   colleagues.	   	   These	   investigators	   used	   a	   model	  
where	   a	   VEGF-­‐A	   trap	  molecule	  was	   expressed	   specifically	   in	   hepatocytes	   using	   an	  
inducible	  system	  controlled	  by	  administration	  of	  tetracycline	  (Carpenter	  et	  al.,	  2005).	  	  
This	   trap	   was	   able	   to	   deplete	   VEGF-­‐A	   expressed	   by	   hepatocytes	   thus	   preventing	  
activation	   of	   adjacent	   endothelial	   cells.	   	   Furthermore,	   since	   the	   system	   was	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inducible	  it	  was	  possible	  to	  investigate	  the	  role	  of	  VEGF-­‐A	  during	  development,	  and	  
during	   normal	   tissue	   homeostasis	   in	   the	   adult	   liver.	   	   The	   prior	   studies	   in	   VEGF-­‐/-­‐	  
knockout	   animals	   had	   indicated	   that	   VEGF-­‐A	   signalling	   was	   required	   for	   normal	  
development	  of	  the	  liver	  (Gerber	  et	  al.,	  1999)	  but	  using	  the	  inducible	  system	  it	  was	  
apparent	   that	   VEGF	   stimulation	   was	   required	   throughout	   liver	   development	   for	  
normal	   formation	   of	   sinusoidal	   networks.	   	   Further	   it	   was	   noted	   that	   there	   was	  
limited	   lipid	   accumulation	   in	   the	   livers	   of	   tetracycline	   treated	   animals.	   	   Given	   the	  
understanding	   of	   LSEC	   fenestration	   and	   its	   role	   on	   accumulation	   of	   lipoprotein	  
remnant	  the	  authors	  then	  went	  on	  to	  study	  fenestrations	  in	  adult	  mice	  where	  VEGF	  
signalling	   had	   been	   inhibited	   in	   the	   post-­‐natal	   period.	   	   These	  mice	   also	   displayed	  
reduced	   lipoprotein	   remnant	   uptake	   and	   electron	  microscopy	   studies	   of	   the	   liver	  
showed	  significantly	  reduced	  LSEC	  fenestration.	  	  Thus	  in	  vivo	  VEGF	  is	  required	  both	  
for	  the	  normal	  development	  of	  sinusoidal	  networks,	  and	  for	  the	  maintenance	  of	  the	  
normal	  fenestrated	  LSEC	  phenotype.	  	  These	  findings	  have	  been	  further	  supported	  by	  
the	   detection	   of	   abnormalities	   in	   mice	   with	   an	   endothelial	   specific	   conditional	  
deletion	  of	  VEGFR-­‐2	  (Sison	  et	  al.,	  2010).	  
	  
In	  vitro	  evidence	  of	  the	  importance	  of	  VEGF-­‐A	  stimulation	  comes	  from	  studies	  of	  rat	  
LSEC	   immediately	   following	   isolation	   (DeLeve	   et	   al.,	   2004).	   	   In	   these	   experiments	  
endothelial	   cell	   fenestration,	   and	   localisation	   of	   CD31	   was	   monitored	   over	   the	  
following	   72	   hours.	   	   In	   the	   presence	   of	   control	   medium	   there	   was	   rapid	   loss	   of	  
fenestration	   and	   a	   change	   in	   localisation	   of	   CD31	   from	   intracellular	   to	  membrane	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bound.	   	   Interestingly	   these	   changes	   were	   reversed	   by	   incubation	   of	   LSEC	   with	  
hepatocyte	  conditioned	  medium.	  	  The	  authors	  hypothesised	  that	  this	  was	  due	  to	  the	  
presence	   of	   VEGF	   in	   the	   conditioned	   media	   and	   confirmed	   this	   by	   treatment	   of	  
conditioned	  media	  with	  anti-­‐VEGF	  neutralising	  antibody.	  	  The	  function	  of	  VEGF-­‐A	  in	  
LSEC	  was	  described	   to	  be	  mediated	  by	   the	  production	  of	  nitric	  oxide	   (NO),	  a	  well-­‐
established	  downstream	  target	  of	  VEGF-­‐A	  stimulation	  (Fulton	  et	  al.,	  1999).	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1.6	   Vascular	  endothelial	  growth	  factor	  (VEGF)	  biology	  
	  
During	  evolution	  vascular	  networks	  have	  developed	  to	  permit	  increasing	  complexity	  
of	  organisms,	  so	  that	  oxygen	  and	  nutrients	  can	  be	  delivered	  efficiently	  to	  the	  areas	  
of	   need.	   	   Further	   these	   vessels	   allow	   immune	   cells	   to	   patrol	   for	   the	   purpose	   of	  
immune	  surveillance.	  	  Whilst	  vascular	  structures	  allow	  development	  and	  functioning	  
of	   these	   organisms	   they	   also	   permit	   the	   development	   of	   inflammatory	   and	  
malignant	   disease	   by	   provision	   of	   nutrients	   for	   these	   processes.	   	   It	   was	   the	  
association	  with	  malignant	  disease	  that	  cast	  the	  light	  on	  the	  development	  of	  blood	  
vessels	  since	  it	  was	  hypothesised	  that	  targeting	  this	  process	  would	  prevent	  tumour	  
growth	  and	  metastasis	  (Folkman	  et	  al.,	  1971,	  Folkman,	  1971).	  	  	  
	  
Vascular	   endothelial	   growth	   factors	   (VEGFs)	   are	   the	   foremost	   signals	   (amongst	  
many)	   that	   regulate	   the	   complex	   processes	   of	   blood	   vessel	   formation.	   	   The	   VEGF	  
family	   is	   comprised	  of	   five	  distinct	   ligands,	  VEGF-­‐A,	   -­‐B,	   -­‐C	  and	  –D,	  and	   the	   related	  
molecule	   placental	   growth	   factor	   PlGF.	   	   VEGF-­‐A	   is	   the	   dominant	   member	   of	   the	  
family	  during	  vascular	  development.	  	  In	  fact	  formation	  of	  blood	  vessels	  has	  at	  least	  
two	   distinct	   mechanisms	   during	   development:	   firstly	   vasculogenesis	   where	   blood	  
vessels	   are	   formed	   de	   novo	   from	   endothelial	   progenitor	   cells,	   and	   angiogenesis	  
where	   vessels	   form	   from	   sprouting	   of	   existing	   vessels.	   	   VEGF-­‐A	   is	   the	   critical	  
regulator	  of	  each	  of	  these	  processes	  and	  therefore	  is	  necessary	  for	  the	  development	  
of	  the	  organism.	  	  Genetic	  deletion	  of	  even	  a	  single	  allele	  of	  VEGF	  in	  embryonic	  stem	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cells	   results	   in	  embryonic	   lethality	  due	  to	  vascular	  malformations	   (Carmeliet	  et	  al.,	  
1996,	  Ferrara	  et	  al.,	  1996).	  
	  
In	  addition	  to	  important	  roles	  in	  vascular	  development	  VEGF	  family	  ligands	  there	  is	  
emerging	   evidence	   to	   support	   a	   role	   for	   continued	   VEGF	   signalling	   in	   endothelial	  
cells.	   This	   signalling	   has	  many	   diverse	   functions	   depending	   on	   the	   organ	   involved	  
and	  for	  example	  endothelial	  cells	  have	  been	  shown	  to	  promote	  maintenance	  of	  the	  
stem	   cell	   niche	   (Hooper	   et	   al.,	   2009,	   Kobayashi	   et	   al.,	   2010),	   to	   control	   tissue	  
metabolism	   (Hagberg	   et	   al.,	   2010,	   Hagberg	   et	   al.,	   2012),	   and	   to	   promote	  
tumorigenesis	   (Butler	  et	  al.,	  2010).	   	  These	  data	   indicate	   that	  endothelial	   cells,	  and	  
VEGF	  signalling,	  are	  more	  important	  than	  simply	  providing	  oxygen	  and	  nutrients	  to	  
tissues.	   	   Rather	   these	   cells	   are	   intimately	   involved	   in	   maintaining	   organ	   function	  
largely	   through	   the	   provision	   of	   paracrine	   (or	   angiocrine	   due	   to	   the	   origin	   from	  
vascular	  endothelium)	  signals.	  
	  
The	  structure	  of	  VEGFs	  and	  related	  receptors	  
The	  VEGFs	  are	  a	  family	  of	  homodimeric	  glycoproteins	  approximately	  40kDa	  in	  size.	  	  
Each	  of	  the	  family	  members	  has	  distinct	  properties	   in	  angiogenesis	  and	   in	  vascular	  
function.	   	   As	   an	   additional	   layer	   of	   complexity	   these	   ligands	   also	   display	  
heterogeneity	   in	   receptor	   binding.	   	   The	   patterns	   of	   receptor	   binding	   to	   the	   three	  











Figure	  1-­‐5.	  	  Vascular	  endothelial	  growth	  factor	  (VEGF)	  receptor	  specificity.	  	  	  
VEGFs	  may	  bind	  to	  three	  receptor	  tyrosine	  kinases	  denoted	  VEGF	  receptor	  (VEGFR)	  -­‐
1,	   VEGFR-­‐2	   and	   VEGFR-­‐3	   leading	   to	   the	   formation	   of	   receptor	   homodimers	   and	  
heterodimers.	   	   PlGF	   and	   VEGF-­‐B	   bind	   exclusively	   to	   VEGFR1	   homodimers	   whilst	  
VEGF-­‐E	  binds	  only	  to	  VEGFR-­‐2	  homodimers.	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VEGF-­‐A	  is	  recognised	  as	  the	  major	  angiogenic	  growth	  factor	  (Nagy	  et	  al.,	  2007),	  and	  
is	  the	  most	  abundant	  expressed	  (Carmeliet	  and	  Jain,	  2011).	  	  VEGF-­‐A	  is	  unique	  in	  that	  
it	  binds	  to	  both	  VEGFR-­‐1,	  and	  VEGFR-­‐2	  whereas	  VEGF-­‐B,	  and	  PlGF	  bind	  to	  VEGFR-­‐1.	  	  
These	  ligands	  also	  bind	  to	  the	  co-­‐receptor	  neuropilin-­‐1	  that	  was	  originally	  described	  
as	   an	  axon	  guidance	  molecule	   (Gu	  et	   al.,	   2003),	   and	   that	   regulates	  VEGF	   receptor	  
activation	  (Fuh	  et	  al.,	  2000,	  Pan	  et	  al.,	  2007).	  	  VEGF-­‐C	  and	  -­‐D	  are	  primarily	  involved	  
in	  lymphangiogenesis	  and	  bind	  to	  VEGFR-­‐3	  (Tammela	  and	  Alitalo,	  2010).	  	  In	  addition	  
the	  family	  members	  listed	  above	  there	  are	  additional	  structurally	  related	  molecules	  
that	   are	   useful	   for	   in	   vitro	   studies	   since	   they	   bind	   exclusively	   to	   one	   of	   the	   VEGF	  
receptors.	  	  One	  such	  molecule	  is	  VEGF-­‐E	  that	  was	  identified	  in	  parapoxvirus	  and	  that	  
binds	  exclusively	  to	  VEGFR-­‐2	  (Meyer	  et	  al.,	  1999).	  	  
	  
The	   VEGFRs	   are	   members	   of	   the	   receptor	   tyrosine	   kinase	   family.	   	   For	   signalling	  
VEGFRs	   dimerise	   depending	   on	   the	   ligand	   bound	   and	   are	   thus	   able	   to	   form	   both	  
homo-­‐	   and	   heterodimers	   (Dixelius	   et	   al.,	   2003)	   (Fig.	   1-­‐5).	   	   Following	   dimerization	  
there	   is	   activation	   of	   the	   receptor-­‐kinase	   activity	   and	   recruitment	   of	   interacting	  
partners	   for	   downstream	   signalling	   (Olsson	   et	   al.,	   2006).	   	   Importantly	   the	   signal	  
transduction	  mechanisms	  of	   different	   homo-­‐and	  heterodimers	   are	   not	   completely	  
understood	  (Waltenberger	  et	  al.,	  1994).	  
	  
VEGFR-­‐2,	   also	   termed	   fetal	   liver	   kinase	   1	   (FLK-­‐1),	   is	   the	   major	   receptor	   for	   the	  
activation	  of	  angiogenesis	  (Quinn	  et	  al.,	  1993,	  Shalaby	  et	  al.,	  1995).	  	  	  	  This	  receptor	  is	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potently	   activated	   by	   VEGF-­‐A,	   and,	   following	   ligand	   binding	   receptor	   dimerisation	  
and	   autophosphorylation	   occur.	   	   Downstream	   signalling	   leads	   to	   a	   number	   of	  
outcomes.	   	   These	   include	   survival	   and	   proliferation	   regulated	   by	   tyrosine	  
phosphorylation	  at	  position	  1175	  in	  human	  cells	  and	  activation	  of	  phospholipase-­‐Cγ	  
(PLCγ)	   signalling	   (Takahashi	   and	   Shibuya,	   1997,	   Koch	   et	   al.,	   2011).	   	   In	   contrast,	  
permeability	   and	   migration	   is	   regulated	   by	   several	   different	   pathways	   including	  
tyrosine	  phosphorylation	  at	  position	  1214	  and	  activation	  of	  p38	  mitogen-­‐activated	  
protein	   kinase	   (MAPK)	   (Rousseau	   et	   al.,	   1997,	  McMullen	   et	   al.,	   2005,	   Koch	   et	   al.,	  
2011).	  
	  
VEGFR-­‐1,	  also	  termed	  FMS-­‐like	  tyrosine	  kinase	  1	  (FLT-­‐1),	  is	  a	  more	  complex	  receptor.	  	  
VEGFR-­‐1	   has	   a	   much	   greater	   affinity	   for	   VEGF-­‐A	   than	   VEGFR-­‐2	   with	   dissociation	  
constant	   values	   (Kd)	   of	   10-­‐20	   pM	   and	   75-­‐125	   pM	   respectively	   (Sato	   et	   al.,	   2000).	  	  
Perhaps	   not	   surprisingly	   genetic	   deletion	   of	   VEGFR-­‐1	   is	   also	   embryonically	   lethal,	  
however	  in	  these	  embyros	  there	  is	  disorganised	  (and	  excessive)	  rather	  than	  absent	  
vessel	   formation	   (Fong	   et	   al.,	   1995).	   	   This	   finding	   suggested	   that	   VEGFR-­‐1	   was	  
involved	   in	   vessel	   patterning	   and	   regulation	   rather	   than	   in	   endothelial	   cell	  
proliferation	  per	  se.	  	  Indeed	  in	  vitro	  studies	  had	  previously	  shown	  markedly	  different	  
signal	   transduction	   pathways	   between	   VEGFR-­‐1	   and	   R-­‐2	   (Seetharam	   et	   al.,	   1995),	  
and	   that	   phosphorylation	   of	   VEGFR-­‐1	   was	   much	   weaker	   than	   that	   of	   VEGFR-­‐2	  
(Waltenberger	  et	  al.,	  1994).	   	  To	  confirm	  a	  role	   in	  control	  of	  angiogenesis	  Hiratsuka	  
and	   colleagues	  deleted	   the	   tyrosine	   kinase	  domain	  of	  VEGFR-­‐1	   and	  expressed	   the	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truncated	  form	  in	  VEGFR-­‐1	  null	  mice	  (Hiratsuka	  et	  al.,	  1998).	  	  These	  mice	  developed	  
normally	   suggesting	   that	   the	  kinase	  domain	   is	  not	  necessary	   for	  VEGFR-­‐1	   function	  
and	   that	   this	   receptor	   rather	  acts	  as	  a	  decoy	   for	  VEGF-­‐A	   thus	  preventing	  aberrant	  
activation	   of	   VEGFR-­‐2.	   	   Interestingly	   VEGFR-­‐1	   is	   also	   alternatively	   processed	   to	   a	  
soluble	  form	  that	  is	  secreted	  and	  may	  act	  as	  an	  extracellular	  trap	  for	  VEGF-­‐A	  (Fischer	  
et	  al.,	  2008).	   	  The	  functions	  of	  soluble	  VEGFR-­‐1	  are	  not	  completely	  understood	  but	  
expression	   is	   increased	   in	   a	   number	   of	   diseases	   including	   pre-­‐eclampsia	   –	   a	  
condition	  characterised	  by	  endothelial	  cell	  dysfunction	  (Levine	  et	  al.,	  2004).	  	  VEGFR-­‐
1	   has	   also	   been	   identified	   to	   have	   a	   role	   in	   pathological	   angiogenesis,	   likely	   due	  
increased	  expression	  of	  PlGF	  and	  to	  cross-­‐talk	  with	  VEGFR-­‐2	  (Carmeliet	  et	  al.,	  2001,	  
Autiero	  et	  al.,	  2003)	  although	  this	  too	  is	  incompletely	  understood.	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1.7	   Targeting	  VEGF	  in	  the	  treatment	  of	  human	  disease	  
	  
The	   identification	   of	   VEGF-­‐A	   and	   its	   receptors	   as	   the	   critical	   regulators	   of	  
angiogenesis	  lead	  many	  researchers	  to	  investigate	  strategies	  to	  target	  this	  axis	  with	  
the	  aim	  of	   slowing	  or	  preventing	   the	  progression	  of	  malignant	  disease.	   	  Two	  main	  
approaches	   were	   used	   to	   develop	   these	   strategies.	   	   First	   neutralising	   antibodies	  
targeting	   VEGF-­‐A	  were	   developed.	   	   The	   lead	   antibody	   bevacizumab	   (Avastin)	   was	  
developed	  by	  Genentech	  and	  was	   first	   tested	   in	  patients	  with	  advanced	  colorectal	  
cancer	   in	   combination	  with	   standard	  of	   care	  chemotherapy.	   	   This	  high-­‐profile	   trial	  
confirmed	   the	   benefits	   of	   anti-­‐angiogenic	   therapy	   but	   overall	   the	   findings	   were	  
disappointing	  (Hurwitz	  et	  al.,	  2004).	  	  Only	  a	  minority	  of	  patients	  responded,	  and	  the	  
median	  improvement	  in	  survival	  was	  less	  than	  five	  months.	   	   	  The	  second	  approach	  
has	  been	  to	  use	  small	  molecule	  inhibitor	  of	  receptor	  tyrosine	  kinases,	  including	  the	  
VEGFRs.	   	   This	   approach	   has	   been	   studied	   in	   a	   number	   of	   malignancies	   but	   most	  
relevantly	   in	   primary	   liver	   cell	   cancer	   (hepatocellular	   carcinoma,	   HCC).	   	   In	   these	  
clinical	  studies	  there	  were	  again	  small	  clinical	  improvements	  in	  the	  length	  of	  overall	  
survival	   (Cheng	  et	  al.,	  2009,	  Llovet	  et	  al.,	  2008).	   	  Overall	   these	  studies	  have	  shown	  
that	   targeting	  VEGF	  signalling	  has	  some	  effect,	  usually	  by	  prolonging	  survival	   for	  a	  
few	  months	  although	  those	  patients	  who	  do	  initially	  respond	  later	  progress.	  
	  
The	  mechanisms	  defining	  progression	  of	  disease	  despite	  anti-­‐angiogenic	  therapy	  are	  
unclear	   and	   several	   have	   been	   suggested	   (Bergers	   and	   Hanahan,	   2008).	   	   There	   is	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evidence	   to	   suggest	   that	   endothelial	   cells	   can	   become	   resistant	   to	   anti-­‐VEGF	  
treatment	   by	   upregulation	   of	   additional	   angiogenic	   molecules	   including	   FGFs	  
(Casanovas	   et	   al.,	   2005).	   	   It	   has	   also	   been	   suggested	   that	   release	   of	   angiogenic	  
factors	  from	  the	  tumour	  stroma	  can	  drive	  blood	  vessel	  development	  in	  the	  absence	  
of	   VEGF-­‐A	   (Gaengel	   et	   al.,	   2009).	   	   Importantly	   two	   recent	   reports	   suggest	   that	  
inhibition	   of	   VEGF-­‐A	   signalling	   before	   dissemination	   of	   cancer	   cells	   can	   accelerate	  
the	   development	   of	   metastasis	   and	   the	   progression	   of	   disease	   (Paez-­‐Ribes	   et	   al.,	  
2009,	  Ebos	  et	  al.,	  2009).	   	  This	  latter	  finding	  suggests	  that	  VEGF-­‐A	  signalling	  may	  be	  
important	   in	   the	  metastatic	   niche	   to	   prevent	   the	   development	   of	  metastasis,	   and	  
when	  signalling	  is	  lost	  metastasis	  is	  permitted	  more	  readily.	  
	  
Finally	  anti-­‐VEGF	  therapy	  is	  associated	  with	  a	  number	  of	  well	  characterised	  toxicities	  
including	  hypertension,	  bleeding,	  renal	  dysfunction,	  and	  bowel	  perforation	  (Eremina	  
et	   al.,	   2008,	   Hapani	   et	   al.,	   2009,	   Carmeliet	   and	   Jain,	   2011,	   Potente	   et	   al.,	   2011).	  	  
Some	   of	   these	   toxicities	   are	   predictable	   when	   one	   considers	   the	   diverse	   roles	   of	  
VEGF-­‐A	  signalling	  in	  the	  endothelium	  (Lee	  et	  al.,	  2007).	  	  In	  contrast	  however	  the	  risk	  
of	   gut	   perforation	   is	   not	   understood	   and	   hence	   there	   is	   a	   need	   for	   a	   better	  
understanding	   of	   the	   role	   of	   VEGF-­‐A	   in	   the	   homeostasis	   of	   normal	   tissues	   and	  
organs.	   	  
	  	  
37	  
1.8	   The	  role	  of	  VEGF	  in	  the	  response	  of	  LSEC	  to	  liver	  injury	  
	  
VEGF-­‐A	   expression	   in	   the	   liver	   is	   critical	   for	   development	   and	   for	   the	   normal	  
function	  of	  LSEC.	  	  The	  potential	  role	  for	  VEGF-­‐A	  in	  liver	  injury	  was	  first	  investigated	  
in	  partial	  hepatectomy	  models	  of	  liver	  regeneration.	  	  In	  these	  studies	  expression	  of	  
VEGF-­‐A	  was	  noted	  soon	  after	  resection	  peaking	  at	  approximately	  72	  hours	  (Mochida	  
et	   al.,	   1998,	   Sato	  et	   al.,	   2001).	   	   At	   this	   time	  after	   injury	   there	   is	   evidence	  of	   LSEC	  
proliferation	  that	  is	  likely	  mediated	  by	  VEGF-­‐A	  (Shimizu	  et	  al.,	  2001,	  Taniguchi	  et	  al.,	  
2001).	  	  The	  proliferation	  of	  hepatocytes	  occurs	  earlier,	  peaking	  between	  24	  and	  72	  
hours	   (Ding	   et	   al.,	   2010),	   suggesting	   that	   this	   initial	   proliferation	   is	   required	   to	  
stimulate	  later	  LSEC	  expansion.	  
	  
Whilst	   increased	   VEGF-­‐A	   expression	   in	   hepatocytes	   is	   expected	   to	   cause	   LSEC	   to	  
proliferate	   in	   response	   to	   injury	   there	   are	   several	   reports	   that	   LSEC	   may	   also	  
respond	  to	  VEGF-­‐A	  activation	  by	  secreting	  hepatotrophic	  factors.	  	  In	  2003	  LeCouter	  
and	   colleagues	   reported	   support	   of	   hepatocyte	   proliferation	   by	   endothelial	  
expressed	   factors,	  namely	   interleukin-­‐6	   (IL-­‐6),	  and	  hepatocyte	  growth	   factor	   (HGF)	  
(LeCouter	   et	   al.,	   2003).	   	   Interestingly	   this	  was	   reported	   to	  occur	  by	   stimulation	  of	  
LSEC	  VEGFR-­‐1.	  	  The	  authors	  were	  also	  able	  to	  show	  that	  VEGF-­‐A	  primed	  LSEC	  were	  
able	   to	   ameliorate	   chemical	   liver	   injury	   suggesting	   that	   this	   mechanism	   may	   be	  
active	   in	  many	   forms	   of	   liver	   injury.	   	  More	   recently	   however	   these	   findings	   have	  
been	   questioned.	   	   Using	   endothelial	   cell	   specific	   conditional	   VEGFR-­‐2	   knock-­‐out	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animals	  Ding	  and	  co-­‐workers	   identified	  a	  role	  for	  endothelial	  cell	  expressed	  Wnt2b	  
and	   HGF	   in	   response	   to	   VEGF-­‐A	   stimulation	   in	   the	   regeneration	   of	   the	   liver	   after	  
partial	  hepatectomy	  (Ding	  et	  al.,	  2010).	  	  In	  this	  model	  there	  was	  no	  evidence	  of	  an	  
effect	  of	  VEGFR-­‐1	  stimulation.	  	  These	  findings	  together	  illustrate	  the	  importance	  of	  
LSEC	  in	  liver	  regeneration	  and	  suggest	  a	  wider	  role	  in	  the	  protection	  of	  the	  liver	  from	  
injury.	  	  Specifically	  the	  findings	  further	  support	  a	  role	  for	  endothelial	  cell	  expressed	  
factors	   regulated	   by	   VEGFR-­‐2	   stimulation	   in	   the	   maintenance	   of	   normal	   liver	  
function.	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1.9	   Epidemiology	  and	  natural	  history	  of	  hepatitis	  C	  virus	  infection	  
	  
Hepatitis	   C	   virus	   (HCV)	   infection	   poses	   a	   global	   health	   problem:	   as	   many	   as	   170	  
million	  individuals	  are	  chronically	  infected	  with	  HCV	  (Shepard	  et	  al.,	  2005).	  	  Many	  of	  
these	  individuals	  will	  develop	  progressive	  disease	  culminating	  in	  the	  development	  of	  
cirrhosis,	  end-­‐stage	  liver	  disease,	  and/or	  primary	  liver	  cancer.	  	  	  
	  
The	   identification	   of	  HCV	  was	   predated	  by	   a	   realisation	   that	   blood	  products	  were	  
contaminated	  with	   an	   agent	   that	   caused	   hepatitis.	   	   At	   this	   time,	   hepatitis	   A,	   and	  
hepatitis	   B	   had	   been	   identified	   and	   the	   clinical	   syndrome	   was	   named	   post-­‐
transfusion	  non-­‐A,	  non-­‐B	  hepatitis	  (Alter	  et	  al.,	  1975,	  Feinstone	  et	  al.,	  1975).	  	  Later	  
HCV	  was	  the	  first	  virus	  identified	  from	  its	  genetic	  material	  that	  was	  identified	  in	  the	  
serum	   of	   an	   affected	   patient	   (Choo	   et	   al.,	   1989).	   	   Since	   that	   time	   the	   molecular	  
characteristics	  of	  HCV	  have	  been	  extensively	  studied.	  	  HCV	  has	  been	  classified	  as	  the	  
only	   member	   of	   the	   Hepacivirus	   genus	   in	   the	   family	   Flaviviridae.	   	   There	   are	   6	  
recognised	   genotypes	   that	   are	   evolutionarily	   distinct	   and	   that	   have	   important	  
clinical	   differences	   (Simmonds	   et	   al.,	   2005).	   	   The	   phylogenetic	   tree	   of	   these	  
genotypes	  is	  illustrated	  in	  Fig.	  1-­‐6.	  	  	  
	  












Figure	  1-­‐6.	  	  Phylogenetic	  analysis	  of	  HCV	  non-­‐structural	  protein	  5B.	  	  	  
This	  evolutionary	  tree	  illustrates	  the	  sequence	  diversity	  in	  the	  HCV	  RNA	  dependent	  
RNA	  polymerase	  and	   the	  highlights	   the	  areas	  of	  high-­‐diversity,	  e.g.	   Southeast	  Asia	  
(Simmonds	  et	  al.,	  2005).	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In	   the	   United	   Kingdom	   approximately	   230,000	   individuals	   are	   chronically	   infected	  
with	  HCV,	   largely	   as	   a	   consequence	  of	   injecting	   drug	   use	   (Harris	   et	   al.,	   2012).	   	  Of	  
those	   individuals	   ever	   infected	  with	   HCV	   approximately	   1	   in	   5	   will	   spontaneously	  
clear	   infection,	   a	   process	   associated	   with	   a	   vigorous	   immune	   response	   to	   acute	  
infection	  (Rehermann,	  2009).	  	  Of	  the	  remaining	  80%	  there	  is	  progressive	  liver	  injury	  
over	   the	   course	  of	  many	   years.	   	   At	   30	   years	   after	   infection	   approximately	   30%	  of	  
individuals	  will	  have	  cirrhosis	  and	  be	  at	  risk	  of	  complications	  of	  liver	  disease	  (Ferenci	  
et	   al.,	   2007).	   	   Due	   to	   the	   of	   patterns	   of	   injecting	   drug	   use	   many	   of	   these	   were	  
infected	  at	  a	  young	  age	  and	  there	  is	  a	  large,	  and	  growing,	  group	  of	  individuals	  who	  
have	  advanced	  HCV	  infection	  and	  are	  now	  beginning	  to	  present	  with	  complications	  
of	   liver	  disease	  and	  primary	   liver	  cancer	   (Davis	  et	  al.,	  2010).	   	  Since	  at	   this	  stage	  of	  
disease	   no	   medical	   treatment	   is	   available	   HCV	   infection	   is	   a	   leading	   reason	   to	  
consider	  liver	  transplantation	  (Brown,	  2005).	  
	  
At	  the	  early	  stages	  of	  disease	  individuals	  chronically	  infected	  with	  HCV	  often	  have	  no	  
symptoms.	   	   Thus,	   only	   a	   minority	   of	   patients	   have	   ever	   been	   diagnosed	   with	  
infection	  (Culver	  et	  al.,	  2000)	  and	  only	  this	  subgroup	  of	  patients	  can	  be	  considered	  
for	  treatment.	  	  For	  this	  reason	  birth	  cohort	  screening	  has	  recently	  been	  proposed	  as	  
a	   method	   to	   reduced	   morbidity	   and	   mortality	   from	   HCV	   infection	   in	   the	   United	  
States	  	  (Rein	  et	  al.,	  2012).	  	  Following	  identification	  of	  infected	  individuals	  it	  is	  logical	  
to	   consider	   antiviral	   treatment.	   	   Indeed	   the	   non-­‐specific	   antiviral	   interferon	   alpha	  
was	  used	   to	   treat	  non-­‐A,	  non-­‐B	  hepatitis	  before	  HCV	  was	   identified	   (Jacyna	  et	  al.,	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1989).	   	   Over	   the	   course	   of	   the	   next	   20	   years	   there	   were	   pharmacological	  
improvements	   to	   that	   treatment,	   and	   the	   addition	   of	   ribavirin	   but	   treatment	  
outcomes	   remained	   sub-­‐optimal	   with	   cure	   only	   possible	   in	   less	   than	   50%	   of	   all	  
patients	   treated	   (McHutchison	   et	   al.,	   2009).	   	   However	   recent	   developments	   of	  
directly	  acting	  antivirals	  for	  HCV	  infection	  promise	  much	  for	  the	  outlook	  of	  patients	  
with	  HCV	  infection.	  	  Two	  medicines,	  boceprevir	  and	  telaprevir,	  are	  now	  licensed	  for	  
treatment	  in	  combination	  with	  interferon	  and	  ribavirin	  (Rowe	  and	  Mutimer,	  2011).	  	  
These	   drugs	   that	   act	   to	   inhibit	   the	   viral	   protease	   increase	   cure	   rates	   to	  
approximately	   65%	   in	   genotype	   1	   but	   at	   the	   expense	   of	   an	   increased	   side	   effect	  
profile.	   	  There	  are	  many	  other	  medicines	   in	  development	  that	  promise	  to	   increase	  
cure	  rates	  to	  greater	  than	  80%	  (Poordad	  and	  Dieterich,	  2012).	  
	  
Liver	   transplantation	   has	   proved	   to	   be	   a	   successful	   (albeit	   limited)	   treatment	   for	  
patients	  with	  end-­‐stage	   liver	  disease	  and	  HCV	  infection.	   	  Following	   implantation	  of	  
the	   donor	   organ	   hepatitis	   C	   virions	   in	   the	   plasma	   rapidly	   enter	   the	   liver	   to	   re-­‐
establish	  infection	  (Garcia-­‐Retortillo	  et	  al.,	  2002,	  Powers	  et	  al.,	  2006,	  Dragun	  et	  al.,	  
2011).	  	  There	  is	  always	  a	  marked	  fall	  in	  plasma	  HCV	  RNA	  at	  the	  time	  of	  implantation.	  	  
One	  month	  later	  levels	  of	  plasma	  HCV	  RNA	  have	  usually	  increased	  to	  greater	  than	  1	  
log10	  higher	  than	  pre-­‐transplant.	  	  Short-­‐term	  outcomes	  after	  transplant	  are	  good	  but	  
the	  prognosis	  of	  patients	  with	  HCV	  later	  after	  transplant	  is	  inferior	  to	  recipients	  with	  
other	  underlying	  diseases	  (Mutimer	  et	  al.,	  2006).	  	  This	  is	  due	  to	  progressive	  fibrosis	  
in	  the	  allograft	  and	  graft	  loss	  due	  to	  recurrent	  disease	  (Rowe	  et	  al.,	  2008).	  	  There	  is	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therefore	   a	  need	   to	  develop	   strategies	   to	  prevent	   infection	  of	   the	   allograft	   at	   the	  
time	   of	   transplantation.	   	   In	   hepatitis	   B	   virus	   infection	   recurrent	   disease	   has	   been	  
effectively	  eradicated	  by	  a	  combination	  of	  hepatitis	  B	   immunoglobulin	  and	  specific	  
antivirals.	   	  Unfortunately	  strategies	  employing	  HCV	  immunoglobulin	  have	  not	  been	  
effective	  (Davis	  et	  al.,	  2005,	  Schiano	  et	  al.,	  2006)	  and	  the	  focus	  of	  attention	  has	  now	  
shifted	  to	  targeting	  the	  host	  proteins	  involved	  in	  HCV	  entry	  into	  hepatocytes.	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1.10	   Molecular	  biology	  of	  hepatitis	  C	  virus	  infection	  
	  
Since	   the	   identification	   of	   HCV	   as	   the	   causative	   agent	   of	   non-­‐A,	   non-­‐B	   hepatitis	  
many	   investigators	   struggled	   to	   establish	   cell	   culture	   systems	   to	   study	   the	   HCV	  
lifecycle	   (Lindenbach	   and	   Rice,	   2005,	  Moradpour	   et	   al.,	   2007).	   	   The	   difficulties	   in	  
visualising	   the	   virus,	   and	   in	   identifying	   infected	   cells	   in	   the	   liver	   (either	   by	   RNA	  
analysis	  or	  immunohistochemistry)	  initially	  gave	  the	  impression	  that	  viral	  replication	  
was	  inefficient.	  	  However	  it	  is	  now	  known	  that	  plasma	  titres	  are	  usually	  in	  the	  region	  
of	   106	   genome	   copies	   per	   mL,	   and	   that	   approximately	   1012	   viral	   particles	   are	  
produced	  per	   day	   (Neumann	  et	   al.,	   1998)	   indicating	   that	  HCV	   replication	   is	   highly	  
efficient	  in	  vivo.	  	  	  
	  
HCV	   is	   a	   single	   positive	   stranded	   RNA	   virus	   of	   approximately	   9.6kb	   in	   length.	   	   It	  
contains	  a	  single	  open	  reading	  frame	  (ORF)	  that	  is	  translated	  as	  a	  single	  polyprotein	  
comprising	  about	  3000	  amino	  acids.	  	  The	  ORF	  is	  flanked	  by	  conserved	  untranslated	  
regions	   (UTRs).	   	   The	   5’	   UTR	   contains	   an	   internal	   ribosome	   entry	   site	   (IRES)	   that	  
initiates	  translation	  of	  the	  polyprotein	  (Penin	  et	  al.,	  2004).	  	  The	  polyprotein	  codes	  10	  
proteins	  that	  are	  cleaved	  both	  during,	  and	  after	  translation.	  	  These	  proteins	  can	  be	  
separated	  into	  the	  structural,	  and	  non-­‐structural	  proteins	  (Fig.	  1-­‐8).	  	  Cleavage	  of	  the	  
structural	   proteins	   is	   achieved	  by	   the	   endoplasmic	   reticulum	   (ER)	   signal	   peptidase	  
whilst	   the	   non-­‐structural	   proteins	   are	   cleaved	   by	   the	   two	   viral	   proteases	  
(Moradpour	  et	  al.,	  2007).	  The	  structural	  proteins	  that	  form	  the	  physical	  structure	  of	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the	  viral	  particle	  are	   the	  core	  protein,	  and	   the	  envelope	  proteins	  E1,	  and	  E2.	   	  The	  
non-­‐structural	   (NS)	  proteins	   include	  p7,	  an	   ion	  channel,	  the	  NS2	  protease,	  the	  NS3	  
serine	  protease,	  NS4B	  and	  NS5A,	  and	  NS5B,	   the	  RNA	  dependent	  RNA	  polymerase.	  	  
Notably	  this	  polymerase	   lacks	  a	  proof	  reading	  mechanism	  and,	  when	  coupled	  with	  
the	  high	  levels	  of	  replication,	  this	  accounts	  for	  the	  high	  level	  of	  genetic	  diversity	  that	  
is	  seen	  within	  and	  between	  HCV	  genotyopes.	  	  








Figure	  1-­‐7.	  	  Hepatitis	  C	  virus	  polyprotein	  structure	  and	  processing.	  	  	  
	  
The	  HCV	  genome	  encodes	  a	   single	  polyprotein	  with	  3	   structural	  proteins	   (core,	  E1	  
and	  E2),	  and	  7	  non-­‐structural	  proteins	  (p7,	  NS2,	  NS3,	  NS4A,	  NS4B,	  NS5A	  and	  NS5B).	  	  
Functions	  of	   the	   individual	  proteins	   (where	  known)	  are	  noted	  below	  the	   individual	  
proteins.	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Intact	  HCV	  particles	  remain	  to	  be	  well	  visualised	  but	  are	  approximately	  50-­‐65nm	  in	  
diameter	   (Shimizu	   et	   al.,	   1996).	   	   Virions	   present	   in	   the	   plasma	  may	   be	   associated	  
with	  low	  density	  lipoprotein	  (LDL),	  and	  very	  low	  density	  lipoprotein	  (vLDL)	  and	  these	  
particles	   (termed	   lipoviral	   particles	   [LVP])	   are	   likely	   the	   infectious	   fraction	  
(Bassendine	  et	  al.,	  2011).	   	  Virions	  may	  also	  be	  associated	  with	   immunoglobulin,	  or	  
free	   in	   the	   plasma	   (Thomssen	   et	   al.,	   1993).	   	   The	   association	   of	   HCV	  with	   vLDL	   is	  
interesting	  since	  it	  has	  long	  been	  recognised	  that	  HCV	  is	  frequently	  associated	  with	  
lipid	   accumulation	   in	   the	   liver	   (Asselah	   et	   al.,	   2006).	   	   The	   relatively	   recent	  
development	   of	   tools	   to	   study	   HCV	   assembly	   and	   release	   have	   identified	   critical	  
roles	  for	  pathways	  related	  to	  vLDL	  synthesis	  (Gastaminza	  et	  al.,	  2008,	  Bartenschlager	  
et	   al.,	   2011).	   	   	   For	   example,	   the	   role	   of	   apolipopritein	   E	   (apoE)	   in	   vLDL	   assembly	  
suggested	  a	  role	  in	  the	  HCV	  lifecycle.	   	  Several	   laboratories	  have	  now	  reported	  that	  
apoE	  is	  required	  for	  assembly	  and	  virus	  production	  (Chang	  et	  al.,	  2007,	  Benga	  et	  al.,	  
2010).	  	  
	  
Tools	  to	  study	  hepatitis	  C	  virus	  replication	  
The	   first	   in	   vitro	   generated	   tools	   for	   studying	   HCV	   replication	   were	   cDNA	   clones.	  	  
The	  RNA	  transcripts	  from	  these	  clones	  were	  infectious	  in	  the	  chimpanzee	  –	  the	  only	  
animal	  model	  thus	  far	  identified	  to	  be	  permissive	  for	  HCV	  –	  after	  direct	  inoculation	  
into	  the	  liver	  (Kolykhalov	  et	  al.,	  1997).	  	  These	  clones	  however	  were	  not	  infectious	  in	  
cell	  culture.	  	  The	  most	  significant	  step	  forward	  in	  the	  study	  of	  viral	  replication	  was	  in	  
the	  development	  of	  the	  replicon	  system	  (Lohmann	  et	  al.,	  1999).	  	  This	  system	  initially	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used	  a	  consensus	  sequence	  from	  an	   infected	  human	  liver	  but	  to	  allow	  selection	  of	  
replicating	  clones	  the	  structural	  region	  was	  replaced	  by	  a	  neomycin	  resistance	  gene.	  	  
This	   development	   allowed	   for	   the	   first	   time	   characterisation	   of	   the	   viral	   proteins,	  
and	   the	   testing	   of	   replication	   inhibitors	   in	   vitro.	   	   Importantly	   for	   the	   efficient	  
replication	  of	  HCV	  a	  number	  of	  mutations	   (cell	   culture	  adaptations)	  were	  required	  
(Blight	  et	  al.,	  2000,	  Lohmann	  et	  al.,	  2001)	  although	  the	  significance	  of	  these	  remains	  
uncertain.	  	  	  
	  
These	  developments	   required	   the	  use	  of	   the	  human	  hepatoma	   cell	   line	  Huh-­‐7	   for	  
the	   most	   efficient	   replication.	   	   Shortly	   after	   the	   replicon	   system	   was	   developed	  
Blight	   and	   colleagues	   established	   a	   sub-­‐clone	   of	   Huh-­‐7,	   termed	   Huh-­‐7.5	   that	   was	  
more	  permissive	  for	  HCV	  replication	  (Blight	  et	  al.,	  2002).	  	  It	  was	  later	  demonstrated	  
that	   this	  was	   due	   to	   a	  mutation	   in	   the	   retinoic	   acid-­‐inducible	   gene	   I	   (RIG-­‐I)	   and	   a	  
failure	   of	   intracellular	   double	   stranded	  RNA	   sensing	   in	   these	   cells	   (Sumpter	   et	   al.,	  
2005).	  
	  
To	   study	  other	   aspects	   of	   the	   viral	   lifecycle,	   i.e.	   viral	   entry,	   assembly,	   and	   release	  
additional	   tools	  were	   necessary.	   	   To	   study	   viral	   entry	   pseudoparticles	   bearing	   the	  
HCV	  envelope	  proteins	  were	  developed	  and	  were	  termed	  HCVpp.	  	  Rather	  than	  using	  
the	   HCV	   machinery	   for	   assembly	   and	   replication	   however,	   these	   particles	   were	  
generated	  using	  a	  retroviral	  core	  protein	  and	  carry	  a	  reporter	  gene	  (most	  frequently	  
luciferase)	   (Drummer	  et	  al.,	  2003,	  Hsu	  et	  al.,	  2003,	  Bartosch	  et	  al.,	  2003a).	   	  These	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particles	   enabled	   the	   functional	   studies	   of	   the	   envelope	   glycoproteins,	   and	   also	  
permitted	  characterisation	  of	  the	  host	  entry	  receptors.	  	  The	  initial	  proof	  of	  concept	  
was	   confirmed	   by	   neutralisation	   of	   entry	   by	   anti-­‐E2	   antibodies	   and	   serum	   from	  
patients	  infected	  with	  HCV.	  	  These	  particles,	  whilst	  powerful,	  did	  not	  allow	  study	  of	  
the	  complete	  viral	  lifecycle.	  
	  
The	   ability	   to	   study	   the	   entire	   viral	   lifecycle	   was	   realised	   in	   2005	   when	   several	  
laboratories	   reported	   a	   strain	   of	   HCV	   that	   were	   able	   to	   replicate	   in	   cell	   culture	  
(HCVcc)	   (Lindenbach	   et	   al.,	   2005,	   Wakita	   et	   al.,	   2005,	   Zhong	   et	   al.,	   2005).	   	   This	  
genotype	  2a	  strain	  from	  a	  Japanese	  patient	  with	  fulminant	  hepatitis	  (termed	  JFH-­‐1)	  
is	  able	  to	  replicate	  at	  high	  efficiency	  in	  vitro	  although	  the	  reasons	  why	  have	  not	  been	  
identified.	   	   Importantly	   the	   replication	   of	   HCVcc	   in	   Huh-­‐7.5	   cells	   resulted	   in	   the	  
production	  of	  infectious	  viruses	  into	  the	  culture	  media	  that	  could	  be	  used	  to	  infect	  
both	   naïve	   cells,	   and	   the	   chimpanzee	   (Lindenbach	   et	   al.,	   2006).	   	   Later	   multiple	  
chimaeric	  viruses	  were	  developed	  expressing	  the	  structural	  proteins	  of	  viruses	  from	  
all	   of	   the	   major	   genotypes	   (Gottwein	   et	   al.,	   2009)	   but	   replication	   required	   the	  
presence	  of	   the	   JFH-­‐1	  strain	   replication	  complex.	   	  This	   system	  has	  accelerated	   the	  
study	   and	   understanding	   of	   processes	   relating	   to	   the	   steps	   of	   viral	   entry	   post-­‐
binding,	  as	  well	  as	  packaging	  and	  release	  that	  until	  the	  development	  of	  HCVcc	  was	  





The	  viral	  lifecycle	  
To	  gain	  access	  to	  cells	  to	  permit	  replication	  the	  virus	  must	  first	  interact	  with	  specific	  
cellular	   receptors	   on	   the	   cell	   surface.	   	   Following	   attachment	   the	   particle	   is	  
internalised	  by	  clathrin-­‐dependent	  endocytosis	  (Blanchard	  et	  al.,	  2006)	  and	  after-­‐pH	  
dependent	  fusion	  of	  the	  viral	  and	  endosomal	  membranes	  the	  encapsulated	  genome	  
is	  released	  into	  the	  cytoplasm	  (Koutsoudakis	  et	  al.,	  2006,	  Tscherne	  et	  al.,	  2006).	  	  This	  
process	   allows	   the	   template	   RNA	   to	   be	   translated	   on	   the	   endoplasmic	   reticulum,	  
and	   then	   transcribed	   by	   the	   viral	   polymerase.	   	   The	   viral	   replication	   complex	   is	  
composed	   of	   viral	   proteins,	   viral	   RNA,	   and	   abnormal	   cellular	  membranes	   that	   are	  
recognised	  as	  a	  hallmark	  of	  all	  known	  positive	  strand	  RNA	  viruses	  (Moradpour	  et	  al.,	  
2007).	   	   This	   membraneous	   web	   structure	   was	   identified	   as	   the	   site	   of	   HCV	  
replication	  and	  is	  induced	  by	  the	  actions	  of	  NS4B	  (Gosert	  et	  al.,	  2003,	  Moradpour	  et	  
al.,	  2004).	   	  Nascent	  particles	  are	  then	  assembled	  and	  packaged	  in	  the	  endoplasmic	  
reticulum	   by	   co-­‐opting	   pathways	   of	   lipoprotein	   assembly	   (Bartenschlager	   et	   al.,	  
2011).	   	   These	   complete	   virions	   are	   then	   released	   into	   blood	   to	   further	   propagate	  
infection.	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1.11	   Hepatitis	  C	  virus	  entry	  receptors	  
	  
The	  process	  of	  HCV	  entry	  is	  complex	  and	  requires	  the	  engagement	  of	  multiple	  host	  
cell	   receptors	   for	   internalisation	   of	   the	   virion.	   	   The	   study	   of	   HCV	   entry	   was	  
accelerated	   by	   the	   development	   of	   the	   HCVpp	   system	   and	   these	   early	   reports	  
identified	  tetraspanin	  CD81	  as	  the	  first	  member	  of	  the	  HCV	  receptor	  complex	  (Hsu	  
et	   al.,	   2003).	   	   Further	   receptors,	   scavenger	   receptor	  BI	   (SR-­‐BI)	   (Grove	  et	   al.,	   2007,	  
Kapadia	  et	  al.,	  2007),	  and	  tight	   junction	  proteins	  claudin-­‐1	   (Evans	  et	  al.,	  2007)	  and	  
occludin	   (Ploss	   et	   al.,	   2009)	   have	   subsesequenly	   been	   identified	   as	   necessary	  
components	   of	   host	   cell	   machinery	   for	   viral	   entry.	   	   Latterly	   additional	   factors	  
regulating	   entry	   have	   been	   identified	   including	   epidermal	   growth	   factor	   receptor	  
(EGFR),	  ephrin	  receptor	  A2	  (EphA2)	  (Lupberger	  et	  al.,	  2011),	  and	  	  Niemann-­‐Pick	  C1-­‐
like-­‐1	  (NPC1L1)	  (Sainz	  et	  al.,	  2012).	  
	  
Tetraspanin	   CD81	   –	   CD81	   is	   ubiquitously	   expressed	   on	   nucleated	   cells	   but	   the	  
physiological	  functions	  of	  CD81	  are	  only	  partially	  defined.	  	  For	  instance,	  it	  forms	  part	  
of	   the	   B-­‐cell	   receptor	   complex	   but	   is	   dispensable	   for	   B-­‐cell	   function.	   	   CD81	   was	  
identified	   as	   a	   potential	   receptor	   for	   HCV	   from	   its	   ability	   to	   bind	   soluble	   E2	  
glycoprotein	   (Pileri	   et	   al.,	   1998).	   	   Subsequent	   functional	   assays	   have	   shown	   that	  
both	   antibodies	   to	   CD81,	   and	   soluble	   CD81,	   potently	   inhibit	   infection	   by	   HCVpp	  
(Zhang	  et	  al.,	  2004,	  McKeating	  et	  al.,	  2004,	  Lavillette	  et	  al.,	  2005)	  as	  well	  as	  HCVcc	  
(Lindenbach	  et	  al.,	  2005,	  Wakita	  et	  al.,	  2005,	  Zhong	  et	  al.,	  2005).	  	  Whilst	  the	  CD81-­‐
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negative	   Hep-­‐G2	   cell	   line	   is	   non-­‐permissive	   to	   HCVpp	   infection,	   transduction	   of	  
functional	  CD81	  into	  these	  cells	  restores	  susceptibility	  (Flint	  et	  al.,	  2006).	   	  Recently	  
studies	  have	  shown	  that	   ligation	  of	  CD81	  by	  antibody,	  recombinant	  E2,	  and	  HCVcc	  
can	  stimulate	  CD81	  endocytosis	  suggesting	  a	  role	  for	  HCV	  in	  stimulating	  endocytosis	  
and	   particle	   internalisation	   (Farquhar	   et	   al.,	   2012).	   	   These	   findings	   also	   suggested	  
that	   the	   increase	   in	   internalisation	   of	   CD81	   in	   HCV	   infection	   is	   related	   to	   the	  
involvement	   of	   partner	   proteins	   since	   deletion	   of	   the	   C-­‐terminal	   of	   CD81	   had	   no	  
effect	  on	  receptor	  internalisation.	  
	  
Scavenger	   receptor	  BI	   (SR-­‐BI)	  –	  SR-­‐BI	  was	  first	   identified	  for	  its	  ability	  to	  bind	  high	  
density	  lipoprotein	  (HDL)	  in	  the	  liver	  (Acton	  et	  al.,	  1996).	  	  In	  a	  process	  similar	  to	  the	  
identification	  of	  CD81	  as	  a	  cellular	  receptor	  for	  HCV	  SR-­‐BI	  was	  initially	  shown	  to	  bind	  
soluble	   E2	   glycoprotein	   (Scarselli	   et	   al.,	   2002).	   	   Functional	   studies	   have	   confirmed	  
that	  SR-­‐BI	  mediates	  HCV	  entry	   in	  both	  HCVpp	  and	  HCVcc	  systems	  (Lavillette	  et	  al.,	  
2005,	  Kapadia	  et	  al.,	  2007,	  Grove	  et	  al.,	  2007,	  Dreux	  et	  al.,	  2009).	  	  Importantly	  only	  
SR-­‐BI	  and	  not	  CD81	  is	  able	  to	  interact	  with	  HCVcc	  when	  these	  proteins	  are	  expressed	  
in	  Chinese	  hamster	  ovary	  cells	  indicating	  that	  SR-­‐BI	  might	  act	  as	  the	  primary	  cellular	  
receptor	   for	  HCV	   infection	  (Evans	  et	  al.,	  2007).	   	  The	  role	  of	  SR-­‐BI	   in	  HCV	  entry	  has	  
been	  further	  confirmed	  in	  chimeric	  mouse	  model	  using	  a	  well	  characterised	  panel	  of	  
monoclonal	  antibodies	   (Catanese	  et	  al.,	  2010,	  Meuleman	  et	  al.,	  2012,	  Lacek	  et	  al.,	  
2012).	   	  These	  studies	  have	  highlighted	  the	  therapeutic	  potential	  of	  targeting	  SR-­‐BI,	  
particularly	  at	  the	  time	  of	  liver	  transplantation.	  	  Indeed	  ITX5061,	  a	  chemical	  inhibitor	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of	  SR-­‐BI	   (Syder	  et	  al.,	  2011),	   is	  under	   study	   in	  patients	  undergoing	   transplantation	  
(clinicaltrials.gov	  NCT01292824).	  
	  
Claudin-­‐1	  (CLDN-­‐1)	  –	  Following	  the	  development	  of	  the	  HCVpp	  system	  it	  was	  noted	  
that	   expression	   of	   both	   CD81	   and	   SR-­‐BI	   alone	   was	   insufficient	   to	   render	   cells	  
permissive	  to	  infection	  indicating	  that	  other	  receptors	  were	  required	  (Bartosch	  et	  al.,	  
2003b,	   Hsu	   et	   al.,	   2003).	   	   The	   tight	   junction	   protein	   CLDN-­‐1	   was	   subsequently	  
identified	   as	   a	   late-­‐step	   cellular	   receptor	   for	   HCV	   entry	   (Evans	   et	   al.,	   2007).	  	  
Expression	   of	   CLDN-­‐1	   in	   cells	   expressing	   CD81	   and	   SR-­‐B1	   rendered	   those	   cells	  
permissive	   to	   HCV	   entry	   and	   conversely	   knockdown	   of	   CLDN-­‐1	   in	   cells	   normally	  
susceptible	   to	  HCV	  entry	  blocked	  virus	  entry.	   	  CLDN-­‐1	   functions	  as	  a	   tight	   junction	  
protein	   and	   notably	   is	   expressed	   at	   high	   levels	   around	   the	   bile	   canuliculi	   of	  
hepatocytes	   (Reynolds	   et	   al.,	   2008).	   	   The	   role	   of	   interactions	   between	   CD81	   and	  
CLDN-­‐1	  has	   been	   investigated	   to	  begin	   to	   understand	   the	  nature	  of	  HCV	   receptor	  
complexes.	   	   These	   studies	   have	   identified	   direct	   interactions	   between	   these	   two	  
molecules	   that	   are	   essential	   for	   HCV	   entry	   (Harris	   et	   al.,	   2010).	   	   Interestingly	   site	  
directed	  mutagenesis	  studies	  have	  identified	  amino	  acid	  residues	  on	  CD81	  that	  are	  
necessary	  for	  interactions	  with	  CLDN-­‐1	  but	  not	  for	  E2	  binding	  confirming	  a	  role	  for	  
protein	   protein	   interactions	   in	   HCV	   entry	   (Davis	   et	   al.,	   2012).	   	   Indeed	   CD81	   and	  
claudin-­‐1	  have	  been	  observed	  to	  co-­‐internalise	  on	  live-­‐cell	  imaging	  (Farquhar	  et	  al.,	  
2012).	   	   Claudin-­‐1	  monoclonal	   antibodies	   have	   also	   been	   described	   (Fofana	   et	   al.,	  
2010).	   	   These	   neutralise	   HCVpp	   and	   HCVcc	   and	   a	   role	   the	   prevention	   of	   graft	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infection	   has	   been	   suggested	   however	   the	   critical	   role	   of	   claudins	   in	   gut	   tight	  
junction	  integrity	  (Tamura	  et	  al.,	  2011,	  Wada	  et	  al.,	  2012)	  provides	  a	  cautionary	  note	  
in	  the	  clinical	  development	  of	  these	  antibodies.	  
	  
Occludin	   (OCLN)	   –	   The	  most	   recently	   identified	   cellular	   receptor	   for	  HCV	   is	   also	   a	  
tight	  junction	  protein	  and	  like	  CLDN-­‐1	  is	  involved	  in	  maintenance	  of	  bile	  canulicular	  
structures.	   	   OCLN	  was	   identified	   as	   a	   receptor	   for	   HCV	   through	   several	   strategies	  
including	  RNA	   interference	  of	  occludin	   (rendering	  permissive	   cells	   non-­‐permissive)	  
and	   transduction	   of	   normally	   non-­‐permissive	   cells	   with	   occludin	   (rendering	   those	  
cells	  susceptible	  to	  HCV	  entry)	   (Ploss	  et	  al.,	  2009,	  Liu	  et	  al.,	  2009,	  Benedicto	  et	  al.,	  
2008).	   	   Direct	   interactions	   between	   E2	   and	   occludin	   have	   not	   been	   confirmed	  
(Wilson	   et	   al.,	   2012)	   suggesting	   that	   OCLN	  may	   form	   part	   of	   a	   receptor	   complex	  
rather	  than	  directly	  interacting	  with	  the	  virus	  to	  stimulate	  entry.	  
	  
Epidermal	  growth	  factor	  receptor	  (EGFR)	  and	  ephrin	  receptor	  A2	  (EphA2)	  –	  These	  
two	   receptor	   kinases	   were	   identified	   in	   a	   siRNA	   screen	   of	   host	   cell	   kinases	  
(Lupberger	  et	  al.,	  2011).	   	  The	  effect	  of	  blockade	  of	   receptor	   function	  was	   to	  block	  
the	  formation	  of	  the	  CD81-­‐CLDN-­‐1	  receptor	  complex	  and	  thereby	  to	  block	  the	  entry	  
of	   HCV.	   	   This	   was	   especially	   relevant	   since	   an	   EGFR	   kinase	   inhibitor	   (erlotinib)	   is	  
licensed	  for	  the	  treatment	  of	  malignant	  disease.	  	  Furthermore	  the	  authors	  showed	  a	  
modest	  decrease	  in	  HCV	  RNA	  load	  in	  a	  chimaeric	  mouse	  model	  treated	  with	  erlotinib	  
suggesting	  a	  role	  in	  the	  treatment	  of	  HCV	  infection.	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Niemann-­‐Pick	  C1-­‐like-­‐1	  (NPC1L1)	  –	  This	  is	  a	  cholesterol	  absorption	  receptor	  that	  has	  
also	  recently	  been	  implicated	  in	  HCV	  entry	  (Sainz	  et	  al.,	  2012).	  	  The	  function	  of	  this	  
receptor	  in	  vivo	  is	  in	  cholesterol	  homeostasis	  and	  thus	  in	  HCV	  infection	  NPC1L1	  may	  
interact	  directly	  with	  LVPs	   to	   remove	   lipid	  and	  promote	   interaction	  of	  E2	  with	   the	  
cellular	   receptors	   for	   HCV,	   or	   rather	   may	   alter	   cholesterol	   levels	   and	   membrane	  
function.	  
	  
There	  are	  a	  number	  of	  other	  receptors	  that	  function	  as	  possible	  attachment	  factors	  
and	  are	  present	  on	  cell	  types	  in	  the	  liver.	  	  The	  functions	  of	  these	  molecules	  are	  less	  
clear	  in	  the	  process	  of	  HCV	  entry.	  
	  
Glycosaminoglycans	   (GAGs)	   –	   These	   polysaccharides	   present	   on	   the	   surface	   of	  
many	  cells	   that	  have	  been	  shown	  to	  bind	  HCV	  amongst	  other	  viruses	   (Barth	  et	  al.,	  
2006,	   Germi	   et	   al.,	   2002).	   	   The	   ability	   to	   bind	   HCV	   is	   thought	   to	   be	   through	  
interaction	  with	  the	  E2	  glycoprotein	  and	  occurs	  preferentially	  with	  highly	  sulphated	  
GAGs	   such	   as	   heparin	   sulphate	   (Barth	   et	   al.,	   2003,	   Barth	   et	   al.,	   2006,	   Jiang	   et	   al.,	  
2012).	   	   These	   molecules	   are	   unlikely	   to	   be	   specific	   receptors	   for	   HCV	   but	   may	  
facilitate	  interactions	  between	  HCV	  and	  its	  high	  affinity	  receptors.	  	  
	  
LDL	   receptor	   (LDLR)	   –	   In	   the	   plasma	   of	   infected	   patients,	   HCV	   particles	   are	  
associated	  with	  LDL	  and	  several	  investigators	  have	  suggested	  that	  LDLr	  is	  involved	  in	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the	  uptake	  of	  HCV	  into	  hepatocytes	  (Germi	  et	  al.,	  2002,	  Agnello	  et	  al.,	  1999,	  Molina	  
et	   al.,	   2007).	   	   There	   is	   some	   evidence	   that	   liver	   sinusoidal	   endothelial	   cells	   may	  
modulate	  uptake	  of	  HCV-­‐like	  particles	  in	  to	  hepatocytes	  via	  the	  LDLR	  (Nahmias	  et	  al.,	  
2006).	  
	  
C-­‐type	   lectins	   (DC-­‐SIGN	   and	   L-­‐SIGN)	   –	   These	   molecules	   are	   not	   expressed	   on	  
hepatocytes	   but	   rather	   predominantly	   on	   dendritic	   cells	   or	   liver	   sinusoidal	  
endothelial	   cells	   respectively	   (Soilleux	  et	  al.,	   2002,	   Jameson	  et	  al.,	   2002,	   Lai	  et	  al.,	  
2006).	  They	  have	  been	  shown	  to	  bind	  HCV	  and	  other	  viruses	  but	  due	  to	  their	  pattern	  
of	   expression	   they	   are	   unlikely	   to	   be	   involved	   in	   infection	   (Lozach	   et	   al.,	   2003,	  
Pohlmann	  et	  al.,	  2003).	  	  However,	  some	  investigators	  have	  reported	  transmission	  of	  
DC-­‐SIGN	   or	   L-­‐SIGN	   bound	  HCVpp	   to	   susceptible	   cells	   in	   co-­‐culture	   and	   thus	   these	  
molecules	  may	  have	  a	  role	  in	  capturing	  HCV	  and	  transferring	  infection	  to	  permissive	  
hepatocytes	  (Lozach	  et	  al.,	  2004,	  Cormier	  et	  al.,	  2004).	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1.12	   The	  role	  of	  LSEC	  in	  HCV	  pathogenesis	  
	  
The	  liver	  is	  the	  major	  site	  of	  HCV	  replication.	  	  Studies	  of	  HCV	  kinetics	  on	  treatment	  
and	  during	  liver	  transplantation	  indicate	  that	  >95%	  of	  viral	  replication	  occurs	  in	  that	  
organ	  (Powers	  et	  al.,	  2006).	  	  In	  the	  liver	  it	  is	  the	  hepatocyte	  that	  has	  been	  identified	  
as	  the	  target	  cell	  for	  HCV	  however	  only	  a	  minority	  of	  hepatocytes	  (10-­‐20%)	  appear	  
to	   be	   infected	   at	   any	   one	   time	   (Powers	   et	   al.,	   2006,	   Liang	   et	   al.,	   2009).	   	   Viral	  
replication	   is,	  as	  noted	  above,	  efficient	  with	  sufficient	  particles	  produced	  each	  day	  
(1012)	   to	   infect	   every	   hepatocyte	   in	   the	   liver.	   	  Hepatocytes	   are	   typically	   long-­‐lived	  
and	   although	   there	   is	   evidence	   for	   increased	   hepatocyte	   turnover	   in	   chronic	   HCV	  
infection	  (Marshall	  et	  al.,	  2005)	  it	  is	  highly	  unlikely	  that	  infection	  rates	  are	  that	  high.	  	  
Furthermore	  the	  half-­‐life	  of	  viral	  particles	  in	  the	  plasma	  is	  short	  (Garcia-­‐Retortillo	  et	  
al.,	   2002,	   Powers	   et	   al.,	   2006)	   and	   these	   divergent	   aspects	   of	   chronic	   infection	  
together	  suggest	  that	  efficient	  clearance	  systems	  are	  in	  place.	  
	  
The	  function	  of	  LSEC	  in	  HCV	  infection	  has	  been	  largely	  suggested	  to	  involve	  capture	  
of	   circulating	   virions,	   concentrating	   these	   in	   the	   sinusoid	  and	  permitting	  access	   to	  
underlying	   hepatocytes	   (Lai	   et	   al.,	   2006,	   Protzer	   et	   al.,	   2012).	   	   Indeed	   LSEC	   have	  
previously	  been	  shown	  to	  bind	  soluble	  E2	  glycoprotein	  (Lai	  et	  al.,	  2006)	  but	  to	  date	  
there	  have	  been	  no	  studies	  with	  viruses	  capable	  of	   the	  complete	   lifecycle	   in	  vitro.	  	  
The	  roles	  of	  LSEC	  as	  a	  dynamic	  sieve,	  and	  as	  a	  clearance	  mechanism	  suggests	  rather	  
that	   LSEC	  will	   permit	   access	   to	   hepatocytes	   through	   fenestrated	   sieve	   plates,	   and	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will	   clear	   particles	   that	   are	   taken	   up	   from	   the	   circulation	   (Elvevold	   et	   al.,	   2008,	  
Ganesan	  et	  al.,	  2011).	  	  The	  fate	  of	  these	  particles	  is	  not	  clear	  but	  the	  mathematical	  
modelling	   indicates	   that	   large	  scale	  clearance	   is	  occurring,	  and	  the	  biology	  of	  LSEC	  
suggests	  that	  it	  is	  these	  cells	  that	  are	  responsible.	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1.13	   Aims	  of	  the	  project	  
	  
The	   overarching	   aim	  of	   this	   project	  was	   to	   understand	   the	   role	   of	   liver	   sinusoidal	  
endothelial	  cells	  (LSEC)	  in	  hepatitis	  C	  virus	  infection	  (HCV)	  of	  the	  liver.	  	  The	  specific	  
objectives	   of	   the	   studies	  were	   to	   firstly	   understand	   the	   role	   of	   LSEC	   in	   the	   initial	  
infection	  of	  hepatocytes,	  and	  secondly	  to	  define	  the	  role	  of	  LSEC	  in	  chronic	  infection	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Chapter	  2	   	  	  Materials	  and	  methods	  
	  
2.1	   Tissue	  samples	  
	  
All	   tissue	   samples	  were	   from	   the	  Queen	   Elizabeth	   Hospital	   Birmingham	   Liver	   and	  
Hepatobiliary	   Unit.	   	   All	   material	   was	   collected	   in	   accordance	   with	   local	   research	  
ethics	  approvals	  and	  with	  the	  consent	  of	  patients	  or	  their	  relatives.	   	  Diseased	   liver	  
was	   from	   patients	   undergoing	   liver	   transplantation	   for	   various	   indications	   whilst	  
normal	   tissue	   was	   from	   tissue	   surplus	   to	   requirements	   at	   transplant,	   or	   from	  
macroscopically	  normal	   liver	  removed	  during	  resection	  of	  secondary	   liver	  tumours.	  	  
Tissue	   was	   processed	   fresh	   for	   isolation	   of	   constituent	   cell	   types:	   liver	   sinusoidal	  
endothelial	   cells,	   biliary	   epithelial	   cells,	   or	   activated	   liver	   myofibroblasts.	   	   For	  
messenger	  RNA	  and	  protein	  analysis	  1x1x1cm	  cubes	  of	  liver	  were	  snap	  frozen	  over	  
liquid	  nitrogen	  and	  stored	  at	  -­‐80oC	  until	  required	  for	  processing.	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2.2	  	   Isolation	  of	  liver	  sinusoidal	  endothelial	  cells	  
	  
An	   enzymatic	  method	  was	   used	   to	   isolate	   liver	   sinusoidal	   endothelial	   cells	   (LSEC)	  
(Lalor	  et	  al.,	  2006,	  Liaskou	  et	  al.,	  2010,	  Shetty	  et	  al.,	  2011).	   	  Approximately	  30g	  of	  
liver	   tissue	   was	   cut	   into	   small	   pieces	   and	   digested	   with	   a	   type-­‐1A	   collagenase	  
digestion	   (2mg/mL,	   Sigma	   Aldrich	   Ltd.,	   Poole,	   UK)	   for	   45	   minutes	   at	   37oC.	  	  
Undigested	  tissue	  was	  removed	  by	  passing	  the	  digestate	  through	  a	  sterile	  fine	  mesh.	  	  
The	   remaining	   suspension	   was	   sedimented	   by	   centrifugation.	   	   This	   crude	   cell	  
preparation	  was	  then	  separated	  over	  a	  Percoll	  gradient	  (Amersham	  Biosciences,	  GE)	  
at	  450g	   for	  25	  minutes.	   	  Biliary	  epithelial	   cells	  were	   removed	  by	   indirect	  magnetic	  
separation	   using	   an	   antibody	   raised	   against	   the	   epithelial	   cell	   surface	   specific	  
glycoprotein	   HEA-­‐125	   (10μg/mL,	   Progen	   Biotechnik,)	   followed	   by	   a	   secondary	  
antibody	   conjugated	   to	   magnetic	   beads	   (sheep	   anti-­‐mouse	   Dynabeads,	   Dynal,	  
Invitrogen).	   	   Sinusoidal	   endothelial	   cells	   were	   isolated	   from	   the	   remaining	  
suspension	  by	  a	  second	   immunomagnetic	  separation	  using	  antibody	  raised	  against	  
CD31	  (10μg/mL)	  directly	  conjugated	  to	  magnetic	  beads.	  
	  
During	   this	   process	   those	   biliary	   epithelial	   cells	   isolated	   were	   retained.	   	   The	  
remaining	   cell	   suspension	   following	   isolation	   of	   biliary	   epithelial	   cells	   and	   LSEC	  




2.3	  	   Cell	  culture	  	  
	  
All	   tissue	   culture	   work	   was	   done	   in	   class	   II	   microflow	   safety	   cabinets.	   	   Aseptic	  
techniques	  were	  used	  at	  all	  times.	  	  All	  cells	  were	  maintained	  at	  37oC	  and	  5%	  CO2.	  
	  
Primary	  cells	  
Isolated	   LSEC	   were	   cultured	   in	   endothelial	   basal	   media	   (Invitrogen,	   UK)	  
supplemented	   with	   10%	   heat	   inactivated	   normal	   human	   AB	   serum	   (HD	   Supplies,	  
Bucks,	  UK),	  10ng/mL	  hepatocyte	  growth	  factor	  (HGF),	  10ng/mL	  vascular	  endothelial	  
growth	   factor	   A	   (VEGF-­‐A,	   both	   PeproTech,	   UK),	   and	   50units/mL	   benzylpenicillin	  
streptomycin	  (Gibco)	  in	  type	  I	  collagen	  (Sigma-­‐Aldrich)	  coated	  flasks.	  
	  
Activated	   liver	   myofibroblasts	   (aLMF)	   were	   cultured	   in	   gelatin-­‐coated	   flasks	   in	  
Dulbecco’s	  modified	  Eagle	  medium	  (DMEM)	  (Gibco,	  California,	  USA),	  supplemented	  
with	   10%	   foetal	   bovine	   serum,	   1%	   glutamine,	   and	   50units/mL	  
benzylpenicillin/streptomycin.	  
	  
Biliary	  epithelial	  cells	  (BEC)	  were	  cultivated	  on	  type	  I	  collagen	  coated	  flasks.	  	  Growth	  
media	  consisted	  of	  DMEM	  supplemented	  with	  10%	  human	  serum,	  and	  50units/mL	  
benzylpenicillin/streptomycin.	   	   In	   addition,	   the	   following	  growth	   factors	   and	  drugs	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were	   added:	   epidermal	   growth	   factor	   (Peprotech,	   10ng/mL),	   HGF	   (10ng/ml),	  
triiodothyronine	   (Sigma-­‐Aldrich,	   2nM),	   insulin	   (Sigma-­‐Aldrich,	   0.124U/mL),	  
hydrocortisone	   (Queen	  Elizabeth	  Hospital	  Birmingham,	  2µg/mL),	  and	  cholera	   toxin	  
(Sigma-­‐Aldrich,	   10ng/mL).	   	   For	   each	   of	   these	   non-­‐parenchymal	   cell	   types	   spent	  
media	  was	  replaced	  every	  3	  days.	  	  
	  
Primary	  human	  hepatocytes	  were	  a	  gift	  from	  Dr	  Ragai	  Mitry	  (King’s	  College	  Hospital,	  
London).	  	  These	  were	  isolated	  according	  to	  published	  protocols	  (Mitry,	  2009,	  Mitry	  
et	   al.,	   2010)	   and	  maintained	   in	  Williams	   Essential	   Eagles	  Medium	   (Sigma-­‐Aldrich),	  
supplemented	   with	   10%	   human	   serum,	   1%	   L-­‐glutamine,	   1%	   non-­‐essential	   amino	  
acids	   and	   50units/ml	   benzylpenicillin/streptomycin.	   	   Spent	   media	   were	   replaced	  
daily.	  
	  
Human	   umbilical	   vein	   endothelial	   cells	   (HUVEC)	   were	   a	   gift	   from	   Professor	   Roy	  
Bicknell.	   	   These	   cells	   were	   isolated	   according	   to	   laboratory	   protocols,	   and	   were	  
maintained	   in	   human	   endothelial	   basal	   media,	   supplemented	   with	   10%	   heat	  
inactivated	  normal	   human	  AB	   serum	  and	   50units/ml	   benzylpenicillin/streptomycin	  
on	  gelatin	  coated	  tissue	  culture	  plastic	  for	  the	  purposes	  of	  experiments	  outlined	  in	  
this	  thesis.	  
	  




Huh-­‐7.5	   cells	   (provided	   by	   C.	   Rice,	   Rockefeller	   University,	   New	   York,	   USA)	   were	  
cultured	   in	  DMEM,	   supplemented	  with	   10%	   foetal	   bovine	   serum,	   1%	   L-­‐glutamine,	  
1%	  non-­‐essential	  amino	  acids	  and	  50units/mL	  benzylpenicillin/streptomycin.	  	  
	  
Chinese	  Hamster	  Ovary	  (CHO)	  cells	  were	  from	  the	  American	  Type	  Culture	  Collection,	  
Virginia	  USA	  and	  were	  maintained	   in	   F12	  medium	   (Invitrogen)	   supplemented	  with	  
1%	  non-­‐essential	  amino	  acids	  and	  50units/ml	  benzylpenicillin/streptomycin	  (Gibco).	  	  
CHO	  cells	  stably	  expressing	  SR-­‐BI	  were	  previously	  generated	  as	  described	  (Grove	  et	  
al.,	  2007).	  	  	  	  
	  
Cell	  culture	  
Cells	  were	  cultured	  in	  conditions	  described	  above	  and	  growth	  was	  assessed	  using	  an	  
inverted	  phase	  contrast	  microscope.	  	  The	  cells	  were	  monitored	  daily	  for	  normal	  cell	  
morphology,	   changes	   in	   media	   colour	   and	   clarity,	   and	   cell	   density.	   	   When	  
appropriate	   cells	   were	   passaged	   using	   proteolytic	   enzymes:	   TrypLE	   (Trypsin	   like	  
enzyme	   Express,	   Invitrogen)	   for	   primary	   cells,	   and	   trypsin	   (Gibco)	   for	   cell	   lines.	  	  
Culture	  media	  was	  discarded	  and	  cells	  washed	   in	  sterile	  phosphate	  buffered	  saline	  
(PBS).	   	   An	   appropriate	   volume	   of	   proteolytic	   enzyme	   was	   added	   and	   cells	   were	  
incubated	  for	  1-­‐5	  minutes	  before	  gentle	  agitation	  to	  ensure	  that	  cells	  were	  detached.	  	  
PBS	   was	   then	   added	   to	   the	   cells	   and	   the	   suspension	   centrifuged	   at	   550g	   for	   5	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minutes.	   	   The	   pelleted	   cells	   were	   then	   resuspended	   in	   fresh	   growth	   media	   into	  
(where	  necessary,	  coated)	  tissue	  culture	  plastic	  flasks.	  
	  
Freezing	  cells	  
Stored	  cells	  were	  preserved	  in	  liquid	  nitrogen.	  	  After	  pelleting	  the	  cells	  as	  above	  cells	  
were	   resuspended	   in	   freezing	   media	   (95%	   FBS,	   5%	   DMSO	   [Sigma-­‐Aldrich])	   and	  
transferred	  into	  cryovials	  for	  freezing.	  	  Cryovials	  were	  placed	  in	  a	  MrFrosty	  freezing	  
container	  (Wessigton	  Cryogenics)	  and	  transferred	  to	  a	  -­‐80oC	  freezer.	  	  After	  overnight	  
storage	  the	  cryovials	  were	  transferred	  to	  liquid	  nitrogen.	  
	  
When	   cells	   were	   required	   for	   experiments	   cryovials	   were	   removed	   from	   liquid	  
nitrogen,	   thawed,	  washed	   in	  PBS,	  and	  centrifuged	  to	   remove	  cellular	  debris.	   	  Cells	  
were	   then	   counted	   and	   viability	   assessed	   using	   trypan	   blue	   exclusion.	   	   Cells	  were	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2.4	  	  	   Antibodies	  and	  reagents	  
	  
The	  antibodies	  used	  in	  these	  studies	  are	  listed	  in	  Table	  2-­‐1,	  and	  growth	  factors	  and	  
proteins	  are	  listed	  in	  Table	  2-­‐2.	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Primary	  antibodies	   	   	   	  
Antigen	   Clone	   Application(s)	   Source	  
CD81	   2s.131	   FC	   In	  house	  
SR-­‐BI	   R25	   FC	   T.Huby,	   Université	   Pierre	   et	  
Marie	  Curie	  
Claudin-­‐1	   Polyclonal	  sera	   FC	   T	   Baumert,	   Université	   de	  
Strasbourg	  
Occludin	   OC-­‐3F10	   FC	   Invitrogen	  
L-­‐SIGN	   604	   IF	   R&D	  Systems	  
NS5A	   9E10	   IF	   C	  Rice,	  Rockefeller	  University	  
VEGFR-­‐1	   IMC-­‐18F1	   Neutralisation	   Imclone	  
VEGFR-­‐1	   321	   WB	   R&D	  Systems	  
VEGFR-­‐2	   IMC-­‐1121	   Neutralisation	   Imclone	  
VEGFR-­‐2	   55B11	   WB/IHC	   Cell	  Signalling	  
Phospho-­‐VEGFR-­‐2	  
(Tyr1175)	  
19A10	   WB	   Cell	  Signalling	  
BMP4	   757	   WB/Neutralisation	   R&D	  Systems	  
β-­‐actin	   AC-­‐74	   WB	   Sigma	  Aldrich	  Ltd.	  
VEGF-­‐A	   293	   Neutralisation	   R&D	  Systems	  
p38	  MAPK	   9212	   WB	   Cell	  Signalling	  
Phospho-­‐p38	  MAPK	   9211	   WB	   Cell	  Signalling	  
	   	   	   	  
	   	   	   	  
Secondary	  antibodies	   	   	   	  
Name	   Antigen	   Application(s)	   Source	  
Mouse	  Alexa	  Fluor	  488	   Mouse	  IgG	   IF/FC	   Molecular	  Probes,	  Invitrogen	  
Rat	  Alexa	  Fluor	  488	   Rat	  IgG	   IF/FC	   Molecular	  Probes,	  Invitrogen	  
Mouse/rabbit	  
universal	  
Mouse/rabbit	  IgG	   IHC	   Vector	  Laboratories	  
Anti-­‐mouse-­‐HRP	   Mouse	  IgG	   WB	   GE	  Healthcare	  
Anti-­‐rabbit-­‐HRP	   Rabbit	  IgG	   WB	   GE	  healthcare	  
Anti-­‐goat-­‐HRP	   Goat	  IgG	   WB	   Santa	  Cruz	  Biotechnology	  
	  
Table	  2-­‐1.	  Antibodies	  used	  in	  this	  study.	  	  
Applications	   listed	   are:	   FC,	   flow	   cytometry;	   IF,	   immunofluorescence;	   IHC,	  






Name	   Source	   Concentration	  
VEGF-­‐A	   Peprotech	   Various	  
VEGF-­‐E	   RELIATech	   10ng/mL	  
PlGF	   Peprotech	   10ng/mL	  
BMP4	   Peprotech	   Various	  
HGF	   Peprotech	   10ng/mL	  
PD98059	   Sigma-­‐Aldrich	   10	  μM	  
SB203580	   Sigma-­‐Aldrich	   Various	  
Wortmannin	   Sigma-­‐Aldrich	   10	  μM	  
U73122	   Sigma-­‐Aldrich	   10	  μM	  
	  
Table	  2-­‐2.	  Growth	  factors	  and	  chemicals	  used	  in	  this	  study.	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2.5	   Routine	  techniques	  
	  
Indirect	  immunofluorescence	  
Liver	   sinusoidal	   endothelial	   cells	   were	   seeded	   at	   4x104	   cells	   per	   well	   on	   type	   I	  
collagen	  coated	  borosilicate	  glass	  coverslips	  and	  cultured	  until	  confluent.	  	  Cells	  were	  
fixed	   in	   ice-­‐cold	  methanol	   for	  5	  minutes,	  washed	  and	   then	  permeablised	  with	  PBS	  
containing	   0.5%	   bovine	   serum	   albumin	   and	   saponin	   for	   30	   minutes.	   	   Cells	   were	  
incubated	  with	  primary	  antibody	  for	  one	  hour	  in	  PBS,	  1%	  BSA,	  and	  1%	  saponin.	  	  Cells	  
were	   then	   washed	   three	   times	   and	   incubated	   with	   the	   appropriate	   Alexa-­‐488	  
conjugated	   anti-­‐species	   secondary	   antibody	   diluted	   1:1000	   in	   PBS-­‐BSA-­‐saponin	   at	  
room	   temperature.	   	   Finally	   cells	   were	   washed	   three	   times	   in	   PBS-­‐BSA-­‐saponin,	  
counterstained	  with	  4’,6’-­‐diamidino-­‐2-­‐phenylindole	   (DAPI)	   (Invitrogen)	   in	  PBS	   for	  5	  
minutes	  and	  coverslips	  mounted	  on	  glass	  slides	  (ProLong	  Gold	  Antifade,	  Invitrogen).	  	  
Slides	  were	  viewed	  with	  a	  Nikon	  Eclipse	  TE2000-­‐S	  microscope	  at	  a	  magnification	  of	  
x200	  and	  images	  taken	  using	  a	  Hamamatsu	  C4742-­‐65	  camera	  (Nikon).	  
	  
Flow	  cytometry	  for	  HCV	  receptor	  expression	  
For	   CD81,	   SR-­‐BI	   and	   claudin-­‐1	   staining	   2x105	   cells	   were	   incubated	   in	   phosphate-­‐
buffered	  saline	  containing	  1%	  bovine	  serum	  albumin	  and	  0.01%	  sodium	  azide.	   	  For	  
occludin	   staining	   2x105	   cells	  were	   fixed	   in	   1%	  paraformaldehyde	   and	   incubated	   in	  
phosphate-­‐buffered	  saline	  containing	  1%	  BSA	  and	  1%	  saponin.	  	  2μg	  receptor	  specific	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antibody	  or	   irrelevant	   IgG	  controls	  were	   incubated	   in	  cells	   in	  azide	  for	  30	  minutes.	  	  
Unbound	   antibody	   was	   removed	   by	   washing.	   	   Secondary	   anti-­‐mouse,	   anti-­‐rat	   or	  
anti-­‐rabbit	  Alex-­‐488	  conjugated	  antibodies	  were	  incubated	  with	  cells	  for	  a	  further	  30	  
minutes	  and	  the	  cells	  washed	  and	  fixed	  in	  1%	  paraformaldehyde.	  	  Antibody	  binding	  
was	  assessed	  by	  flow	  cytometry	  using	  a	  FACSCalibur	  (BD	  Biosciences)	  and	  data	  were	  
analysed	  with	  FlowJo	  software	  (TreeStar).	  
	  
Western	  blotting	  
LSEC	  were	  lysed	  in	  situ	  in	  ice-­‐cold	  lysis	  buffer	  (CelLytic	  MT,	  Sigma-­‐Aldrich)	  containing	  
protease	  (Complete,	  Roche),	  and	  phosphatase	  (Roche)	  inhibitors	  for	  30	  minutes	  on	  
ice.	   	   Whole	   liver	   samples	   were	   homogenised	   in	   M-­‐tubes	   (Miltenyi)	   using	   a	  
gentleMACS	   dissociator	   (Miltenyi).	   	   Lysates	   were	   clarified	   by	   centrifugation	  
(20,000xg	   for	   15	   minutes)	   and	   the	   supernatant	   stored	   at	   -­‐20oC.	   	   Protein	  
concentration	  was	  determined	  using	  the	  Protein	  Assay	  Reagent	  (Pierce)	  according	  to	  
the	  manufacturer’s	  instructions	  (Fig.	  2-­‐1).	  	  	  
	  










Figure	  2-­‐1.	  	  BCA	  protein	  assay	  standard	  curve.	   	  





















7%	  sodium	  dodecyl	  sulphate-­‐polyacrylamide	  gel	  electrophoresis	  gels	  were	  cast	  and	  
samples	   of	   equal	   protein	   content	   were	   prepared	   by	   adding	   equal	   amounts	   of	  
protein	   to	   4x	   Laemmli	   loading	   dye	   (H2O,	   30%	   v/v	   glycerol,	   6%	   SDS,	   0.2%	   v/v	  
bromophenol	  blue	  and	  0.2M	  Tris-­‐HCV;	  pH	  6.8)	  with	  (reducing	  conditions),	  or	  without	  
(non-­‐reducing	   conditions)	   10%	   2-­‐β-­‐mercaptoethanol.	   	   The	   total	   volume	   was	  
adjusted	   to	   20μL	   with	   H20	   and	   samples	   heat	   denatured	   at	   95oC	   for	   5	   minutes.	  	  
Samples	  were	  cooled	  before	  loading.	  
	  
20μg	   of	   protein	   lysates	   were	   loaded	   in	   addition	   to	   a	   prestained	   standard	   (Novex	  
Sharp,	   Invitrogen).	   	  Protein	  electrophoresis	  was	  performed	  at	  200V	  for	  35	  minutes	  
using	   the	   Mini	   Protean	   3	   system	   (Bio-­‐Rad	   Laboratories)	   and	   transferred	   to	  
polyvinylidene	   difluoride	   membranes	   (Millipore)	   at	   350A	   for	   60	   minutes.	  	  
Membranes	   were	   blocked	   with	   5%	   skimmed	   milk,	   or	   5%	   BSA	   and	   subsequently	  
incubated	   in	   blocking	   buffer	   with	   primary	   antibody.	   	   The	   blots	   were	   washed	   and	  
incubated	   with	   appropriate	   secondary	   antibodies	   conjugated	   to	   horseradish	  
peroxidase.	   	   The	   membranes	   were	   then	   repeatedly	   washed	   and	   immunoreactive	  
bands	  detected	  using	  enhanced	  chemoluminescence	  (Pico	  SuperSignal,	  Pierce).	  
	  
Cell	  proliferation	  assay	  
LSEC	  were	  seeded	  at	  2x104	  cells	  per	  well	  in	  a	  type	  I	  collagen	  coated	  24-­‐well	  plate	  in	  
endothelial	   basal	   media	   containing	   10%	   heat	   inactivated	   normal	   human	   serum,	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60μg/mL	   benzylpenicillin	   and	   100μg/mL	   streptomycin.	   	   After	   16	   hours	   LSEC	   were	  
treated	   in	   duplicate	   for	   72	   hours	   with	   recombinant	   VEGF-­‐A,	   VEGF-­‐E,	   or	   PlGF.	  	  
Following	   treatment	   LSEC	   were	   washed	   and	   incubated	   in	   200μl	   endothelial	   basal	  
media	   containing	   10%	   heat	   inactivated	   normal	   human	   AB	   serum,	   60μg/ml	  
benzylpenicillin	  and	  100μg/ml	  streptomycin	  plus	  10μl	  3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐5-­‐
(3-­‐carboxymethoxyphenyl)-­‐2-­‐(4-­‐sulphophenyl)-­‐2H-­‐tetrazolium	   (MTS)	   (Promega).	  	  
After	  2	  hours	  100μl	  of	  the	  MTS	  solution	  was	  removed	  and	  transferred	  to	  a	  96-­‐well	  
assay	   plate	   and	   absorbance	   measured	   at	   490nm	   in	   a	   microplate	   photometer	  
(Multiskan	  Ascent,	  Fischer	  Thermo	  Scientific).	   	  Relative	  cell	  number	  was	  calculated	  
by	  subtracting	  the	  mean	  absorbance	  from	  MTS	  solution	  alone	  from	  the	  readings	  for	  
the	  LSEC	  samples	  and	  then	  normalised	  to	  the	  untreated	  LSEC	  sample,	  i.e.	  the	  mean	  
absorbance	  of	  the	  untreated	  LSEC	  sample	  was	  defined	  as	  1.	  
	  
Immunohistochemistry	  
Tissue	  blocks	  fixed	  in	  formalin	  were	  obtained	  from	  tissue	  unused	  for	  transplantation.	  	  
Representative	  3μm	  sections	  were	  placed	  onto	  charged	  slides	  (Surgipath)	  and	  stored	  
at	  room	  temperature	  until	  required.	  	  Sections	  were	  de-­‐parafinised	  for	  10	  minutes	  in	  
Xylene	  (Surgipath)	  and	  then	  rehydrated	  in	  H2O.	  	  Endogenous	  peroxidase	  activity	  was	  
blocked	  by	   incubation	   in	  0.3%	  hydrogen	  peroxide	   in	  H2O.	   	  Epitopes	  were	  retrieved	  
by	  placing	  sections	   in	  EDTA	  (pH	  8.0)	  and	  this	  was	  then	  microwaved	  for	  20	  minutes	  




Sections	  were	  then	  mounted	  onto	  a	  Shandon	  Sequencer	  (Thermo	  Scientific).	  	  These	  
were	   blocked	   in	   2%	   casein	   (Vector	   Labs)	   diluted	   in	   Tris-­‐buffered	   saline	   (pH	   7.5).	  	  
Specimens	   were	   incubated	   with	   antibodies	   specific	   for	   VEGFR-­‐2	   or	   an	   irrelevant	  
isotype	  control	  overnight	  at	  4oC.	  	  Antibodies	  were	  diluted	  in	  Tris-­‐buffered	  saline	  with	  
0.1%	  Tween	  (TBS-­‐T)	  and	  5%	  goat	  serum.	  
	  
Specimens	  were	  washed	  with	  TBS-­‐T	  three	  times	  and	  then	  incubated	  with	  secondary	  
antibody	   reagent	   (ImPress	  Universal	  anti-­‐mouse	   IgG/anti-­‐rabbit	   IgG	  peroxidase	  kit,	  
Vector	   Labs)	   according	   to	   the	  manufacturer’s	   instructions.	   	   Specimens	  were	   again	  
washed	  three	  times	  in	  TBS-­‐T	  and	  antibodies	  were	  visualised	  with	  ImPact	  DAB	  Diluent	  
and	   Chromogen	   Kit	   (Vector	   Labs).	   	   Sections	   were	   then	   counterstained	   with	  
haematoxylin	  (Surgipath).	  	  Slides	  were	  mounted	  after	  xylene	  dehydration	  and	  were	  
sealed	  with	  24mm	  coverslips	  using	  DPX	  mounting	  reagent	  (VWR).	  	  Slides	  were	  dried	  
in	   a	   laminar	   fume	   cupboard	   overnight.	   	   Images	   were	   obtained	   the	   following	   day	  
using	  a	  Nikon	  Eclipse	  E400	  microscope	  (Nikon).	  	  Immunohistochemistry	  studies	  were	  
performed	  with	  the	  help	  of	  Dr	  Garrick	  Wilson.	  
	  
Messenger	  RNA	  extraction	  
Cell	  preparations	  (4x104	  cells)	  were	  lysed	  in	  situ	  whilst	  whole	  liver	  whole	  liver	  tissue	  
was	  disrupted	   in	  an	  M-­‐tube	  and	  using	   the	  gentle	  MACS	  dissociator.	   	   Total	   cellular	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RNA	   was	   extracted	   using	   the	   RNeasy	   mini	   kit	   (Qiagen)	   according	   to	   the	  
manufacturers	  instructions.	  
	  
Quantitative	  Reverse	  Transcriptase	  Polymerase	  Chain	  Reaction	  
Purified	   RNA	   was	   amplified	   for	   various	   target	   genes,	   including	   VEGF-­‐A,	   BMP4,	  
VEGFR-­‐1,	   and	   VEGFR-­‐2	   with	   commercially	   available	   quantification	   kits	   (Applied	  
Biosystems).	  	  HCV	  RNA	  was	  amplified	  using	  primers	  targeting	  a	  conserved	  region	  of	  
core	  (Primer	  Design).	  
	  
Reactions	  were	  conducted	  in	  triplicate	  for	  each	  condition	  in	  a	  single	  tube	  RT-­‐PCR	  in	  a	  
MicroAmp	  96	  optimal	   reaction	  plate	   (Applied	  Biosystems),	  and	   in	  accordance	  with	  
the	   manufacturers	   instructions	   (Cells	   Direct	   Kit,	   Invitrogen).	   	   Fluorescence	   was	  
monitored	   in	  a	   Stratagene	  RT-­‐PCR	  machine	   (MX3000P,	   Stratagene,	  Agilent).	   	   In	   all	  
reactions	   the	   housekeeping	   gene	   glyceraldehyde-­‐3-­‐phosphate	   dehydrogenase	  
(GAPDH)	  was	  included	  as	  an	  internal	  endogenous	  control	  for	  amplification	  efficiency	  
and	   RNA	   quantification	   (primer-­‐limited	   endogenous	   control;	   Applied	   Biosystems).	  	  
The	  PCR	  reaction	  was	  done	  using	  the	  following	  program:	  30	  mins	  at	  50oC,	  5	  mins	  at	  
95oC,	  followed	  by	  50	  cycles	  of	  15	  seconds	  at	  95oC	  and	  60	  seconds	  at	  60oC.	  
	  
In	  experiments	   to	  quantify	  HCV	  RNA	  a	  pre-­‐prepared	  standard	   (Primer	  Design)	  was	  











Figure	  2-­‐2.	  	  HCV	  RNA	  standard	  curve.	   	  

















2.6	   HCVpp	  generation	  and	  infection	  
	  
Hepatitis	  C	  virus	  pseudoparticles	  (HCVpp)	  were	  generated	  according	  to	  the	  method	  
of	   Hsu	   (Hsu	   et	   al.,	   2003).	   	   293T	   cells	   (American	   Type	   Culture	   Collection,	   Virginia,	  
USA)	  were	  transfected	  with	  two	  plasmids,	  one	  encoding	  human	   immunodeficiency	  
provirus	   expressing	   luciferase	   and	   the	   other	   containing	   the	   HCV	   strain	   H77	  
glycoproteins	   (E1	   and	   E2),	   the	   vesicular	   stomatitis	   virus	   (VSV)	   envelope,	   or	   the	  
murine	  leukaemia	  virus	  (MLV)	  envelope,	  or	  a	  no-­‐envelope	  control.	  	  Virus	  containing	  
supernatants	  were	  harvested	  after	  48	  hours,	  clarified	  and	  sterile	  filtered	  through	  a	  
0.45μm	  membrane.	   	  To	  assess	  HCV	  entry	  diluted	  virus	  containing	  supernatant	  was	  
incubated	  with	   target	   cells	   for	  8	  hours	   in	   triplicate	  wells,	   unbound	  virus	   removed,	  
and	   culture	  maintained	   in	   target	   cell	   specific	  medium.	   	  At	   72	  hours	  post	   infection	  
media	  was	  removed	  and	  cells	  lysed	  in	  cell	  lysis	  buffer	  (Promega).	  	  Luciferase	  activity	  
was	   detected	   after	   the	   addition	   of	   luciferase	   substrate	   and	   measurements	   were	  
taken	   for	   10	   seconds	   in	   a	   luminometer	   (Lumat	   LB9507).	   	   Infectivity	   expressed	   as	  
relative	   light	   units	   was	   calculated	   by	   subtracting	   the	   mean	   no-­‐envelope	   control	  
signal	  from	  the	  HCVpp,	  VSVpp	  or	  MLVpp	  signals.	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2.7	   HCVcc	  generation	  and	  infection	  
	  
Plasmids	   encoding	   full-­‐length	   HCV	   strain	   JFH-­‐1	   (provided	   by	   T.	   Wakita,	   National	  
Institute	  of	  Infectious	  Disease,	  Tokyo,	  Japan)	  (Lindenbach	  et	  al.,	  2005,	  Wakita	  et	  al.,	  
2005,	  Zhong	  et	  al.,	  2005)	  was	  used	  to	  generate	  RNA	  as	  previously	  described.	   	  RNA	  
transcripts	  were	  generated	  using	  the	  T7	  RNA	  polymerase	  kit	  (Promega)	  according	  to	  
the	  manufacturers	  instructions	  and	  electroporated	  into	  Huh-­‐7.5	  cells.	  	  To	  determine	  
productive	  infection	  cells	  were	  fixed	  in	  ice-­‐cold	  methanol	  and	  stained	  for	  NS5A	  with	  
the	   anti-­‐NS5A	   monoclonal	   antibody	   (9E10	   [provided	   by	   C.	   Rice,	   Rockefeller	  
University])	   and	   an	   Alexa	   488-­‐conjugated	   anti-­‐mouse	   IgG	   (Molecular	   Probes,	  
Invitrogen,	  Fig.	  2.3).	  	  The	  supernatants	  containing	  HCVcc	  were	  collected	  at	  72	  and	  96	  
hours	  post	  infection,	  pooled	  and	  stored	  immediately	  at	  -­‐80oC.	  	  	  
	  
Virus	   containing	   supernatant	  was	   used	   to	   infect	   target	   cells:	   cells	  were	   incubated	  
with	  HCVcc	  for	  four	  hours	  washed	  and	  then	  culture	  maintained	  for	  48	  or	  72	  hours	  as	  
specified	   in	   the	   figure	   legends.	   Infection	   was	   quantified	   by	   enumerating	   NS5A	  
positive	  foci	  in	  triplicate	  wells	  and	  infectivity	  defined	  as	  the	  number	  of	  focus	  forming	  
units	  per	  millilitre	  of	  inoculum.	  
	  







Figure	  2-­‐3.	  	  Electroporated	  Huh-­‐7.5	  cells	  stained	  for	  viral	  antigen	  NS5A.	  	  	  
Huh-­‐7.5	  cells	  were	  electroporated	  with	  JFH-­‐1	  RNA	  and	  48	  hours	  later	  were	  fixed	  in	  
ice-­‐cold	  methanol	  and	  stained	  for	  NS5A.	  	  Original	  magnification	  x200.	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2.8	  	  	   Liver	  sinusoidal	  endothelial	  cell	  transfer	  of	  infection	  to	  Huh-­‐7.5	  cell	  
	  
Isolated	  LSEC,	  CHO	  cells	  and	  Huh-­‐7.5	  cells	  were	  seeded	  at	  2x104	  cells	  per	  well	  of	  a	  
24-­‐well	   plate	   and	   maintained	   for	   16	   hours.	   	   The	   cells	   were	   then	   incubated	   with	  
HCVcc	  for	  two	  hours	  at	  37oC	  and	  then	  washed	  extensively	  to	  remove	  any	  unbound	  
viral	   particles.	   	   2x104	   Huh-­‐7.5	   cells	   per	   well	   were	   labelled	   with	   5μM	   5-­‐
chloromethylfluorescein	   diacetate	   (CMFDA)	   according	   to	   the	   manufacturers	  
instructions	   (Invitrogen)	   and	   then	   added	   to	   the	   LSEC,	   CHO	   cell	   or	   Huh-­‐7.5	   cell	  
monolayers	   and	   culture	   maintained	   for	   a	   further	   72	   hours	   in	   VEGF-­‐A	   free	   LSEC	  
medium.	   	  After	   this	   time	   the	  cells	  were	   fixed	   in	   ice-­‐cold	  methanol	  and	  stained	   for	  
NS5A.	  	  This	  is	  summarised	  in	  Fig.	  2-­‐4.	  
	  
	  









Figure	  2-­‐4.	  	  Transfer	  of	  infection	  from	  LSEC	  to	  Huh-­‐7.5	  cells.	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2.9	  	   Conditioned	  media	  
	  
Conditioned	  media	  was	  generated	  by	  seeding	  4x104	  cells	  per	  well	  of	  a	  24-­‐well	  plate	  
in	   1ml	   media.	   	   For	   LSEC	   cultures	   were	   maintained	   in	   endothelial	   basal	   media	  
containing	   10%	   heat	   inactivated	   human	   serum,	   50units/ml	  
benzylpenicillin/streptomycin.	   After	   24	   hours	   conditioned	   media	   was	   carefully	  
removed,	  aliquoted,	  and	  stored	  at	  -­‐20oC.	  	  	  
	  
For	   the	   treatment	   of	   Huh-­‐7.5	   cells	   conditioned	  media	   was	   diluted	   1:2	   with	   fresh	  
media.	  	  Conditioned	  media	  were	  then	  incubated	  with	  Huh-­‐7.5	  cells	  overnight	  before	  
incubation	   for	  4	  hours	  with	  HCVcc	  as	  described	  above.	   	  Following	  this	  conditioned	  
media	  were	  again	  incubated	  with	  Huh-­‐7.5	  cells	  for	  the	  duration	  of	  infection.	  
	  
Conditioned	   media	   were	   also	   fractionated	   using	   size	   exclusion	   membranes	   in	  
manufactured	   15mL	   tubes	   (VivaSpin	   6,	   Sartorius).	   	  Membranes	   excluding	   proteins	  
>100,	   >50,	   >30,	   and	   >10	   kDa	   were	   used.	   	   The	   media	   retrieved	   from	   above	   the	  
membrane	  were	  diluted	  with	  fresh	  media	  to	  equalise	  the	  volume	  of	  media	  to	  that	  of	  
the	  input.	  	  These	  media	  were	  further	  diluted	  1:2	  with	  fresh	  media	  to	  treat	  Huh-­‐7.5	  
cells	  as	  above.	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2.10	   Co-­‐culture	  of	  liver	  sinusoidal	  endothelial	  cells	  and	  Huh-­‐7.5	  cells	  
	  
LSEC	  and	  CHO	  cells	  were	  seeded	  at	  2x104	  per	  cm2	  in	  a	  type	  I	  collagen	  coated	  48-­‐well	  
plate	  in	  endothelial	  basal	  media	  containing	  10%	  heat	  inactivated	  normal	  human	  AB	  
serum,	  60μg/ml	  benzylpenicillin	  and	  100μg/ml	  streptomycin.	  	  After	  two	  hours	  Huh-­‐
7.5	   cells	   were	   added	   at	   2x104	   per	   cm2	   and	   cultured	   for	   16	   hours.	   	   Huh-­‐7.5	   cell	  
monoculture	  was	  established	  by	  seeding	  4	  x104	  per	  cm2	  in	  a	  type	  I	  collagen	  coated	  
48-­‐well	   plate	   in	   endothelial	   basal	   media	   containing	   10%	   heat	   inactivated	   human	  
serum,	   and	   50units/ml	   benzylpenicillin/streptomycin	   for	   16	   hours.	   After	   this	   time	  
cells	   were	   incubated	   with	   HCVcc	   JFH-­‐1	   for	   two	   hours,	   following	   this	   cells	   were	  
washed	   and	   media	   replaced	   with	   endothelial	   basal	   media	   containing	   10%	   heat	  
inactivated	   human	   serum,	   50units/ml	   benzylpenicillin/streptomycin	   for	   48	   hours.	  	  
Cells	  were	  then	  fixed	  in	  ice-­‐cold	  methanol	  and	  stained	  for	  NS5A.	  
	  
For	  experiments	  where	   co-­‐culture	  of	   LSEC	  and	  Huh-­‐7.5	   cells	  was	   required	  without	  
heterotypic	  cell	   contact	   specially	  designed	  slides	  were	  used	   (Ibidi	  2x9	  well	  μ-­‐Slide)	  
according	   to	   the	  manufacturers	   instructions.	   	   Briefly,	   LSEC	   and	  Huh-­‐7.5	   cells	  were	  
diluted	  to	  7.5x104	  per	  mL	  and	  50μl	  of	  the	  cell	  suspension	  was	  added	  to	  each	  of	  the	  
wells	  as	  illustrated	  in	  Fig.	  2-­‐5.	  	  The	  LSEC	  were	  seeded	  in	  the	  central	  minor	  well	  and	  
the	  Huh-­‐7.5	  cells	  were	  seeded	  in	  the	  surrounding	  wells.	  	  After	  two	  hours	  the	  major	  
well	   was	   flooded	   with	   500μl	   of	   media	   to	   allow	   exchange	   of	   soluble	   mediators	  








Figure	  2-­‐5.	  	  Ibidi	  2x9	  well	  μ-­‐Slide	  for	  co-­‐culture	  without	  heterotypic	  cell	  contact.	  	  	  
LSEC	  were	  seeded	  in	  the	  central	  well,	  in	  this	  example	  coloured	  green.	  	  Huh-­‐7.5	  cells	  
were	   then	   seeded	   in	   the	   surrounding	  wells,	   coloured	   blue.	   	   After	   attachment	   the	  
major	  well	  was	  flooded	  with	  media	  to	  allow	  exchange	  of	  soluble	  factors.	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2.11	   Endothelial	  cell	  microarray	  
	  
Sample	  preparation	  
LSEC	   and	   HUVEC,	   each	   from	   2	   independent	   donors,	   were	   grown	   in	   duplicate	   to	  
confluence	  on	  gelatin	  coated	  10cm	  tissue	  culture	  plastic	  plates	  in	  their	  usual	  growth	  
media.	   	   At	   pre-­‐confluence	   the	   media	   was	   changed	   to	   endothelial	   basal	   media	  
supplemented	   with	   10%	   human	   serum,	   and	   50units/ml	  
benzylpenicillin/streptomycin.	   	  Following	  culture	   for	  24	  hours	   the	  supernatant	  was	  
replaced	   with	   untreated,	   or	   VEGF-­‐A	   (10ng/mL)	   treated	   endothelial	   basal	   media	  
supplemented	  with	  10%	  human	  serum,	  and	  60μg/ml	  benzylpenicillin	  and	  100μg/ml	  
streptomycin.	  	  Treatment	  was	  maintained	  for	  18	  hours	  and	  cells	  were	  then	  lysed	  in	  
situ	  for	  RNA	  extraction	  as	  described	  above.	  
	  
Analysis	  of	  RNA	  quality	  
RNA	   extracted	   from	   each	   of	   the	   samples	   was	   quantified	   (NanoDrop,	   Thermo	  
Scientific)	   and	   the	  quality	   checked	  using	  a	  Bioanalyser	  machine	   (2100	  Bioanalyser,	  
Agilent).	  	  The	  outputs	  of	  these	  analyses	  are	  illustrated	  in	  Fig.	  2-­‐5.	  	  The	  RNA	  used	  for	  
microarray	   analysis	   was	   all	   of	   high	   quality.	   	   RNA	   integrity	   number	   (RIN)	   values	  
obtained	   using	   Bioanalyser	   analysis	   were	   all	   >9.5	   indicating	   that	   there	   was	   no	  
significant	  RNA	  degradation	  and	   initial	   concentrations	  of	  RNA	   isolated	  were	   in	   the	  







Figure	  2-­‐6.	  	  Bioanalyser	  output.	  	  	  
Indicative	   output	   of	   endothelial	   cell	   messenger	   RNA	   analysed	   for	   RNA	   quality.	  	  
Electropherogram	  of	  samples	  included	  in	  microarray	  analysis:	  Sample	  1-­‐4	  LSEC	  plus	  
VEGF-­‐A	  stimulation,	  Sample	  5-­‐8	  HUVEC	  minus	  VEGF-­‐A	  stimulation,	  and	  Sample	  9-­‐12	  
HUVEC	  plus	  VEGF-­‐A	  stimulation	  (A).	  	  Graphical	  interpretation	  of	  the	  electrophogram	  
for	  samples	  1	  and	  2(B).	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RNA	  labelling	  and	  hybridisation	  
Total	   messenger	   RNA	   was	   labelled	   using	   the	   Quick	   Amp	   Labelling	   Kit	   (Agilent)	  
according	   to	   the	   manufacturer’s	   instructions.	   	   Untreated	   endothelial	   cell	  
complementary	   RNA	   was	   labelled	   with	   Cy3,	   and	   VEGF-­‐A	   treated	   samples	   were	  
labelled	  with	  Cy5.	   	  A	  diagrammatic	   summary	  of	   the	  process	   is	  provided	   in	  Fig	   2-­‐6.	  	  
Following	  labelling	  complementary	  RNA	  was	  purified	  using	  an	  RNeasy	  kit.	  
	  
Hybridisation	   was	   done	   using	   a	   Gene	   Expression	   Hybridisation	   Kit	   (Agilent)	   in	  
conjunction	   with	   human	   4x44k	   oligo	   arrays	   (Agilent)	   and	   according	   to	   the	  
manufacturer’s	   protocol.	   	   825ng	   of	   each	   labelled	   sample	   was	   using	   in	   the	  
hybridisation	  protocol.	  	  The	  hybridisation	  was	  performed	  for	  17	  hours	  at	  65oC	  at	  10	  
revolutions	   per	   minute	   in	   a	   hybridisation	   oven.	   	   Following	   hybridisation	   the	  
microarray	   slides	  were	  washed	  according	   to	   the	  manufacturer’s	  protocols	   in	  wash	  
buffers	  1,	  and	  2,	  and	  then	  in	  wash	  buffer	  2	  at	  37	  oC,	  each	  for	  one	  minute.	  	  	  
	  
The	  slides	  were	  scanned	  immediately	  on	  an	  Agilent	  2505C	  scanner	  and	  images	  were	  
quantified	  using	  the	  Agilent	  Feature	  Extraction	  software	  (v.	  10.5.1.1).	  
	  




Extracted	  data	  were	  analysed	  using	  GeneSpring	  GX	  (v.	  7.3.1,	  Silicon	  Genetics).	   	  The	  
normalised	   log10	   ratio	   (Cy5/Cy3)	   representing	   the	   target	   to	   reference	   ratio	   was	  
calculated.	  	  Genes	  regulated	  more	  than	  1.8-­‐fold,	  with	  a	  false	  discovery	  rate	  of	  <0.05	  
were	  selected	  for	  further	  analysis.	  
	  
Microarray	   data	   were	   deposited	   in	   the	   National	   Center	   for	   Biotechnology	  
Information	  (NCBI)	  Gene	  Expression	  Omnibus	  database	  with	  the	  accession	  number	  
GSE41110.	  	  The	  record	  is	  available	  to	  view	  at:	  
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=hpgzpgiigemmynm&acc=GS





Figure	   2-­‐7.	   	   Schematic	   diagram	   of	   messenger	   RNA	   processing	   for	   2-­‐colour	  
microarray	  analysis.	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2.12	   Plasma	  HCV	  RNA	  quantitation	  during	  liver	  transplantation	  
	  
Patients	  enrolled	   in	   the	   ITX5061	   in	   liver	   transplant	   recipients	   study	  gave	   informed	  
consent	   to	   blood	   sampling	   during	   liver	   transplantation	   (clinicaltrials.gov	  
NCT01292824).	   	   Samples	   were	   taken	   at	   admission	   to	   hospital,	   at	   induction	   of	  
anaesthesia,	   at	   the	   time	   that	   there	   was	   no	   blood	   flow	   through	   the	   liver	   and	   the	  
patient	  was	  functionally	  anhepatic	  (literally	  no	  liver),	  and	  30	  minutes	  later.	  	  Further	  
samples	  were	   taken	   immediately	  before	  blood	   flowed	   through	   the	   implanted	   liver	  
(reperfusion),	  and	  1	  hour	  after	  that.	  	  Once	  the	  patient	  returned	  to	  the	  intensive	  care	  
unit	   further	   samples	   were	   taken	   at	   4	   hourly	   intervals	   in	   the	   first	   day	   after	  
transplantation.	  
	  
Plasma	   samples	   were	   sent	   directly	   to	   the	   regional	   Health	   Protection	   Agency	  
Laboratory	  at	  Birmingham	  Heartlands	  Hospital	  for	  analysis.	  	  HCV	  RNA	  was	  quantified	  
using	  the	  Roche	  Cobas	  Amplicor	  2.0	  assay.	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2.13	   Statistical	  analysis	  
	  
Results	  are	  shown	  as	  the	  mean	  ±	  standard	  deviation	  unless	  otherwise	  stated.	  	  Data	  
were	   compared	   using	   non-­‐parametric	   statistics	   since	   normality	   of	   small	   samples	  
cannot	  be	  readily	  established.	   	  For	  comparisons	  of	  two	  groups	  the	  Mann-­‐Witney	  U	  
test	   was	   used.	   	   For	   experiments	   containing	   multiple	   comparisons	   data	   were	  
compared	   with	   the	   Kruskal-­‐Wallis	   test	   using	   Dunn’s	   correction	   for	   multiple	  
comparisons.	   	   Linear	   regression	   analyses	   were	   used	   as	   indicated	   to	   explore	  
relationships	   between	   continuous	   variables,	   and	   to	   calculate	   protein	   and	   RNA	  
concentrations	  from	  standard	  curves.	   	  All	  statistical	  analyses	  were	  done	  with	  Prism	  
5.0	  (GraphPad).	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Chapter	  3	   Liver	  sinusoidal	  endothelial	  cells	  restrict	  HCV	  infection	  
	  
The	  liver	  is	  a	  large	  and	  complex	  organ	  containing	  multiple	  cell	  types	  including	  LSEC,	  
biliary	   epithelial	   cells,	   stellate	   and	   Kuppfer	   cells,	   as	   well	   as	   hepatocytes.	  	  
Hepatocytes	  are	  the	  only	  cell	  type	  in	  the	  liver	  known	  to	  support	  HCV	  replication	  and	  
the	  majority	   of	   published	   studies	   are	   limited	   to	   this	   cell	   type.	   	   In	   the	   liver	   lobule	  
hepatocytes	   are	   in	   close	   proximity	   to	   LSEC	   and	   blood	   flowing	   through	   the	   liver	   is	  
distributed	   through	   the	   sinusoids.	   	   Thus	   HCV	   particles	   in	   the	   blood	   are	   likely	   to	  
encounter	   LSEC	   and	   it	   is	   important	   to	   understand	   the	   role	   of	   LSEC	   in	   the	   virus	  
lifecycle.	  	  	  
	  
LSEC	  have	  been	  reported	  to	  express	  HCV	  receptor	  CD81	  and	  the	  lectin	  L-­‐SIGN	  and	  to	  
bind	   recombinant	   viral	   envelope	   proteins	   or	   virus	   like	   particles	   (Lai	   et	   al.,	   2006,	  
Nahmias	   et	   al.,	   2006).	   	   Since	   these	   studies	   indicated	   that	   LSEC	   express	   receptors	  
capable	   of	   binding	   HCV	   it	   has	   been	   suggested	   that	   the	   major	   role	   of	   LSEC	   is	   to	  
capture	   circulating	   virions	   and	   potentiate	   the	   infection	   of	   underlying	   hepatocytes	  
(Cormier	  et	  al.,	  2004,	  Lai	  et	  al.,	  2006,	  Lozach	  et	  al.,	  2004).	  The	  development	  of	  the	  
HCVcc	   system	  permits	   investigation	   into	   the	   role	  of	   non-­‐parenchymal	   cells	   in	  HCV	  
replication	  and	   I	  established	  co-­‐culture	  model	  systems	  to	  study	  the	  role	  of	  LSEC	   in	  
HCV	  lifecycle.	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3.1	   Phenotypic	  characteristics	  of	  isolated	  liver	  sinusoidal	  endothelial	  cells	  
	  
LSEC	   were	   isolated	   from	   whole	   liver	   as	   previously	   described	   (Lalor	   et	   al.,	   2006,	  
Liaskou	  et	  al.,	  2010,	  Shetty	  et	  al.,	  2011).	   	   In	  culture	  these	  cells	  maintained	  classical	  
endothelial	   cell	   morphology	   until	   at	   least	   passage	   4	   (Fig.	   3-­‐1A).	   	   Isolated	   cells	  
expressed	  calcium	  dependent	  the	  c-­‐type	  lectin	  L-­‐SIGN	  that	   is	  reported	  to	  be	  highly	  
expressed	  on	  liver	  endothelial	  cells	  in	  vitro	  and	  has	  been	  advocated	  as	  an	  excellent	  
marker	  of	  this	  cell	  type	  (Lalor	  et	  al.,	  2006)	  (Fig.	  3-­‐1B).	  







Figure	   3-­‐1.	   LSEC	   retain	   endothelial	   cell	   morphology	   and	   express	   characteristic	  
phenotypic	  marker	  L-­‐SIGN	  in	  vitro.	  	  	  
LSEC	   were	   propagated	   under	   standard	   culture	   conditions	   and	   fixed	   for	   phase	  
contrast	   microscopy	   (magnification	   x100)	   (A).	   	   Cells	   were	   stained	   for	   L-­‐SIGN	   as	  





HCV	   entry	   into	   permissive	   cells	   is	   dependent	   on	   four	   critical	   entry	   factors:	   CD81,	  
scavenger	  receptor	  BI	  (SR-­‐BI),	  claudin-­‐1,	  and	  occludin.	  Isolated	  LSEC	  were	  studied	  to	  
determine	   the	   expression	   of	   these	   four	   critical	   entry	   receptors	   using	   both	  
quantitative	  RT-­‐PCR	  (Fig.	  3-­‐2A),	  and	  flow	  cytometry	  (Fig.	  3-­‐2B).	  LSEC,	  as	  previously	  
described,	  expressed	  high	  levels	  of	  CD81,	  low	  levels	  of	  SR-­‐BI	  whilst	  claudin-­‐1	  was	  not	  
detected	  (Reynolds	  et	  al.,	  2008).	  	  However	  since	  that	  report	  occludin	  was	  described	  
as	  a	  critical	  factor	  for	  entry	  and	  LSEC	  express	  low	  levels	  of	  this	  entry	  factor	  (Fletcher	  
et	   al.,	   2012).	   	   In	   summary	   these	   data	   show	   that	   LSEC	   do	   not	   express	   the	   full	  
complement	   of	   HCV	   receptors,	   predicting	   that	   LSEC	   are	   non-­‐permissive	   for	   HCV	  
entry	  and	  subsequent	  infection.	  




Figure	  3-­‐2.	  	  HCV	  receptor	  expression	  in	  LSEC.	  	  	  
Expression	  of	  HCV	   receptors	  CD81,	   SR-­‐BI,	   claudin-­‐1,	   and	  occludin	  was	  assessed	  by	  
quantitative	  RT-­‐PCR	  in	  LSEC,	  Huh-­‐7.5	  cells	  and	  primary	  human	  hepatocytes	  (PHH)	  (A).	  	  
Gene	  expression	   is	   shown	   relative	   to	  expression	  of	  GAPDH	  using	   the	  2-­‐ΔCt	  method	  	  
(n=3	  LSEC	  and	  PHH	  donors).	  	  Flow	  cytometric	  analysis	  of	  HCV	  receptor	  expression	  (B).	  	  
The	  blue	  histogram	  shows	  receptor	  expression	  and	  the	  red	  histogram	  illustrates	  an	  

































































































































3.2	   LSEC	  do	  not	  support	  HCV	  infection	  
	  
Previous	   studies	   have	   suggested	   that	   LSEC	   are	   capable	   of	   binding	   infectious	   HCV	  
virions	  due	  to	  their	  expression	  of	  HCV	  capture	  receptors	  CD81	  and	  SR-­‐BI.	  However	  
there	   is	   limited	   evidence	   to	   confirm	   that	   LSEC	   associate	   with	   infectious	   virus	  
particles	  in	  this	  way.	  	  To	  ascertain	  whether	  LSEC	  did	  indeed	  interact	  with	  infectious	  
virions,	  LSEC	  were	  incubated	  with	  HCVcc	  for	  2	  hours	  and	  unbound	  virus	  removed	  by	  
washing.	   	   Cell	   bound	   virus	   was	  measured	   by	   quantitative	   RT-­‐PCR	   analysis	   of	   HCV	  
RNA	   genome	   copies.	   	   Huh-­‐7.5	   hepatoma	   cells	  were	   included	   as	   a	   positive	   control	  
and	  non-­‐human	  Chinese	  hamster	  ovary	   (CHO)	  cell	   line	  as	  a	  non-­‐permissive	  control	  
cell	   type.	   	   HCV	   binding	   was	   observed	   at	   similar	   levels	   between	   LSEC	   and	   the	  
permissive	   Huh-­‐7.5	   cell	   line	   and,	   more	   surprisingly,	   I	   also	   observed	   comparable	  
binding	  to	  the	  CHO	  cells	   (Fig.	   3-­‐3A).	   	  This	  binding	  was	  possibly	  due	  to	  non-­‐specific	  
interactions	  and	   to	  ascertain	  HCV	   receptor	  dependency	  of	  binding	  CHO	  cells	  were	  
transduced	  to	  express	  human	  SR-­‐BI	  (Grove	  et	  al.,	  2007).	  	  When	  HCVcc	  was	  incubated	  
with	   CHO	   cells	   or	   CHO-­‐SR-­‐BI	   cells	   comparable	   levels	   of	   virus	   bound	   to	   both	   the	  
parental	   and	   transduced	  CHO	   cells	   (Fig.	   3-­‐3B).	   	   This	   suggested	   the	   possibility	   that	  
non-­‐specific	   interactions	   rather	   than	   receptor	   dependent	   binding	   govern	   initial	  
interactions	  with	  infectious	  HCV	  in	  vivo.	  	  
	  
Following	   the	  observation	   that	   LSEC	  can	  bind	   infectious	  HCVcc	   I	  was	   interested	   to	  
know	  whether	   LSEC	   support	   HCV	   entry	   and	   replication.	   	   Screening	   for	   HCV	   entry	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using	  the	  HCVpp	  system	  I	  was	  unable	  to	  demonstrate	  productive	  entry	  into	  LSEC	  (Fig.	  
3-­‐3C).	   	   In	  keeping	  with	   this	   finding	   I	  was	  unable	   to	  detect	  HCVcc	   infection	  of	  LSEC	  
using	  either	   the	  genotype	  2a	   strain	   JFH-­‐1	   (Fig.	   3-­‐3D)	   and	   the	   chimeric	   genotype	  1	  
strain	  J6/JFH-­‐1	  (data	  not	  shown).	  	  Infectivity	  for	  the	  Huh-­‐7.5	  cell	  line	  was	  confirmed	  
with	   approximately	   100,000	   focus	   forming	   units	   (FFU)	   per	   mL	   of	   inoculum,	  
demonstrating	  that	  LSEC	  do	  not	  support	  HCV	  infection	  in	  vitro.	  







Figure	  3-­‐3.	  	  LSEC	  are	  non-­‐permissive	  for	  HCV	  infection.	  	  	  
LSEC,	  Huh-­‐7.5	  cells,	  and	  Chinese	  Hamster	  Ovary	  (CHO)	  cells	  were	  incubated	  at	  37oC	  
for	  2	  hours	  with	  JFH-­‐1	  HCVcc,	  unbound	  virus	  was	  removed	  by	  washing	  and	  the	  cells	  
lysed	  to	  measure	  HCV	  RNA	  by	  quantitative	  RT-­‐PCR	  (n=3	  LSEC	  donors)	  (A).	  	  Parental	  
CHO	  cells	  and	  those	  transduced	  to	  express	  human	  SR-­‐BI	  were	  treated	  identically	  and	  
HCV	  RNA	  binding	  assessed	  by	  quantitative	  RT-­‐PCR	   (n=2	   independent	  experiments)	  
(B).	  	  LSEC	  and	  Huh-­‐7.5	  cells	  were	  inoculated	  with	  HCVpp	  strain	  H77	  and	  control	  VSV-­‐
Gpp	   luciferase	   reporter	   viruses	   for	   8	   hours,	   unbound	   virus	   removed	   and	   the	   cells	  
maintained	   in	  culture	   for	  72	  hours.	   Luciferase	  activity	  was	  measured	  and	   the	  data	  
expressed	  as	  relative	  light	  units	  (RLU)	  (n=4	  donor	  LSEC)	  (C).	  	  In	  replicate	  experiments	  
LSEC	   and	   Huh-­‐7.5	   cells	   were	   incubated	   with	   HCVcc	   JFH-­‐1	   for	   4	   hours	   and	   the	  
cultures	  maintained	  for	  72	  hours	  (n=4	  experiments	  with	  donor	  LSEC)	  (D).	  	  Cells	  were	  
fixed	   and	   infection	   assessed	   by	   staining	   for	   viral	   antigen	   NS5A.	   Infectivity	   was	  









































































3.3	   LSEC	  trans-­‐infection	  of	  Huh-­‐7.5	  is	  inefficient	  
	  
The	  current	  literature	  supports	  a	  role	  for	  LSEC	  to	  capture	  HCV	  particles	  from	  portal	  
blood	  and	   to	  concentrate	  virus	   in	   the	  sinusoids,	   thus	  permitting	  contact	  with	   (and	  
infection	   of)	   permissive	   hepatocytes	   (Protzer	   et	   al.,	   2012).	   	   It	   has	   also	   been	  
suggested	   that	   LSEC	   actively	   transfer	   infectious	   virus	   to	   hepatocytes,	   defined	   as	  
trans-­‐infection,	  as	  previously	  reported	  for	  duck	  hepatitis	  B	  virus	  (Breiner	  et	  al.,	  2001).	  
To	  assess	  this	  potential	  role	  for	  LSEC	  in	  promoting	  HCV	  infectivity	  I	  adapted	  a	  model	  
successfully	  used	  to	  demonstrate	  HCV	  trans-­‐infection	  by	  B	   lymphocytes	  (Stamataki	  
et	  al.,	  2009).	   	  LSEC	  were	  incubated	  with	  HCVcc	  JFH-­‐1	  for	  two	  hours,	  unbound	  virus	  
was	  removed	  by	  washing	  and	  fluorescent	  labelled	  Huh-­‐7.5	  hepatoma	  cells	  added	  to	  
achieve	  a	  confluent	  culture.	  The	  culture	  was	  maintained	  for	  72	  hours,	  fixed,	  and	  the	  
cells	   stained	   for	   HCV	   antigen	   NS5A	   (Fig.	   3-­‐4A).	   	   As	   a	   control	   CHO	   cells	   that	   we	  
previously	  demonstrated	  bound	  HCVcc	  at	  comparable	  levels	  to	  LSEC	  were	  included.	  
	  
In	   initial	   experiments	   the	   cells	   were	   seeded	   at	   a	   1:1	   ratio	   and	   I	   noted	   that	  
transmission	   events	   were	   rare	   in	   the	   LSEC	   containing	   co-­‐cultures.	  When	   the	   cells	  
were	  mixed	   each	   cell	   type	   separated	   out	   such	   that	   there	  were	   distinct	   islands	   of	  
labelled	   Huh-­‐7.5	   cells	   surrounded	   by	   LSEC.	   In	   an	   attempt	   to	   promote	   viral	  
transmission	  events	  the	  ratio	  of	  LSEC	  to	  Huh-­‐7.5	  was	   increased	  to	  2:1	  to	  provide	  a	  
greater	  contact	  area	  between	  LSEC	  and	  Huh-­‐7.5	  cells.	  	  Using	  this	  approach	  there	  was	  
a	   small	   increase	   in	   trans-­‐infection	   events	   but	   these	   events	   were	   rare	   (Fig.	   3-­‐4B).	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Indeed	   in	  comparison	   to	  cell-­‐free	  HCV	   infectivity,	   LSEC	   trans-­‐infection	  was	  at	   least	  
1000-­‐fold	   less	  efficient.	   	  These	  data	  suggest	   that	  LSEC	  do	  not	  have	  a	  major	   role	   in	  








Figure	  3-­‐4.	  	  LSEC	  ineffeicently	  trans-­‐infect	  Huh-­‐7.5	  cells.	  	  	  
LSEC	   and	   CHO	   cells	   were	   incubated	   with	   HCVcc	   JFH-­‐1	   (concentration	   100,000	  
FFU/ml)	   for	   2	   hours	   at	   37oC	   and	  washed	   extensively.	   	   CMFDA	   (cell-­‐tracker	   green)	  
labelled	   Huh-­‐7.5	   cells	   were	   added	   at	   a	   ratio	   of	   1	   Huh-­‐7.5	   cell	   to	   2	   LSEC	   and	   the	  
culture	  maintained	  for	  72	  hours.	  	  Cells	  were	  fixed	  and	  stained	  for	  HCV	  antigen	  NS5A	  
(red).	  	  Islands	  of	  Huh-­‐7.5	  cells	  are	  identified	  by	  the	  dotted	  line	  (A).	  Infectivity	  of	  cell	  
bound	  HCV	  was	  quantified	  by	  enumerating	  NS5A	  expressing	   cells	   (B).	   Infectivity	   is	  
expressed	  as	  FFU	  per	  mL	  of	  inoculum.	  	  Statistical	  comparisons	  were	  made	  with	  the	  
Kruskall-­‐Wallis	  test	  where	  ***	  P<0.001	  as	  indicated	  (n=5	  donor	  LSEC).	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3.4	   Clearance	  of	  HCV	  RNA	  from	  the	  plasma	  after	  liver	  transplantation	  
	  
HCV-­‐related	  liver	  disease	  is	  one	  of	  the	  leading	  indications	  for	  liver	  transplantation	  in	  
the	  western	  world	   (Brown,	  2005).	   	   Following	   implantation	  of	   the	  allograft	   there	   is	  
inevitable	   infection	   of	   the	   graft	   with	   HCV	   in	   the	   plasma	   at	   the	   time	   of	   surgery.	  	  
Monitoring	   changes	   in	   peripheral	   HCV	   RNA	   during	   this	   period	   affords	   the	  
opportunity	  to	  study	  virus	  clearance.	  	  As	  part	  of	  an	  on-­‐going	  clinical	  trial	  of	  a	  small	  
molecule	  inhibitor	  of	  SR-­‐BI	  (clinicaltrials.gov	  NCT01292824)	  HCV	  RNA	  was	  monitored	  
in	  the	  plasma	  of	  untreated	  patients	  to	  understand	  viral	  clearance	  kinetics.	  
	  
During	   chronic	   infection	   there	   is	   some	  variability	   in	   the	   viral	   load	  of	   patients	  with	  
end-­‐stage	   liver	   disease	   (Fig.	   3-­‐5A).	   	   At	   the	   time	  of	   liver	   transplantation	  however	   I	  
observed	  profound	   changes	   in	  plasma	  HCV	  RNA	   (Fig.	   3-­‐5B).	   	  During	   the	  operation	  
blood	  supply	  to	  the	  diseased	  liver	  is	  interrupted	  signifying	  the	  onset	  of	  the	  anhepatic	  
(literally	  “no	  liver”)	  phase.	  	  During	  this	  time	  there	  is	  no	  blood	  flow	  through	  the	  liver	  
and,	   since	   the	   liver	   is	   the	   site	   of	   HCV	   replication,	   no	  HCV	   RNA	   enters	   the	   plasma	  
from	   the	   liver.	   	   A	   slow	   decline	   in	   viral	   load	   was	   observed	   in	   the	   majority	   of	  
participants	  (Fig.	  3-­‐5B&C)	  suggesting	  that	  HCV	  is	  relatively	  unstable	  in	  the	  periphery.	  	  
	  
Following	  implantation	  of	  the	  allograft	  a	  second	  pattern	  was	  observed	  (Fig.	  3-­‐5B&C).	  	  
In	  all	  participants	  there	  was	  a	  sharp	  fall	  in	  plasma	  viral	  RNA	  levels	  by	  approximately	  
	  	  
104	  
90%	   within	   1	   hour	   of	   perfusing	   the	   new	   liver.	   This	   represents	   clearance	   of	  
approximately	  108	  RNA	  genomes	  during	  this	  period.	   	  Such	  rapid	  clearance	  suggests	  
the	  involvement	  of	  specialised	  systems	  and	  the	  kinetics	  are	  consistent	  with	  the	  liver	  
being	   the	   major	   site	   of	   clearance.	   	   One	   of	   the	   primary	   roles	   of	   LSEC	   is	   to	   clear	  
macromolecules	   from	   the	  portal	   circulation	   (Elvevold	  et	   al.,	   2008),	   lending	   further	  
support	  for	  a	  protective	  role	  of	  LSEC	  in	  HCV	  infection.	  





Figure	  3-­‐5.	  HCV	  is	  cleared	  rapidly	  from	  the	  plasma	  during	  liver	  transplantation.	  	  	  
HCV	  RNA	  levels	  were	  measured	  in	  patients	  undergoing	  liver	  transplantation.	   In	  the	  
recruitment	   phase	   patients	   had	   blood	   sampled	   for	   HCV	   RNA	   quantitation	   during	  
screening	  and	  on	  any	  subsequent	  admission	   for	  potential	   liver	   transplantation	   (A).	  	  
After	  admission	  for	  liver	  transplant	  samples	  were	  taken	  at	  induction	  of	  anaesthesia	  
(Ind),	   when	   the	   blood	   flow	   into	   the	   liver	   was	   clamped	   and	   the	   patient	   became	  
anhepatic	   (Anh),	   and	   immediately	   before	   the	   new	   liver	   was	   perfused	   with	   blood	  
(reperfusion	   –	   Rep).	   Additional	   samples	   were	   taken	   at	   intervening	   timepoints	   to	  
indicate	  clearance	  rates	  as	   indicated	  (B&C).	   	  Data	  are	  mean	  ±	  SD	  for	  n=13	  patients	  
(C).	   	  












































































3.5	   LSEC	  reduce	  HCVcc	  infectivity	  in	  co-­‐culture	  
	  
The	  observations	  that	  LSEC	  trans-­‐infection	  of	  hepatocytes	  is	  inefficient	  and	  that	  LSEC	  
are	  likely	  to	  play	  a	  major	  role	  in	  clearing	  HCV	  from	  the	  circulating	  blood	  raised	  the	  
question	   as	   to	   whether	   LSEC	   exert	   additional	   protective	   effects.	   To	   address	   this	  
question	   I	   established	   co-­‐cultures	  of	   LSEC	   and	  Huh-­‐7.5	   cells	   at	   a	   ratio	  of	   1:1.	   	   Co-­‐
cultures	  were	  seeded	  to	  give	  a	  confluent	  culture	  after	  overnight	  incubation	  to	  limit	  
the	   effects	   of	   differential	   growth	   kinetics.	   	   As	   previously	   described	   each	   cell	   type	  
separated	   into	   distinct	   islands	   that	  were	   readily	   identifiable	   due	   to	   their	   differing	  
phenotypic	  characteristics	  (Fig.	  3-­‐6A).	  	  
	  
When	   co-­‐cultures	   were	   infected	   with	   HCVcc	   for	   48	   hours	   I	   noted	   a	   substantial	  
reduction	  in	  the	  infectious	  titres	  compared	  to	  Huh-­‐7.5	  cell	  mono-­‐culture.	  	  Indeed	  in	  
LSEC	   containing	   co-­‐cultures	   infectivity	  was	   reduced	  by	  more	   than	  80%	   (Fig.	   3-­‐6B).	  	  
Co-­‐culturing	  LSEC	  with	  Huh-­‐7.5	  cells	  in	  a	  1:1	  ratio	  reduced	  the	  number	  of	  permissive	  
target	   cells	   by	   50%	   however	   the	   reduction	   in	   infectivity	   mediated	   by	   LSEC	   was	  
always	   greater	   than	   this.	   	   These	   findings	   suggest	   that	   any	   reduction	   in	   permissive	  
cell	   number	   (or	   cell	   surface	   area)	   that	  would	   predictably	   reduce	  HCV	   infectivity	   is	  
unlikely	  to	  completely	  explain	  the	  effect	  of	  LSEC	  in	  co-­‐culture.	  










Figure	  3-­‐6.	  	  	  LSEC	  limit	  HCV	  infectivity	  in	  co-­‐culture.	  	  	  
LSEC	  and	  Huh-­‐7.5	  cells	  were	  co-­‐cultured	  at	  a	   ratio	  of	  1:1	  and	   infected	  with	  HCVcc	  
JFH-­‐1.	  	  LSEC	  were	  labelled	  with	  CMFDA	  (cell	  tracker	  green)	  to	  discriminate	  between	  
cell	   types	   (A).	   Infectivity	   was	   determined	   by	   staining	   for	   HCV	   antigen	   NS5A	   and	  
enumerating	  positive	  foci.	  	  Infectivity	  is	  expressed	  relative	  to	  Huh-­‐7.5	  monoculture.	  	  
Statistical	  comparison	  was	  made	  using	  the	  Mann-­‐Witney	  U	  test	  where	  **	  P<0.01	  as	  
indicated	  (n=4	  donor	  LSEC).	  

































3.6	   Heterotypic	  cell	  interactions	  limit	  HCV	  infectivity	  
	  
The	  observation	  that	  LSEC	  limit	  HCVcc	  infectivity	  highlighted	  a	  number	  of	  questions	  
regarding	  the	  influence	  of	  non-­‐permissive	  cells	  in	  the	  liver	  during	  HCV	  infection.	  	  To	  
address	  these	   issues	  I	  established	  both	  LSEC	  and	  CHO	  cell	  co-­‐cultures	  at	   increasing	  
ratios	   of	   Huh-­‐7.5	   cell	   to	   non-­‐permissive	   cell	   (Fig.	   3-­‐7A&B).	   The	   aim	   of	   these	  
experiments	  was	  to	  address	  whether	  the	  number	  of	  permissive	  target	  cells	  in	  the	  co-­‐
culture	   would	   alter	   infectivity.	   A	   positive	   association	   between	   infectivity	   and	   the	  
number	  of	  permissive	  cells	  was	  noted	  in	  the	  co-­‐culture.	  However,	  in	  both	  conditions	  
the	  number	  of	  infected	  foci	  in	  the	  co-­‐culture	  is	  less	  than	  predicted	  by	  considering	  a	  
Huh-­‐7.5	  monoculture	  seeded	  at	  a	  similar	  density	  (as	  indicated	  by	  the	  dotted	  line	  in	  
Fig.	  3-­‐7C).	  
	  
There	  are	  several	  reports	  on	  the	  effect	  of	  heterotypic	  cell	  interactions	  on	  hepatocyte	  
function	   ex	   vivo.	   The	   mechanisms	   underlying	   these	   effects	   include	   cell	   contact,	  
secreted	  factors	  and	  matrix	  derived	  signals	  (Bhatia	  et	  al.,	  1999,	  Hui	  and	  Bhatia,	  2007,	  
Khetani	   et	   al.,	   2004).	   	   To	   clarify	   the	   effect	   of	   LSEC	   and	   CHO	   cell	   contact	   in	   this	  
experimental	  setting	   I	  used	  specially	  designed	  slides	  that	  allow	  cells	  to	  be	  cultured	  
separately	  but	  still	  permit	  the	  sharing	  of	  soluble	  mediators.	  	  In	  these	  experiments	  I	  
observed	   no	   effect	   of	   either	   LSEC	   or	   CHO	   cells	   on	   HCVcc	   infectivity	   (Fig.	   3.7D)	  







Figure	  3-­‐7.	  	  Heterotypic	  cell	  contact	  limits	  HCV	  infection.	  	  	  
LSEC	  Huh-­‐7.5	  cell	  (A),	  and	  CHO	  cell	  Huh-­‐7.5	  cell	  (B)	  co-­‐cultures	  were	  established	  at	  
varying	   ratios	   as	   indicated	   and	   infected	   with	   HCVcc	   JFH-­‐1	   at	   a	   multiplicity	   of	  
infection	  of	  0.01.	   	  Linear	  regression	  analysis	   indicated	  significant	  differences	   in	  the	  
relationship	  between	  permissive	  cell	  number	   in	  the	  presence	  of	  LSEC	  or	  CHO	  cells.	  	  
The	  dotted	  line	  indicates	  the	  hypothetical	  relationship	  in	  the	  absence	  of	  heterotypic	  
cells	   (C).	   	  LSEC	  and	  CHO	  cells	  were	  separated	  from	  Huh-­‐7.5	  cells	  but	  maintained	  in	  
media	  contact	  and	  infected	  with	  HCVcc	  as	  above	  (D).	  	  Infectivity	  was	  determined	  by	  
staining	   for	   viral	   antigen	   NS5A	   and	   enumerating	   positive	   foci.	   	   Infectivity	   is	  
expressed	  relative	  to	  Huh-­‐7.5	  monoculture	  (n=3	  donor	  LSEC	  and	  CHO	  co-­‐cultures).	  















































































































3.7	   Discussion	  
	  
LSEC	  inefficiently	  transfer	  HCV	  to	  hepatocytes	  
Studying	  the	  role	  of	  primary	  human	  LSEC	  in	  the	  HCV	  life	  cycle	  has	  been	  hindered	  by	  
difficulties	   in	   isolating	   these	  endothelial	   cells.	   	  However	   recent	   technical	   advances	  
permit	   the	  study	  of	   this	  cell	   type	   in	  vitro	   (Liaskou	  et	  al.,	  2010,	  Shetty	  et	  al.,	  2011).	  	  
Although	  isolated	  in	  relatively	  small	  numbers	  LSEC	  maintain	  typical	  morphology	  and	  
phenotypic	  markers	  including	  L-­‐SIGN	  until	  at	   least	  passage	  4	  in	  tissue	  culture.	   	  This	  
has	   allowed	   these	   studies	   of	   this	   important	   cell	   type	   in	   co-­‐culture	   systems	   as	   a	  
model	  of	  the	  microenvironment	  of	  the	  liver	  lobule.	  
	  
The	  role	  of	  cells	   in	   the	   liver	  other	   than	  hepatocytes	   in	  HCV	   infection	  has	  not	  been	  
well	  documented.	  	  The	  liver	  is	  large	  and	  complex	  and	  it	  is	  likely	  that	  cells	  other	  than	  
hepatocytes	   will	   impact	   on	   HCV	   replication	   (Protzer	   et	   al.,	   2012).	   	  We	   (Lai	   et	   al.,	  
2006),	   and	   others	   (Cormier	   et	   al.,	   2004,	   Lozach	   et	   al.,	   2004),	   have	   suggested	   that	  
LSEC	   capture	   and	   transmit	   infectious	   HCV	   particles	   to	   underlying	   permissive	  
hepatocytes,	   suggesting	   a	   role	   for	   LSEC	   to	   potentiate	   chronic	   infection.	   The	   data	  





As	   HCV	   enters	   the	   liver	   in	   portal	   (and	   arterial)	   blood	   it	   is	   distributed	   via	   the	  
sinusoidal	  networks	   through	   the	  hepatic	   lobules.	   	   LSEC	  normally	  exert	  a	   scavenger	  
function:	   taking	  up	  macromolecules	   for	   transcytosis	   to	  hepatocytes	  or	   destruction	  
(Elvevold	  et	  al.,	  2008)	  and	  it	  has	  been	  hypothesised	  that	  HCV	  would	  be	  taken	  up	  in	  
the	   same	   way	   (Protzer	   et	   al.,	   2012).	   	   Indeed	   LSEC	   are	   capable	   of	   binding	   HCV	  
particles	  and	  although	  LSEC	  express	  both	  capture	  receptors	  for	  HCV,	  and	  the	  entry	  
receptors	   CD81	   and	   SR-­‐BI,	   this	   binding	   is	   most	   likely	   to	   be	   through	   non-­‐specific	  
interactions	   with	   heparin	   sulphates	   or	   glycoaminoglycans.	   	   This	   hypothesis	   is	  
supported	   by	   the	   observation	   that	   expression	   of	   high	   levels	   of	   SR-­‐BI	   failed	   to	  
significantly	  enhance	  HCV	  binding	  to	  CHO	  cells.	   	  Furthermore	   it	  has	  been	  reported	  
that	  binding	  to	  heparin	  sulphates	   is	  a	  critical	  part	  of	  the	   initial	  attachment	  process	  
and	  occurs	  before	  interaction	  with	  the	  specific	  receptors	  for	  HCV	  (Barth	  et	  al.,	  2006,	  
Jiang	  et	  al.,	  2012).	  There	  are	  no	  reports	  of	  the	  functions	  of	  these	  attachment	  factors	  
on	  LSEC,	  or	  indeed	  on	  any	  other	  non-­‐permissive	  cell	  types.	  The	  specific	  infectivity	  of	  
cell	   culture	   produced	   HCVcc	   is	   low	   (approximately	   1/3000	   particles	   is	   infectious	  
(Lindenbach	  et	  al.,	  2006))	  and	  receptor	  dependent	  binding	   is	  difficult	   to	  accurately	  
quantify	  in	  non-­‐permissive	  cells.	  	  	  
	  
More	  importantly	  however	  is	  the	  functional	  significance	  of	  virus	  binding	  to	  LSEC,	  and	  
this	   relates	   to	   the	   fate	   of	   virus	   particles	   bound.	   	   It	   has	   been	   shown	   in	   a	   duck	  
hepatitis	   B	   virus	   model	   that	   LSEC	   actively	   transfer	   virus	   particles	   from	   sinusoidal	  
blood	  to	  underlying	  hepatocytes	   (Breiner	  et	  al.,	  2001).	   	  To	  determine	  whether	   the	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same	  may	  be	  true	  for	  HCV	  I	  adapted	  previously	  published	  protocols	  for	  lymphoid	  cell	  
HCV	   trans-­‐infection	   of	   permissive	   target	   cells	   (Stamataki	   et	   al.,	   2009).	   	   In	   these	  
experiments	   I	   saw	   very	   little	   transfer	   of	   infection	   from	   LSEC	   loaded	   with	   large	  
quantities	  of	  virus.	  This	  suggests	  that	  most	  virus	  that	  is	  bound	  by	  LSEC	  is	  either	  not	  
internalised	   or	   is	   targeted	   for	   destruction	   or	   antigen	   processing	   following	   uptake.	  
Regardless,	   LSEC	   bound	   HCV	   particles	   are	   largely	   not	   infectious	   for	   Huh-­‐7.5	  
hepatoma	   cells.	   	   Unfortunately	   since	   this	   process	   was	   so	   inefficient	   it	   was	   not	  
possible	  to	  further	  study	  virus	  receptor	  interactions	  and	  tools	  to	  track	  virus,	  e.g.	  with	  
fluorescently	  labelled	  virus,	  are	  not	  yet	  available.	  	  Therefore	  I	  am	  not	  able	  to	  define	  
the	  pathways	  mediating	  these	  effects,	  nor	  am	  I	  able	  to	  define	  the	  fate	  of	  particles	  in	  
LSEC.	  	  	  
	  
It	   has	   been	   recently	   reported	   that	   LSEC	   are	   the	   critical	   cell	   type	   responsible	   for	  
clearing	  blood-­‐borne	  viral	   particles	   from	   the	   circulation	   (Ganesan	  et	   al.,	   2011).	   	   In	  
patients	  with	  HCV	  infection	  and	  end-­‐stage	  liver	  disease	  liver	  transplantation	  affords	  
the	  opportunity	  of	  measuring	  viral	  “clearance”	  both	  in	  the	  presence	  and	  absence	  of	  
liver	   blood	   flow	   (Dragun	   et	   al.,	   2011,	   Garcia-­‐Retortillo	   et	   al.,	   2002,	   Powers	   et	   al.,	  
2006).	   	   As	   part	   of	   a	   clinical	   trial	   of	   a	   small	   molecule	   inhibitor	   of	   SR-­‐BI	   I	   have	  
undertaken	  similar	  viral	  kinetic	  studies	  (clinicaltrials.gov	  NCT01292824).	  Our	  studies	  
confirm	   a	  massive	   clearance	   of	   viral	   particles	   from	   the	   systemic	   circulation	   at	   the	  
time	  of	  allograft	  perfusion	  that	  is	  most	  likely	  mediated	  by	  LSEC.	  One	  hour	  following	  
perfusion	  approximately	   90%	  of	   circulating	  RNA	  genomes	  have	  been	   cleared	   from	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the	   circulation	  highlighting	   the	   capacity	   that	   exists	   for	   scavenger	   function	   in	   LSEC.	  	  
The	   clearance	  of	   infectious	  pathogens	   is	   an	   important	   aspect	  of	   LSEC	  biology	   that	  
would	   be	  worthy	   of	   further	   study	   in	  HCV	   infection	  when	   such	   tools	   are	   available.	  	  
However,	   it	  seems	  most	   likely	  that	  hepatocytes	   interact	  directly	  with	  HCV	  particles	  
in	  the	  sinusoidal	  space	  through	  LSEC	  fenestrations.	  	  Warren	  and	  co-­‐workers	  (Warren	  
et	   al.,	   2006)	   studied	   LSEC	   fenestrations	   by	   electron	   microscopy	   and	   noted	   that	  
hepatocytes	   are	   able	   to	   protrude	   villi	   into	   the	   sinusoidal	   space	   where	   they	   likely	  
contact	  circulating	  HCV	  particles.	   	  Thus	   in	  chronic	   infection	  LSEC	  are	  most	   likely	   to	  
act	   as	   a	   sink	   for	   infectious	   particles	   protecting	   hepatocytes	   rather	   than	   supplying	  
hepatocytes	  with	  infectious	  particles.	  
	  
Heterotypic	  cell	  interactions	  limit	  HCV	  infection	  
Despite	   the	   complexity	  of	   the	   liver,	   there	  are	   relatively	   few	   studies	  on	   the	   role	  of	  
non-­‐parenchymal	  cells	  in	  HCV	  infection.	  To	  study	  the	  role	  of	  LSEC	  in	  HCV	  infection	  I	  
established	   co-­‐cultures	   of	   LSEC	   and	   Huh-­‐7.5	   cells.	   	   Significant	   reductions	   in	   viral	  
infectivity	  in	  LSEC	  and	  CHO	  containing	  co-­‐cultures	  were	  observed.	  	  I	  considered	  that	  
simply	  reducing	  the	  surface	  area	  of	  permissive	  cells	  in	  the	  co-­‐cultures	  would	  act	  to	  
reduce	   HCVcc	   infectivity.	   	   For	   example,	   I	   reasoned	   that	   for	   a	   given	   duration	   of	  
infection	   a	   reduction	   in	   permissive	   cell	   surface	   area	  would	   lead	   to	   a	   proportional	  
reduction	   in	   infectivity	  since	  fewer	   infectious	  particles	  would	  have	  the	  opportunity	  
to	  interact	  with	  a	  permissive	  cell.	  	  Indeed,	  I	  observed	  a	  positive	  association	  between	  
virus	   infectivity	   and	   the	   proportion	   of	   Huh-­‐7.5	   cells	   in	   the	   co-­‐culture.	   However,	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infectivity	  was	  always	  reduced	  in	  co-­‐culture	  when	  compared	  with	  that	  predicted	  by	  
the	  proportion	  of	  permissive	  cells	  included.	  	  Since	  heterotypic	  cell	  contact	  has	  been	  
reported	   to	   regulate	   hepatocellular	   function	   in	   vitro	   (Bhatia	   et	   al.,	   1999,	   Hui	   and	  
Bhatia,	  2007)	  I	  studied	  whether	  cell	  contact	  was	  essential	  to	  limit	  HCV	  infectivity	  in	  
co-­‐culture.	   	   Separating	   the	   cells	   but	   permitting	   exchange	   of	   soluble	   mediators	  
restored	   infectivity	   to	   the	   levels	   seen	   in	   Huh-­‐7.5	   cell	   monoculture	   and	   thus	  
heterotypic	  cell	  contact	  is	  essential	  to	  limit	  HCV	  infectivity.	  
	  
The	  function	  of	  hepatocytes	  in	  vitro	  has	  been	  reported	  to	  be	  maintained	  by	  various	  
methods	  of	  co-­‐culture	  with	  supporting	  cells,	  both	  physiologically	  relevant	  (e.g.	  LSEC	  
(Goulet	  et	  al.,	  1988)),	  or	  irrelevant	  (e.g.	  mouse	  fibroblast	  cell	   line	  3T3	  (Khetani	  and	  
Bhatia,	  2008)).	  	  The	  mechanisms	  that	  regulate	  changes	  in	  hepatocellular	  phenotype	  
have	  been	  extensively	  investigated	  but	  remain	  elusive.	  	  It	  has	  been	  postulated	  that	  
cell	  contact,	  matrix	  derived	  signals,	  and	  soluble	  mediators	  are	  all	  important	  players,	  
however	   it	   is	   apparent	   that	   of	   these	   cell	   contact	   is	   absolutely	   required	   (Hui	   and	  
Bhatia,	  2007).	  	  I	  propose	  that	  these	  contacts	  maintain	  Huh-­‐7.5	  cells	  in	  a	  state	  that	  is	  
less	  favourable	  for	  HCV	  infection.	  The	  literature	  suggests	  a	  role	  for	  supporting	  cells	  
to	   stimulate	   a	   more	   hepatocytic	   phenotype.	   	   In	   this	   circumstance	   expression	   of	  
cellular	  factors	  that	  govern	  HCV	  replication	  may	  be	  modulated	  to	  levels	  comparable	  




The	   study	   of	   HCV	   replication	   in	   primary	   human	   hepatocytes	   is	   complicated	   by	  
limited	  availability	  of	  cells	  and	  variability	  between	  donors	  and	  cell	  isolation	  protocols.	  
Following	   isolation	  hepatocytes	  have	  a	   limited	   lifespan	  of	  up	  to	  only	  10	  days	  since	  
there	   is	  rapid	  dedifferentiation	   in	  culture,	  and	  HCV	  replication	   is	  only	  supported	  at	  
low	   levels	   (Farquhar	   and	  McKeating,	   2008).	   	   Thus	   whilst	   it	   is	   ideal	   to	   study	   HCV	  
replication	  in	  the	  environment	  in	  which	  it	  occurs	  in	  vivo,	  studying	  HCV	  replication	  in	  
primary	  human	  hepatocytes	  is	  difficult,	  and	  may	  be	  misleading.	  	  To	  improve	  this	  line	  
of	   investigation	   human	   hepatocytes	   have	   been	   co-­‐cultured	   on	   micropatterned	  
culture	   plates	   with	   3T3	   fibroblasts	   (Ploss	   et	   al.,	   2010).	   	   The	   rationale	   for	   these	  
studies	   was	   that	   the	   human	   hepatocytes	   would	   maintain	   their	   phenotype	   in	   the	  
presence	  of	  the	  3T3	  cells	  for	  longer	  and	  would	  remain	  permissive	  for	  HCV	  infection.	  	  
Indeed	   the	   authors	   observed	   greater	   permissivity	   to	  HCVcc	   in	   the	   co-­‐cultures	   and	  
suggested	  their	  use	  in	  drug	  screening	  and	  toxicological	  investigation.	  	  These	  results	  
superficially	  appear	  contradictory	  to	  our	  studies:	  on	  one	  hand	  cell	  contacts	  between	  
LSEC	  and	  Huh-­‐7.5	  cells	  reduce	  HCV	  infectivity,	  whilst	  on	  the	  other	  co-­‐culture	  of	  3T3	  
cells	  with	  primary	  human	  hepatocytes	  maintains	  permissivity.	  	  However	  the	  starting	  
point	  for	  each	  experimental	  system	  is	  very	  different	  and	  I	  suggest	  that	  both	  systems	  
argue	  the	  same	  point:	  heterotypic	  cell	  interactions	  maintain	  hepatocytic	  phenotype	  
thus	  regulating	  HCV	  replication.	  	  In	  vivo	  hepatocytes	  are	  permissive	  for	  HCV	  and	  this	  
is	   lost	   following	   isolation	  and	  culture.	   	  3T3	  cells	  maintain	   isolated	  hepatocytes	   in	  a	  
state	   that	   is	   more	   in	   keeping	   with	   the	   in	   vivo	   state,	   and	   therefore	   maintain	  
permissivity.	  	  In	  contrast	  Huh-­‐7.5	  cells	  are	  highly	  permissive	  (probably	  more	  so	  than	  
hepatocytes	   in	   vivo)	   and	   co-­‐culturing	   with	   LSEC	   establishes	   a	   more	   hepatocytic	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phenotype	   thus	   reducing	   permissivity.	   	   Furthermore	   physiologically	   relevant	   cell	  
contacts	   between	   LSEC	   and	   Huh-­‐7.5	   cells	   more	   potently	   reduced	   HCV	   infectivity	  
than	   those	   contacts	   between	   CHO	   cells	   and	   Huh-­‐7.5	   cells	   suggesting	   additional	  
effects	  of	  LSEC	  in	  our	  systems	  that	  have	  not	  been	  previously	  evaluated.	  
In	   summary	   I	   show	  that	  primary	  human	  LSEC	  bind	  HCV	  but	  are	  not	  permissive	   for	  
infection.	   	   However,	   LSEC	   do	   not	   efficiently	  mediate	   trans-­‐infection	   of	   permissive	  
hepatoma	  suggesting	   that	   this	   is	  not	   their	  major	   function	   in	  HCV	   infection.	   	   In	   co-­‐
culture	  with	  Huh-­‐7.5	  cells	  LSEC	  reduced	  HCV	  infectivity	  in	  a	  cell	  contact	  dependent	  
manner	  and	  I	  propose	  that	  the	  major	  role	  of	  LSEC	  in	  HCV	  infection	  may	  be	  protective	  
rather	  than	  potentiating	  infection	  as	  previously	  suggested.	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Chapter	  4	   Vascular	   endothelial	   growth	   factor	   signalling	   in	   liver	  
sinusoidal	  endothelial	  cells	  limits	  hepatitis	  C	  virus	  replication	  
	  
Paracrine	   signalling	   systems	   in	   the	   liver	   are	   critical	   for	   both	   the	   development	   and	  
function	  of	   the	  organ.	   	  The	   foremost	   signalling	  system	   in	   the	  adult	   is	   regulated	  by	  
hepatocyte	   derived	   vascular	   endothelial	   growth	   factor	   (VEGF-­‐A)	   (Carpenter	   et	   al.,	  
2005,	   DeLeve	   et	   al.,	   2004,	   Yamane	   et	   al.,	   1994).	   VEGF-­‐A	   signals	   in	   sinusoidal	  
endothelial	  cells	  to	  maintain	  their	  function	  in	  the	  normal	  healthy	  liver	  and	  following	  
injury	  it	  simulates	  the	  expression	  of	  hepatotrophic	  growth	  factors	  (Ding	  et	  al.,	  2010,	  
LeCouter	  et	  al.,	  2003,	  Greene	  et	  al.,	  2003).	  
	  
During	   HCV	   infection	   the	   expression	   of	   many	   soluble	   inflammatory	   mediators	   is	  
increased.	   	  Many	  of	  these	  have	  been	  described	  in	  the	  context	  of	   inflammatory	  cell	  
recruitment	   to	   the	   liver,	   the	   best	   described	   being	   the	   interferon-­‐γ	   inducibe	  
chemokine	  CXCL10	  (Asselah	  et	  al.,	  2005,	  Harvey	  et	  al.,	  2003,	  Zeremski	  et	  al.,	  2008).	  	  
In	  addition,	  factors	  implicated	  in	  liver	  repair	  including	  VEGF-­‐A	  have	  been	  reported	  to	  
be	   upregulated	   (Hassan	   et	   al.,	   2009).	   	   It	   was	   noted	   that	   this	   increase	   in	   VEGF-­‐A	  
expression	   was	   accompanied	   by	   the	   activation	   of	   endothelial	   cells	   in	   the	   liver	   as	  
evidenced	  by	  the	  proliferation	  of	  these	  cells	  and	  the	  formation	  of	  new	  blood	  vessels	  
(Garcia-­‐Monzon	   et	   al.,	   1995,	   Fernandez	   et	   al.,	   2009).	   	   This	   neoangiogenesis	   is	   a	  
common	  feature	  in	  liver	  pathology	  highlighting	  the	  important	  role	  of	  VEGF-­‐A	  in	  the	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host	   response	   to	   liver	   injury.	   	   LeCouter	   and	   co-­‐workers	   reported	   that	   VEGF-­‐A	  
activation	   of	   sinusoidal	   endothelium	   was	   protective	   in	   a	   chemical	   injury	   murine	  
model	  (LeCouter	  et	  al.,	  2003),	  leading	  the	  authors	  to	  hypothesise	  that	  the	  same	  may	  
be	   true	   in	   viral	   liver	   disease	   but	   the	   lack	   of	   an	   immune	   competent	   small	   animal	  
model	  supporting	  HCV	  replication	  has	  restricted	  studies	  in	  this	  area.	  	  
	  
The	   aims	   of	   this	   study	  were	   to	   characterise	   the	   role	   of	   VEGF-­‐A	   in	   LSEC	  mediated	  
effect(s)	   on	   hepatocellular	   HCV	   replication.	   I	   exploited	   the	   co-­‐culture	   system	  
described	  in	  Chapter	  3	  to	  investigate	  the	  effects	  of	  VEGF-­‐A	  stimulation	  of	  LSEC	  and	  
to	  determine	  whether	   this	   paracrine	   signalling	  was	  protective	   in	  HCV	   related	   liver	  
injury.	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4.1	   LSEC	  express	  VEGF	  receptors	  and	  maintain	  responsiveness	  to	  VEGF-­‐A	  
in	  vitro	  
	  
Vascular	  endothelial	  cell	  responses	  to	  VEGF-­‐A	  are	  mediated	  by	  two	  receptors:	  VEGF	  
receptor-­‐1	   (VEGFR-­‐1)	   and	   VEGF	   receptor-­‐2	   (VEGFR-­‐2).	   	   LSEC	   expression	   of	   these	  
receptors	  was	  confirmed	  by	  quantitative	  RT-­‐PCR	  and	  western	  blotting	  (Fig.	  4-­‐1A&B).	  
I	  observed	  high	  levels	  of	  VEGFR-­‐2	  messenger	  RNA	  expression	  and	  significantly	  lower	  
(approximately	   100-­‐fold	   less)	   VEGFR-­‐1	   levels	   by	   quantitative	   RT-­‐PCR.	   	   Protein	  
analysis	   supported	   these	   conclusions	   indicating	   that	   VEGFR-­‐2	   is	   the	   major	   VEGF	  
receptor	  expressed	  by	  LSEC.	  	  	  
	  






Figure	  4-­‐1.	  	  LSEC	  express	  VEGF	  receptors	  -­‐1,	  and	  -­‐2.	  	  	  
LSEC	  were	  cultured	  in	  standard	  conditions	  and	  lysed	  for	  quantitative	  RT-­‐PCR	  analysis	  



























To	   determine	  whether	   these	   receptors	  were	   functional	   I	   examined	   both	   receptor	  
phosphorylation	   and	   the	   LSEC	   proliferative	   response	   to	   recombinant	   VEGF-­‐A.	  	  
VEGFR-­‐2	  phosphorylation	  was	  readily	  detected	  in	  LSEC	  following	  VEGF-­‐A	  stimulation	  
(Fig.	  4-­‐2A).	  	  In	  parallel	  a	  dose-­‐dependent	  increase	  in	  LSEC	  proliferation	  was	  observed	  
(Fig.	  4-­‐2B)	  confirming	  that	  LSEC	  are	  responsive	  to	  VEGF-­‐A	  in	  vitro.	  	  I	  was	  interested	  
to	   know	  whether	   there	  was	   any	   variability	   amongst	   different	   donor	   LSEC	   in	   their	  
response	  to	  VEGF-­‐A.	  	  Using	  LSEC	  isolated	  from	  six	  independent	  donors	  (one	  of	  each	  
of	   cryptogenic	   cirrhosis,	   fulminant	   seronegative	   hepatitis,	   primary	   biliary	   cirrhosis,	  
and	   autoimmune	   hepatitis,	   and	   two	   from	   uninvolved	   liver	   tissue	   at	   the	   time	   of	  
resection	   for	   colorectal	   cancer	  metastasis)	   I	   observed	   significant	   variability	   in	   the	  
cellular	   proliferative	   response	   to	   VEGF-­‐A	   over	   a	   72	   hour	   period	   (Fig.	   4-­‐2C).	   	   To	  
ascertain	  the	  durability	  of	  the	  response	  to	  VEGF-­‐A	  treatment	  LSEC	  were	  treated	  for	  
defined	   periods	   of	   time	   as	   depicted	   in	   Fig.	   4-­‐2D.	   The	   increase	   in	   cell	   number	  
correlated	  with	  the	  duration	  of	  VEGF-­‐A	  treatment,	  suggesting	  that	  constant	  VEGF-­‐A	  
stimulation	  is	  required	  for	  proliferative	  responses.	  




Figure	  4-­‐2.	  	  LSEC	  respond	  to	  VEGF-­‐A	  in	  vitro.	  	  	  
LSEC	  were	  starved	  of	  VEGF-­‐A	  overnight	  and	  treated	  with	  VEGF-­‐A	   (10ng/mL)	   for	  10	  
minutes.	  	  Cells	  were	  harvested	  for	  western	  blotting	  analysis	  (A).	  	  Following	  overnight	  
VEGF-­‐A	   starvation,	   LSEC	   were	   stimulated	   for	   72	   hours	   with	   VEGF-­‐A	   at	   the	   doses	  
indicated	   and	   proliferative	   responses	   assessed	   using	  MTS	   assay	   as	   described	   (n=4	  
donor	  LSEC)	  (B).	  	  LSEC	  from	  6	  independent	  donors	  (numbered	  1	  to	  6)	  were	  treated	  
with	   VEGF-­‐A	   (10ng/mL)	   and	   proliferative	   responses	   characterised	   (C).	   	   Following	  
overnight	  VEGF-­‐A	  starvation	  LSEC	  were	  treated	  for	  different	  periods	  of	  time	  starting	  
at	   time	  zero	  as	   indicated	  and	  proliferative	   responses	  assessed	  after	  72	  hours	   (n=4	  
donor	  LSEC)	  (D).	  	  Cell	  number	  is	  expressed	  relative	  to	  untreated	  control.	  	  Statistical	  
comparison	  was	  made	  using	  the	  Kruskal-­‐Wallis	  test	  and	  Dunn’s	  correction	  where	  *	  
P<0.05,	  and	  **	  P<0.01	  vs.	  untreated	  control.	   	  













































































To	   discern	   the	   receptor-­‐dependency	   of	   the	   VEGF-­‐A	   effects	   on	   LSEC	   proliferation	   I	  
compared	  the	  efficacy	  of	  ligands	  targeting	  each	  of	  the	  two	  receptors	  in	  the	  presence	  
or	  absence	  of	  receptor-­‐specific	  neutralising	  antibodies.	  	  The	  ligands	  employed	  were	  
VEGF-­‐A	   that	   binds	   both	   VEGFR-­‐1	   and	   VEGFR-­‐2,	   PlGF	   that	   is	   VEGFR-­‐1	   specific	   and	  
VEGF-­‐E	   targets	   only	   VEGFR-­‐2.	   To	   validate	   the	   ligands	   and	   neutralising	   antibodies,	  
VEGF	   receptor	   phosphorylation	  was	   confirmed	   following	   short	   duration	   treatment	  
with	   VEGF-­‐A	   (Fig.	   4-­‐3A).	   These	   studies	   confirmed	   specificity	   of	   VEGF-­‐E	   and	   the	  
neutralising	  antibody	  targeting	  VEGFR-­‐2.	  	  I	  was	  unable	  to	  confirm	  similar	  activity	  for	  
VEGFR-­‐1	   stimulation	   since	   receptor	   phosphorylation	   is	   weak	   and	   there	   are	   no	  
antibodies	   available	   that	   detect	   endogenous	   levels	   of	   phosphorylated	   VEGFR-­‐1	  
(Olsson	  et	  al.,	  2006).	  	  	  
	  
LSEC	   proliferation	   was	   clearly	   mediated	   by	   VEGFR-­‐2	   with	   VEGF-­‐E	   and	   VEGF-­‐A	  
stimulating	   comparable	   levels	   of	   cell	   proliferation	   (Fig.	   4-­‐3B).	   In	   addition,	  
neutralising	  antibody	  targeting	  VEGFR-­‐2	  reduced	  proliferation	  in	  a	  dose	  dependent	  
manner	   whilst	   anti-­‐VEGFR-­‐1	   had	   no	   effect	   (Fig.	   4-­‐3C).	   Thus	   VEGFR-­‐2	   signalling	   is	  
active	  in	  LSEC	  in	  vitro	  and	  this	  stimulates	  proliferation	  of	  this	  cell	  type.	  






Figure	  4-­‐3.	  	  VEGFR-­‐2	  signals	  stimulate	  LSEC	  proliferation.	  	  	  
LSEC	   were	   starved	   of	   VEGF-­‐A	   overnight,	   pretreated	   with	   receptor	   neutralising	  
antibodies	   (αVEGFR-­‐1	   30μg/mL	   and	   αVEGFR-­‐2	   10μg/mL)	   for	   1	   hour,	   and	   then	  
stimulated	   with	   VEGF-­‐A	   (10ng/mL),	   PlGF	   (10ng/mL),	   or	   VEGF-­‐E	   (10ng/mL)	   as	  
indicated	   for	   10	   minutes.	   	   Cells	   were	   then	   harvested	   in	   lysis	   buffer	   for	   western	  
blotting	  analysis	   (A).	   	   Following	  overnight	  VEGF-­‐A	  starvation	  LSEC	  were	   stimulated	  
for	   72	   hours	   with	   VEGF-­‐A,	   or	   VEGF-­‐E	   and	   proliferative	   responses	   of	   LSEC	   were	  
assessed	  using	  MTS	  assay	  as	  described	  (n=6	  donor	  LSEC)	  B).	  	  Cell	  number	  is	  plotted	  
relative	   to	   untreated	   control.	   	   LSEC	   were	   stimulated	   as	   above	   with	   VEGF-­‐A	   after	  
treatment	  with	  receptor	  neutralising	  antibodies.	   	  Cell	  number	   is	  plotted	  relative	  to	  
VEGF-­‐A	   stimulated	   control	   (C).	   Statistical	   comparison	  was	  made	  using	   the	  Kruskal-­‐
Wallis	  test	  and	  Dunn’s	  correction	  where	  *	  P<0.05	  vs.	  untreated	  control.	   	  


































































4.2	   Neutralising	  VEGF-­‐A	  activation	  of	  LSEC	  increases	  HCV	  infectivity	  
	  
VEGF-­‐A	  stimulation	  of	  LSEC	   is	  critical	   in	  their	  response	  to	   liver	   injury	  and	  has	  been	  
postulated	   to	  protect	  against	  viral	   infection.	   	  To	  ascertain	  whether	  VEGF-­‐A	  plays	  a	  
role	  in	  HCV	  infection	  of	  the	  LSEC	  Huh-­‐7.5	  co-­‐culture	  system	  I	  infected	  the	  cells	  in	  the	  
presence	   or	   absence	   of	   a	   neutralising	   anti-­‐VEGF-­‐A	   antibody.	   Neutralising	   VEGF-­‐A	  
promoted	   a	   significant	   increase	   in	   HCV	   infection	   of	   LSEC	   Huh-­‐7.5	   co-­‐cultures	   to	  
levels	   seen	   in	   control	   CHO	   Huh-­‐7.5	   co-­‐cultures	   (Fig.	   4-­‐4A).	   	   In	   contrast,	  
neutralisation	  of	  VEGF-­‐A	  in	  these	  CHO	  cell	  containing	  co-­‐cultures	  had	  no	  effect	  (data	  
not	  shown).	  Importantly,	  the	  neutralizing	  anti-­‐VEGF	  antibody	  had	  the	  same	  effect	  on	  
viral	   infection	   of	   LSEC	   Huh-­‐7.5	   cultures	   when	   cells	   were	   seeded	   in	   Ibidi	   chamber	  
slides	  and	  were	  not	  allowed	  to	  contact.	  	  Notably	  there	  was	  no	  effect	  when	  CHO	  cell	  
containing	  co-­‐cultures	  were	  treated	  with	  neutralising	  anti-­‐VEGF-­‐A	  antibody	  (Fig.	   4-­‐
4B).	  	  Overall,	  these	  data	  suggest	  that	  activation	  of	  LSEC	  by	  hepatocyte	  derived	  VEGF-­‐
A	   may	   suppress	   expression	   of	   a	   proviral	   factor,	   or	   factors,	   thus	   limiting	   HCV	  
infectivity.	  
	  
To	   further	   define	   the	   role	   of	   VEGF-­‐A	   activating	   LSEC	   in	   the	   co-­‐culture	   model	   I	  
infected	   the	   cells	   in	   the	   presence	   or	   absence	   of	   neutralising	   antibodies	   targeting	  
VEGFR-­‐1	  and	  VEGFR-­‐2	  (Fig.	  4-­‐4C).	  Neutralising	  antibodies	  targeting	  VEGFR-­‐2,	  rather	  
than	  VEGFR-­‐1,	  restored	  HCV	  infectivity	  back	  to	  the	  level	  of	  the	  CHO	  cell	  co-­‐cultures	  




Figure	  4-­‐4.	  VEGF-­‐A	  signalling	  reduces	  HCV	  infectivity	  in	  LSEC	  co-­‐culture.	  	  
LSEC	  Huh-­‐7.5	  or	  CHO	  Huh-­‐7.5	  co-­‐cultures	  were	  treated	  with	  neutralizing	  anti-­‐VEGF-­‐A	  
antibody	  or	   irrelevant	   IgG	   (10μg/mL)	  prior	   to	   infecting	  with	  HCV	   JFH-­‐1	   (n=3	  donor	  
LSEC	   and	   for	   CHO	   co-­‐cultures).	   (A).	   Co-­‐culture	   experiments	  were	   repeated	  where	  
the	  different	   cell	   types	  were	  physically	   separated	  but	   allowed	   to	   share	  media	   (B).	  
Infectivity	   was	   determined	   by	   enumerating	   NS5A	   positive	   foci	   and	   is	   expressed	  
relative	   to	   Huh-­‐7.5	   cell	   mono-­‐culture.	   	   Co-­‐cultures	   established	   at	   1:1	   ratios	   were	  
treated	   with	   neutralising	   anti-­‐VEGF-­‐A	   antibody,	   or	   anti-­‐VEGF	   receptor	   antibodies	  
(αVEGFR-­‐1	   30μg/mL	   and	   αVEGFR-­‐2	   10μg/mL)	   and	   infected	   with	   HCV	   JFH-­‐1	   (C).	  	  
Infectivity	   is	   expressed	   relative	   to	   CHO	   cell	   containing	   co-­‐cultures.	   	   Statistical	  
comparison	  was	  made	  using	  the	  Kruskal-­‐Wallis	  test	  and	  Dunn’s	  correction	  where	  **	  
P<0.01	  vs.	  untreated	  control,	  or	  vs.	  CHO	  cell	  control	  co-­‐culture	  (n=4	  donor	  LSEC	  and	  
for	  CHO	  co-­‐cultures).	   	  





















































































4.3	   LSEC	  express	   factors	   that	   increase	  HCV	  replication	   in	   the	  absence	  of	  
VEGF-­‐A	  
	  
Having	   observed	   that	   neutralising	   VEGF-­‐A	   in	   LSEC	   Huh-­‐7.5	   co-­‐cultures	   promoted	  
viral	   infectivity	   I	   hypothesised	   that	   LSEC	   express	   soluble	   factors	   that	   potentiate	  
infection.	  To	   investigate	  this	   further	  conditioned	  media	   from	  LSEC	  after	   incubation	  
for	  24	  hours	  were	  collected,	  and	  used	  to	  treat	  Huh-­‐7.5	  cells	  prior	  to	   infecting	  with	  
HCV.	  	  Using	  this	  approach	  I	  first	  treated	  Huh-­‐7.5	  cells	  with	  conditioned	  media	  from	  
LSEC	   propagated	   in	   the	   absence	   of	   VEGF-­‐A	   and	   observed	   a	   significant	   increase	   in	  
HCV	  infection	  (Fig.	  4-­‐5A).	  I	  used	  this	  approach	  to	  determine	  whether	  the	  increase	  in	  
infectivity	  was	  defined	  at	  the	  level	  of	  HCV	  replication.	  	  Following	  treatment	  of	  Huh-­‐
7.5	   cells,	   either	   infected	   with	   HCVcc	   or	   expressing	   HCV	   replicons,	   with	   LSEC	  
conditioned	  media	   similar	   increases	   in	   HCV	   RNA	   in	   cells	   infected	  with	   HCVcc	   and	  
cells	   expressing	   full-­‐length	   (and	   subgenomic,	   data	   not	   shown)	   HCV	   replicons	   was	  
observed,	  confirming	   the	  stimulatory	  effect	  of	  LSEC	  on	  HCV	  replication	   (Fig.	   4-­‐5B).	  
To	  determine	  whether	  VEGF-­‐A	  activation	  of	  Huh-­‐7.5	  cells	  per	  se	  was	  responsible	  for	  
modulation	  of	  HCVcc	   infectivity	  these	  cells	  were	  treated	  with	  recombinant	  VEGF-­‐A	  
prior	   to	   infecting	  with	  HCV	   JFH-­‐1.	   	  No	   effect	   of	   VEGF-­‐A	   stimulation	  was	   noted	   on	  
HCVcc	   infectivity	   (Fig.	   4-­‐5C).	   	   I	   then	   treated	   LSEC	  with	  VEGF-­‐A	   following	  overnight	  
VEGF-­‐A	   starvation	   and	   screened	   the	   conditioned	   media	   for	   its	   effect	   on	   Huh-­‐7.5	  
permissivity	   to	   support	   HCV	   infection.	   	   A	   dose	   dependent	   decrease	   in	   HCVcc	  
infectivity	   was	   noted	   (Fig.	   4-­‐5D),	   confirming	   that	   VEGF-­‐A	   stimulation	   of	   LSEC	   is	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responsible	   for	   modulating,	   and	   likely	   suppressing,	   expression	   of	   a	   soluble	   factor	  
that	  regulates	  HCV	  replication.	  






Figure	  4-­‐5.	  	  LSEC	  express	  proviral	  factor(s)	  in	  the	  absence	  of	  VEGF-­‐A	  stimulation.	  
Conditioned	  media	  (CM)	  was	  collected	  from	  LSEC	  seeded	  at	  4x104/cm2	  for	  24	  hours	  
in	  the	  absence	  of	  VEGF-­‐A.	  The	  media	  were	  diluted	  1:2	  with	  fresh	  media	  and	  used	  to	  
treat	   Huh-­‐7.5	   cells	   for	   18	   hours	   before,	   and	   for	   48	   hours	   following	   infection	  with	  
HCV	   JFH-­‐1.	   Infection	  was	   enumerated	   by	   quantifying	  NS5A	   expressing	   cells	   (A)	   or	  
HCV	  RNA	   levels	   (B)	  and	   the	  data	  expressed	   relative	   to	  untreated	  or	  mock	  Huh-­‐7.5	  
cells.	   Huh-­‐7.5	   cells	   supporting	   JFH-­‐1	   replicons	  were	   treated	  with	   CM	   for	   48	   hours	  
and	   HCV	   RNA	   levels	   measured	   (B).	   Recombinant	   VEGF-­‐A	   (10ng/mL)	   was	   used	   to	  
treat	  Huh-­‐7.5	  cells	  undergoing	  infection	  with	  HCV	  JFH-­‐1	  and	  infectivity	  assessed	  by	  
enumerating	   NS5A	   positive	   foci	   (C).	   	   CM	   was	   collected	   from	   LSEC	   treated	   with	  
increasing	   concentrations	   of	   recombinant	   VEGF-­‐A	   and	   screened	   for	   its	   effect	   on	  
Huh-­‐7.5	  permissivity	   to	   support	  HCV	   replication,	   as	   indicated	  above	   (D).	   Statistical	  
comparisons	  were	  made	  with	   the	  Mann-­‐Witney	   U	   test,	   or	   the	   Kruskal-­‐Wallis	   test	  
with	   Dunn’s	   correction	   as	   appropriate	   and	   where	   *P<0.05,	   **	   P<0.01,	   and	  
***P<0.001,	  vs.	  Huh-­‐7.5	  monoculture	  or	  mock	  conditioned	  media	  as	  indicated	  (n=4	  

























































































4.4	   VEGFR-­‐2	  and	  p38	  MAPK	  activation	  suppress	  pro-­‐viral	  factor(s)	  in	  LSEC	  
	  
VEGF-­‐A	   signalling	   is	   complex	   and	   activation	   is	  mediated	   by	   two	   critical	   receptors,	  
VEGFR-­‐1	   and	   VEGFR-­‐2	   (Olsson	   et	   al.,	   2006).	   	   The	   co-­‐culture	   experiments	   have	  
identified	  a	  key	  role	  for	  LSEC	  VEGFR-­‐2	  activation	  in	  regulating	  factors	  that	  promote	  
HCV	   replication.	   Using	   the	   conditioned	   media	   systems	   I	   further	   investigated	   the	  
pathways	  of	  LSEC	  activation.	  	  
	  	  
First	  VEGF	   receptor	   specific	   ligands	  were	  used	   to	   confirm	   receptor	  dependence	  of	  
the	  suppression	  of	  proviral	  factors	  in	  LSEC	  (Fig.	  4-­‐6A).	  	  Here	  I	  observed	  that	  signals	  
activating	  VEGFR-­‐2	   (i.e.	  VEGF-­‐E)	   suppressed	  HCVcc	   infectivity	   to	  comparable	   levels	  
achieved	  with	  VEGF-­‐A.	  	  This	  observation	  was	  confirmed	  with	  neutralising	  antibodies	  
targeting	   the	   VEGF	   receptors	   (Fig.	   4-­‐6B).	   	   Neutralising	   anti-­‐VEGFR-­‐2	   antibody	  
treatment	   abrogated	   the	   VEGF-­‐A	   mediated	   suppression	   of	   HCV	   infectivity	   whilst	  
neutralising	  anti-­‐VEGFR-­‐1	  antibody	  treatment	  had	  no	  effect.	  	  	  
	  
I	  previously	  noted	  that	  constant	  VEGF-­‐A	  stimulation	  was	  required	  for	  continued	  LSEC	  
proliferation.	  LSEC	  conditioned	  media	  was	  therefore	  sequentially	  harvested	  every	  24	  
hours	   for	  3	   successive	  days	   and	  used	   to	   treat	  Huh-­‐7.5	   cells	   prior	   to	   infecting	  with	  
HCVcc	  (Fig.	  4-­‐6C).	  	  A	  similar	  suppression	  of	  HCVcc	  infectivity	  was	  observed	  in	  each	  of	  
the	   conditioned	  media	   suggesting	   that	   LSEC	   do	   not	   become	   refractory	   to	   VEGF-­‐A	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stimulation	  of	  proviral	  factor	  expression	  and	  proliferative	  responses,	  both	  of	  which	  
are	  regulated	  by	  activation	  of	  VEGFR-­‐2.	  






Figure	  4-­‐6.	  	  LSEC	  VEGFR-­‐2	  activation	  regulates	  proviral	  factor(s)	  expression.	  	  
Conditioned	  media	  (CM)	  were	  collected	  from	  LSEC	  seeded	  at	  4x104/cm2	  for	  24	  hours	  
that	  were	  unstimulated	  or	  treated	  with	  VEGF-­‐A	  (10ng/mL).	  The	  media	  were	  diluted	  
1:2	  with	  fresh	  media	  and	  used	  to	  treat	  Huh-­‐7.5	  cells	  for	  18	  hours	  before,	  and	  for	  48	  
hours	  following	  infecting	  with	  HCV	  JFH-­‐1	  (A).	  	  Conditioned	  media	  were	  also	  collected	  
from	   LSEC	   pre-­‐treated	   with	   VEGF	   receptor	   neutralising	   antibodies	   (αVEGFR-­‐1	  
30μg/mL	   and	   αVEGFR-­‐2	   10μg/mL)	   and	   subsequently	   stimulated	   with	   VEGF-­‐A	   as	  
indicated	  (B).	  	  Conditioned	  media	  were	  sequentially	  collected	  and	  used	  to	  treat	  Huh-­‐
7.5	   cells	   as	  above	   (C).	   	   Infectivity	  was	  assessed	  by	  enumerating	  NS5A	  positive	   foci	  
and	   is	   expressed	   relative	   to	   mock	   conditioned	   media	   control.	   	   Statistical	  
comparisons	  were	  made	  with	  the	  the	  Kruskal-­‐Wallis	  test	  and	  where	  **	  P<0.01	  (n=4	  






























































































To	  characterise	  the	  intracellular	  signalling	  pathways	  downstream	  of	  VEGFR-­‐2	  I	  used	  
various	   small	   molecule	   inhibitors	   of	   known	   pathways	   activated	   by	   this	   receptor	  
(Olsson	  et	  al.,	  2006,	  Koch	  et	  al.,	  2011)	  (Fig.	  4-­‐7A).	  	  Specifically	  these	  inhibitors	  target	  
MEK1	   (PD98059),	   p38	  MAPK	   (SB203580),	   phospholipase	   C	   (PLC,	   U73122),	   and	   PI3	  
kinase	   (wortmannin).	   	  When	   used	   at	   non-­‐toxic	   concentrations	   only	   one	   inhibitor,	  
SB203580,	   an	   inhibitor	   of	   p38	  MAPK	   signalling	   abrogated	   the	   effect	   of	  VEGF-­‐A	  on	  
LSEC	   conditioned	  media	   (Fig.	   4-­‐7B).	   	   To	   ensure	   that	   p38	  MAPK	   was	   activated	   by	  
VEGFR-­‐2	   LSEC	  were	   treated	  with	  VEGF	   receptor	   specific	   ligands	  or	  with	  VEGF-­‐A	   in	  
the	  presence	  of	  specific	  neutralising	  antibodies	  (Fig.	  4-­‐7C).	   	   I	  noted	  that	  p38	  MAPK	  
was	  indeed	  activated	  by	  VEGFR-­‐2	  ligation	  and	  not	  VEGFR-­‐1.	  	  LSEC	  were	  then	  treated	  
with	  increasing	  doses	  of	  SB203580	  and	  the	  conditioned	  media	  used	  to	  treat	  Huh-­‐7.5	  
cells	  prior	  to	  infecting	  with	  HCV	  JFH-­‐1	  	  (Fig	  4-­‐7D).	  	  This	  experiment	  confirmed	  a	  dose	  
dependent	  effect	  of	  p38	  MAPK	  inhibition	  on	  VEGF-­‐A	  priming	  LSEC	  to	  express	  soluble	  
pro-­‐viral	   factors.	   In	   summary	   these	   studies	   highlight	   a	   role	   for	   VEGFR-­‐2	   and	   p38	  
MAPK	  signalling	  in	  the	  regulation	  of	  endothelial	  expressed	  proviral	  factors.	  




Figure	  4-­‐7.	  	  VEGF-­‐A	  signals	  via	  p38	  MAPK	  to	  suppress	  proviral	  signals.	  	  	  
LSEC	  were	  treated	  with	  chemical	   inhibitors	   (all	  10μM)	  of	  pathways	  downstream	  of	  
VEGFR-­‐2	  for	  1	  hour,	  washed	  and	  viability	  assessed	  24	  hours	  later	  by	  MTS	  assay	  (A).	  	  
Conditioned	  media	  were	  then	  collected	  from	  LSEC	  seeded	  at	  4x104/cm2	  pretreated	  
for	   1	   hour	   with	   inhibitor	   or	   solvent	   control,	   and	   then	   stimulated	   with	   VEGF-­‐A	  
(10ng/mL)	  as	  indicated.	  	  	  The	  media	  were	  diluted	  1:2	  with	  fresh	  media	  and	  used	  to	  
treat	   Huh-­‐7.5	   cells	   for	   18	   hours	   before,	   and	   for	   48	   hours	   following	   infection	  with	  
HCV	   JFH-­‐1	   (B).	   	   LSEC	  were	   starved	   of	   VEGF-­‐A	   overnight,	   pretreated	  with	   receptor	  
neutralising	  antibodies	  (αVEGFR-­‐1	  30μg/mL	  and	  αVEGFR-­‐2	  10μg/mL)	  for	  1	  hour,	  and	  
then	   stimulated	  with	   VEGF-­‐A	   (10ng/mL),	   PlGF	   (10ng/mL),	   or	   VEGF-­‐E	   (10ng/mL)	   as	  
indicated	  for	  10	  minutes.	  	  Cells	  were	  then	  harvested	  for	  western	  blotting	  analysis	  (C).	  	  
Conditioned	  media	  were	  collected	  from	  LSEC	  treated	  as	  above	  with	  increasing	  doses	  
of	  SB203580	  as	  indicated.	  	  Media	  were	  then	  used	  to	  treat	  Huh-­‐7.5	  cells	  as	  above	  (D).	  	  
Infectivity	   was	   determined	   by	   enumerating	   NS5A	   positive	   foci	   and	   is	   expressed	  
relative	  to	  mock	  conditioned	  media	  control.	  	  Statistical	  comparisons	  were	  made	  with	  
the	  Kruskal-­‐Wallis	  test	  with	  Dunn’s	  correction	  and	  where	  *	  P<0.05,	  and	  **	  P<0.01,	  vs.	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4.5	   VEGF-­‐A	  activation	  of	  large	  vessel	  endothelium	  limits	  HCV	  infectivity	  
	  
LSEC	  are	  a	  highly	  specialised	  small	  vessel	  endothelial	  cell	  type	  that	  is	  phenotypically	  
different	  from	  other	  endothelial	  cell	  types	  particularly	  large	  vessel	  endothelia	  (Lalor	  
et	  al.,	  2006,	  Elvevold	  et	  al.,	  2008).	  	  I	  was	  therefore	  interested	  to	  know	  whether	  other	  
endothelial	   cell	   types	   behaved	   in	   a	   similar	   fashion	   to	   LSEC	   in	   regulating	   HCV	  
replication.	  	  	  
	  
To	  investigate	  this	  human	  umbilical	  vein	  cells	  (HUVEC)	  were	  used	  as	  a	  model	  of	  large	  
vessel	   endothelium.	   	   In	   replicate	   experiments	   LSEC	   and	  HUVEC	  were	   treated	  with	  
VEGF-­‐A	   and	   then	   following	   incubation	   for	   24	   hours	   harvested	   conditioned	  media	  
that	  media	  was	  used	  to	  treat	  Huh-­‐7.5	  cells	  undergoing	  infection	  with	  HCVcc	  (Fig.	  4-­‐
8A&B).	   	   I	   noted	   that	   in	   the	   absence	   of	   VEGF-­‐A	   stimulation	   both	   LSEC	   and	  HUVEC	  
increased	   HCVcc	   infection	   to	   comparable	   levels	   suggesting	   that	   expression	   of	  
proviral	  soluble	  factors	  was	  conserved	  between	  these	  cell	  types.	  	  However,	  although	  
VEGF-­‐A	   regulated	   this	   soluble	   factor	   expression	   in	   HUVEC	   the	   VEGF-­‐A	   stimulated	  
reduction	  in	  HCV	  infectivity	  was	  consistently	  greater	  in	  LSEC	  than	  in	  HUVEC.	  








Figure	  4-­‐8.	  	  	  Large	  vessel	  endothelial	  cells	  express	  proviral	  factor(s)	  in	  the	  absence	  
of	  VEGF-­‐A	  stimulation.	  	  	  
Conditioned	  media	  were	   collected	   from	   LSEC	   (A),	   and	  HUVEC	   (B),	   each	   seeded	   at	  
4x104/cm2.	   	  Cells	  were	  untreated,	  or	  were	  stimulated	  with	  VEGF-­‐A	  for	  24	  hours	  as	  
indicated.	  	  The	  media	  were	  diluted	  1:2	  with	  fresh	  media	  and	  used	  to	  treat	  Huh-­‐7.5	  
cells	   for	   18	   hours	   before,	   and	   for	   48	   hours	   following	   infection	   with	   HCV	   JFH-­‐1.	  	  
Infectivity	  was	  assessed	  by	  enumerating	  NS5A	  positive	  foci	  and	  is	  expressed	  relative	  
to	  the	  mock	  conditioned	  media	  control.	  	  Statistical	  comparisons	  were	  made	  with	  the	  
the	  Kruskal-­‐Wallis	  test	  with	  Dunn’s	  correction	  and	  where	  *	  P<0.05,	  and	  **	  P<0.01	  vs.	  
mock	  conditioned	  media	  (n=6	  donor	  LSEC,	  and	  n=4	  HUVEC	  conditioned	  media).	  
	  
	   	  



















































To	  begin	  to	  understand	  the	  mechanism	  underlying	  this	  difference	  I	  examined	  VEGF	  
receptor	  expression	  in	  HUVEC	  and	  compared	  that	  to	  expression	  in	  LSEC.	  	  Measuring	  
VEGF	   receptor	   expression	   by	   quantitative	   RT-­‐PCR	   HUVEC	   expressed	   significantly	  
more	  VEGFR-­‐1,	   and	   less	   VEGFR-­‐2	   than	   LSEC	   (Fig.	   4-­‐9A).	   	   Furthermore	   the	   ratio	   of	  
VEGFR-­‐2	   to	   VEGFR-­‐1	   was	   reduced	   in	   HUVEC	   suggesting	   that	   VEGFR-­‐2	   activation	  
might	  be	   limited	  in	  HUVEC	  in	  response	  to	  VEGF	  stimulation.	   	  To	  characterise	  these	  
differences	   further	   I	   examined	   VEGFR-­‐2	   phosphorylation	   by	   western	   blotting	   and	  
observed	   lower	   phosphorylation	   in	   HUVEC	   with	   maximal	   VEGF-­‐A	   stimulation	  
(10ng/mL)	  in	  keeping	  with	  the	  reduced	  expression	  of	  total	  VEGFR-­‐2	  (Fig.	  4-­‐9B).	  Since	  
VEGFR-­‐1	   may	   act	   as	   a	   decoy	   receptor	   for	   VEGF-­‐A	   I	   examined	   the	   impact	   of	   the	  
VEGFR-­‐2	  to	  VEGFR-­‐1	  ratio	  on	  the	  ability	  of	  VEGF	  stimulation	  of	  HUVEC	  and	  LSEC	  to	  
suppress	  proviral	   factors.	   	  Using	  this	  approach	  the	  different	  cell	  types	  were	  readily	  
segregated	   and	   there	   was	   a	   clear	   correlation	   between	   the	   VEGFR	   ratio	   and	   the	  
suppressive	   ability	   of	   VEGF	   stimulation	   (Fig.	   4-­‐9C).	   	   These	   studies	   suggest	   that	  
VEGFR-­‐1	  may	  be	  a	  limiting	  factor	  in	  VEGFR-­‐2	  activation	  and	  suppression	  of	  proviral	  
factors	  in	  endothelial	  cells.	  




Figure	   4-­‐9.	   	   Increased	   levels	   of	   VEGFR-­‐2	   on	   LSEC	   are	   associated	   with	   increased	  
suppression	  of	  endothelial	  proviral	  signals.	  	  	  
LSEC	  and	  HUVEC	  were	  maintained	  in	  standard	  culture	  conditions	  and	  VEGF	  receptor	  
expression	   was	   assessed	   quantitative	   RT-­‐PCR.	   	   Relative	   gene	   expression	   was	  
calculated	  using	  the	  2-­‐ΔCt	  method	  (n=3	  donor	  LSEC	  and	  HUVEC)	  (A).	  	  Endothelial	  cells	  
were	  starved	  of	  VEGF-­‐A	  overnight	  and	  then	  stimulated	  with	  VEGF-­‐A	   (10ng/mL)	   for	  
10	  minutes.	   	   Cells	  were	   lysed	   for	   analysis	   by	  western	  blotting	   (B).	   	   The	   activity	   of	  
VEGF-­‐A	  stimulation	  was	  determined	  by	   the	  percentage	  decrease	   in	  HCV	   infectivity	  
when	   stimulated	   conditioned	  media	  were	   compared	   to	   unstimulated	  media.	   	   This	  
was	  then	  correlated	  with	  the	  relative	  abundance	  of	  VEGFR-­‐2	  to	  VEGFR-­‐1	  (n=6	  donor	  






























































4.6	   Discussion	  
	  
LSEC	  VEGF	  receptor	  expression	  favours	  VEGFR-­‐2	  responses	  
VEGF-­‐A	  is	  constitutively	  expressed	  by	  hepatocytes	  (Maharaj	  et	  al.,	  2006)	  and	  is	  the	  
critical	  paracrine	  signal	  for	  LSEC	  in	  vivo	  that	  is	  responsible	  for	  normal	  endothelial	  cell	  
function	   (Carpenter	  et	  al.,	  2005,	  DeLeve	  et	  al.,	  2004,	  Yamane	  et	  al.,	  1994).	   	  Here	   I	  
show	   that	   VEGF-­‐A	   stimulation	   of	   LSEC	   VEGFR-­‐2	   and	   p38	   MAPK	   signalling	   is	  
responsible	  for	  maintaining	  an	  environment	  that	  is	  less	  favourable	  for	  HCV	  infection	  
due	  to	  the	  suppression	  of	  a	  soluble	  factor,	  or	  factors,	  that	  otherwise	  acts	  to	  increase	  
viral	  replication.	  
	  
The	  responses	  of	  endothelial	  cells	   in	  general	   to	  VEGF-­‐A	  are	  well	  characterised	  and	  
responses	  of	  isolated	  LSEC	  were	  explored	  as	  a	  facet	  of	  understanding	  the	  response	  
to	   liver	   injury.	   	   I	  noted	  that	   the	  expression	  of	  VEGF	  receptors	   in	  LSEC	  was	  unusual	  
compared	   with	   large	   vessel	   endothelium,	   and	   with	   published	   reports	   of	   VEGF	  
receptor	  ratios	   in	  other	  endothelia	  (Jinnin	  et	  al.,	  2008).	   	  VEGFR-­‐2	  was	  expressed	  at	  
significantly	   higher	   levels	   in	   LSEC	   and	   perhaps	   more	   importantly	   VEGFR-­‐1	   was	  
expressed	   at	   significantly	   lower	   levels.	   	   	   The	   functions	   of	   VEGFR-­‐1	   have	   been	  
variously	   described	  but	   the	  weight	   of	   evidence	   in	   normal	   development	   and	   tissue	  
homeostasis	  supports	  a	  decoy	  function	  that	  protects	  against	  excessive	  activation	  of	  
VEGFR-­‐2	  (Fischer	  et	  al.,	  2008).	  	  These	  findings	  together	  suggest	  that	  LSEC	  are	  primed	  
	  	  
140	  
to	   respond	   to	  VEGFR-­‐2	  mediated	   signals.	   	   Crucially	  VEGFR-­‐2	  has	  been	   reported	   to	  
maintain	  sinusoidal	  fenestrations	  and	  normal	  endothelial	  cell	  phenotype	  (Carpenter	  
et	  al.,	  2005).	  	  Activation	  of	  VEGFR-­‐2	  was	  readily	  detected	  in	  LSEC	  exposed	  to	  VEGF-­‐A	  
or	   the	   VEGFR-­‐2	   specific	   ligand	   VEGF-­‐E.	   	   Similarly	   LSEC	   proliferated	   in	   response	   to	  
VEGF	  in	  a	  VEGFR-­‐2	  dependent	  manner.	  	  This	  response	  was	  limited	  to	  the	  duration	  of	  
VEGF	   stimulation	   indicating	   both	   that	   continued	   stimulation	   (as	   is	   present	   in	   the	  
liver	   (Maharaj	   et	   al.,	   2006))	   is	   required	   for	   continued	  VEGFR-­‐2	   signalling,	   and	   that	  
VEGFR-­‐2	  signalling	   is	  not	   refractory	   to	   repetitive	  stimulation.	   	  The	  unusual	   ratio	  of	  
VEGFR-­‐2	   to	  VEGFR-­‐1	  seen	   in	  LSEC	  suggests	   that	   this	  phenotype	   is	  not	  beneficial	   in	  
other	   endothelia.	   	   Indeed	   this	   is	   predictable	   since	   VEGF-­‐A	   was	   first	   described	   as	  
vascular	   permeability	   factor	   (Senger	   et	   al.,	   1983,	   Senger	   et	   al.,	   1986)	   and	  
permeability	  would	  be	  deleterious	  in	  large	  vessels	  and	  in	  many	  other	  vascular	  beds,	  
for	  example	  in	  the	  lung,	  or	  in	  the	  eye.	  
	  
LSEC	  express	  pro-­‐viral	  factor(s)	  in	  the	  absence	  of	  VEGF-­‐A	  stimulation	  
The	   finding	   that	   in	   the	   absence	   of	   VEGF-­‐A	   stimulation	   LSEC	   provided	   a	   proviral	  
soluble	   signal	   was	   unexpected.	   	   LSEC	   had	   previously	   been	   reported	   to	   provide	  
protective	   signals	   following	  VEGF-­‐A	   stimulation	   in	   chemical	   liver	   injury	   leading	   the	  
authors	  to	  hypothesise	  that	  the	  same	  may	  be	  true	  in	  viral	  infection	  (LeCouter	  et	  al.,	  
2003).	   	   The	   observation	   that	   the	   effect	   of	   VEGF-­‐A	   in	   the	   in	   vitro	   models	   was	   to	  
suppress	  HCV	  infectivity	  following	  VEGFR-­‐2	  stimulation	  was	  broadly	  in	  line	  with	  that	  
hypothesis.	   	   However,	   the	   protective	   effects	   of	   VEGF-­‐A	   in	   the	   early	   rodent	   injury	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models	  were	  reported	  to	  be	  mediated	  by	  VEGFR-­‐1	  signalling	  (LeCouter	  et	  al.,	  2003),	  
however	   a	   later	   report	   studying	   liver	   regeneration	   failed	   to	   substantiate	   this	   and	  
indicated	   a	   VEGFR-­‐2	   mediated	   mechanism	   (Ding	   et	   al.,	   2010).	   	   This	   further	  
highlighted	  the	  importance	  of	  constitutive	  VEGFR-­‐2	  activation	  in	  human	  LSEC.	  	  	  
	  
My	  first	  instinct	  when	  I	  noted	  VEGF-­‐A	  stimulated	  suppression	  of	  HCV	  infectivity	  was	  
to	   look	   for	   evidence	   of	   typical	   anti-­‐viral	   effector	   molecules	   (interferon-­‐α2,	  
interferon-­‐γ,	  and	  tumour	  necrosis	  factor-­‐α)	  in	  the	  LSEC	  culture	  media.	  	  No	  regulation	  
of	   these	   factors	  was	   detected	   and	   in	   retrospect	   it	  was	  more	   likely	   that	   VEGF	  was	  
directly	   regulating	  expression	  of	  a	  proviral	  molecule.	   	   To	  begin	   to	  characterise	   the	  
likely	   effector	   molecule	   we	   screened	   pathways	   downstream	   of	   VEGFR-­‐2	   using	  
chemical	   inhibitors	   (Olsson	   et	   al.,	   2006,	   Koch	   et	   al.,	   2011).	   	   Regulation	   of	   the	  
putative	  proviral	  factor	  by	  p38	  MAPK	  was	  identified.	  	  It	  is	  noteworthy	  that	  LSEC	  (and	  
endothelial	   cells	   in	   general)	   have	  multiple	   roles	   in	  maintaining	   tissue	   architecture	  
through	  expression	  of	   soluble	  mediators,	   termed	   ‘angiocrine’	   factors	   (Butler	  et	  al.,	  
2010).	   	   MAPKs	   have	   recently	   been	   implicated	   in	   this	   pathway	   (Kobayashi	   et	   al.,	  
2010)	  and	  the	  observation	  of	  p38	  MAPK	  involvement	  indicated	  biological	  plausibility	  
to	  the	  VEGF-­‐A	  regulated	  systems	  described.	  	  	  
	  
In	  summary	  these	  data	  highlight	  a	  role	  for	  VEGF-­‐A	  stimulated	  LSEC	  in	  maintaining	  an	  
environment	   that	   is	   less	   permissive	   for	   HCV	   infection	   through	   suppression	   of	   a	  
proviral	  factor,	  or	  factors.	  	  This	  occurs	  through	  VEGF	  stimulation	  of	  VEGFR-­‐2	  and	  p38	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MAPK	   and	   illuminates	   a	   novel	   role	   for	   VEGF-­‐A	   signalling	   and	   LSEC	   in	   chronic	   viral	  
infection.	  	  To	  take	  these	  studies	  forward	  it	  was	  crucial	  to	  identify	  the	  soluble	  factor	  
that	   is	   regulated	   by	   VEGF-­‐A	   and	   to	   determine	   whether	   this	   factor	   is	   of	  
pathophysiological	  importance	  in	  the	  liver	  injury	  associated	  with	  HCV	  infection.	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Chapter	  5	   LSEC	   express	   bone	   morphogenetic	   protein	   4	   that	  
promotes	  HCV	  replication	  	  
	  
Since	  the	  development	  of	  cell	  culture	  methods	  to	  study	  HCV	  replication	  the	  majority	  
of	   reports	  have	   focused	  on	  HCV	   infection	  of	  hepatocytes	   in	   isolation.	  Studying	   the	  
relationship	  between	  different	  cell	   types	   in	  the	   liver	  will	   increase	  understanding	  of	  
HCV	  pathogenesis	  and	  allow	  the	  development	  of	  new	  therapies	   targeting	  host	  cell	  
pathways	  (Zeisel	  et	  al.,	  2012).	  
	  
The	  studies	  on	  LSEC	  hepatocyte	  interactions	  had	  identified	  roles	  for	  both	  cell	  contact	  
and	   VEGF-­‐A	   dependent	   paracrine	   signalling	   to	   regulate	   HCV	   infection	   and	   to	   take	  
these	  observations	  forward	  it	  was	  fundamental	  to	  identify	  the	  endothelial	  expressed	  
soluble	   factor(s)	   that	   are	   regulated	   by	   VEGF-­‐A.	   	   There	   are	   relatively	   few	   soluble	  
factors	   reported	   to	  date	   that	  promote	  HCV	  replication	  and/or	  spread,	   for	   instance	  
transforming	  growth	  factor-­‐β	  (TGFβ)	  (Lin	  et	  al.,	  2008,	  Lin	  et	  al.,	  2010)	  and	  epidermal	  
growth	  factor	   (EGF)	   (Lupberger	  et	  al.,	  2011);	  however,	  neither	  of	   these	  factors	  are	  
known	  to	  be	  regulated	  by	  VEGF-­‐A.	   	  Furthermore,	   there	  were	  no	  data	  to	  support	  a	  
role	   for	   LSEC	   in	   HCV	   infection	   above	   the	   previously	   suggested	   viral	   capture	   and	  




The	   aim	   of	   this	   work	   was	   to	   identify	   the	   VEGF-­‐regulated	   putative	   proviral	   factor	  
expressed	   by	   LSEC	   using	   biochemical	   and	   transciptomic	   analyses.	   	   Following	  
identification	   of	   the	   soluble	   mediator	   I	   planned	   to	   study	   the	   importance	   of	   this	  
molecule,	  or	  molecules	  in	  the	  pathogenesis	  of	  HCV	  infection.	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5.1	   Transcriptome	   analysis	   identifies	   genes	   regulated	   by	   VEGF-­‐A	   in	  
endothelial	  cells	  
	  
I	   previously	   demonstrated	   that	   VEGF-­‐A	   regulates	   LSEC	   expression	   of	   a	   putative	  
proviral	  factor(s).	  	  Since	  similar	  responses	  were	  noted	  with	  HUVEC	  I	  decided	  to	  study	  
the	   global	   gene	   expression	   in	   both	   LSEC	   and	   HUVEC	   in	   response	   to	   VEGF-­‐A	  
stimulation.	   In	   replicate	   conditions	   LSEC	   and	  HUVEC,	   from	   2	   independent	   donors,	  
were	  cultured	  in	  the	  presence	  or	  absence	  of	  VEGF-­‐A	  for	  18	  hours	  prior	  to	  lysis	  and	  
RNA	  extraction	  for	  microarray	  analysis.	  
	  
RNA	  quality	  was	  measured	  as	  outlined	  in	  the	  Materials	  and	  Methods	  and	  was	  used	  
for	  2-­‐colour	  microarray	  analysis	  of	  gene	  expression.	  	  VEGF-­‐A	  upregulated	  273	  genes	  
>1.8-­‐fold	  (with	  a	  false	  discovery	  rate	  of	  <5%)	  in	  LSEC	  and	  almost	  500	  genes	  in	  HUVEC.	  	  
Importantly,	  only	  a	  minority	  of	  these	  genes	  (71)	  were	  upregulated	  in	  both	  cell	  types.	  
A	   smaller	   number	   of	   VEGF	   down	   regulated	   genes	  were	   observed:	   94	   genes	  were	  
down	  regulated	  in	  LSEC	  and	  114	  in	  HUVEC.	  	  Of	  these	  only	  21	  were	  regulated	  in	  both	  
cell	  types	  (Fig.	  5-­‐1A&B).	  	  	  
	  







Figure	  5-­‐1.	  	  Transcriptomic	  analysis	  identifies	  a	  subset	  of	  genes	  regulated	  by	  VEGF-­‐
A	  in	  LSEC	  and	  HUVEC.	  	  	  
LSEC	   and	   HUVEC	   were	   starved	   of	   VEGF-­‐A	   overnight	   and	   stimulated	   with	   VEGF-­‐A	  
(10ng/mL)	  for	  18	  hours.	  	  Cells	  were	  lysed	  for	  RNA	  extraction	  and	  microarray	  analysis.	  	  
Genes	   up-­‐regulated	   (A),	   or	   down-­‐regulated	   (B)	   by	   VEGF-­‐A	   were	   identified	   and	  
overlapping	  regulation	  is	  shown	  in	  the	  Venn	  diagrams.	  	  Transcripts	  predicted	  to	  have	  
a	  soluble	  signal	  product	  are	  highlighted	  in	  red	  circles.	  
	  
	  
	   	  










Importantly	   endothelial	   expressed	   genes	   were	   enriched	   in	   the	   transcriptomic	  
analysis.	   	   Amongst	   those	   transcripts	   identified	   to	   be	   regulated	   by	   VEGF-­‐A	   were	  
genes	  associated	  with	  angiogenesis	  (e.g.	  CXCR4	  (Salcedo	  et	  al.,	  1999,	  Salcedo	  et	  al.,	  
2003)	   and	  VEGFR-­‐1	   (Autiero	   et	   al.,	   2003,	   Fischer	   et	   al.,	   2008)),	   cell	   survival	   (BCL2	  
(Reed	   et	   al.,	   1990,	   Alnemri	   et	   al.,	   1992)),	   and	   one	   that	   was	   characterised	   as	   a	  
consequence	   of	   a	   previous	   cDNA	  microarray	   of	   VEGF-­‐A	   regulated	   endothelial	   cell	  
transcripts	  (VASH	  (Watanabe	  et	  al.,	  2004)).	  
	  
To	  refine	  the	  search	  for	  transcripts	  encoding	  soluble	  molecules	  with	  pro-­‐viral	  activity	  
DAVID	   pathway	   analysis	   was	   employed	   (Huang	   da	   et	   al.,	   2009).	   This	   specialised	  
bioinformatics	  resource	  allows	  the	  extraction	  of	  information	  from	  large	  quantities	  of	  
biological	   information	   such	   as	   gene	   lists.	   The	   transcripts	   were	   classified	   by	  
properties	  of	  the	  gene	  product,	  namely	  whether	  the	  product	  was	  predicted	  to	  be	  a	  
soluble	  or	  paracrine	  signalling	  factor.	  	  Using	  this	  approach	  the	  number	  of	  candidate	  
molecules	   identified	   in	  the	  transcriptomic	  analysis	  was	  reduced	  to	  11	  up-­‐regulated	  
genes	  and	  4	  down-­‐regulated	  genes	  for	  further	  analysis	  (Fig.	  5-­‐1,	  and	  Table	  5-­‐1).	  	  	  
	  




Gene	  Symbol	   Gene	  Name	   LSEC	  FC	   HUVEC	  FC	  
A2M	   Alpha-­‐2-­‐macroglobulin	   5.06	   13.0	  
STAT	   Statherin	   4.78	   4.07	  
PMCH	   Pro-­‐melanin	  concentrating	  hormone	   4.68	   5.07	  
CRLF1	   Cytokine	  receptor-­‐like	  factor	  1	   3.58	   2.24	  
ADAMTS1	   ADAM	  metalloproteinase	  with	  thrombospondin	  type	  
1	  motif	  1	  
3.37	   2.31	  
FLT1	   Fms-­‐related	  tyrosine	  kinase	  1	  (VEGFR-­‐1)	   2.81	   2.25	  
VASH	   Vasohibin	  1	   2.69	   1.85	  
MGP	   Matrix	  gla	  protein	   2.64	   1.87	  
NID2	   Nidogen	  2	   2.67	   2.08	  
MMP1	   Matrix	  metallopeptidase	  1	   2.47	   2.36	  
PLAT	   Plasminogen	  activator	  tissue	   2.12	   4.02	  
	  
B. 
Gene	  Symbol	   Gene	  Name	   LSEC	  FC	   HUVEC	  FC	  
CXCL1	   Chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  1	   -­‐4.74	   -­‐2.80	  
CCL2	   Chemokine	  (C-­‐C	  motif)	  ligand	  2	   -­‐4.03	   -­‐3.85	  
CXCL2	   Chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  2	   -­‐2.14	   -­‐1.86	  
BMP4	   Bone	  morphogenetic	  protein	  4	   -­‐2.11	   -­‐1.93	  
	  
Table	  5-­‐1.	  	  Genes	  regulated	  by	  VEGF-­‐A	  with	  predicted	  soluble	  product.	  	  	  
Genes	  with	  soluble	  product	  that	  were	   identified	  by	  DAVID	  pathway	  analysis	  as	  up-­‐
regulated	  (A),	  or	  down-­‐regulated	  (B),	  in	  both	  endothelial	  cell	  types.	  	  FC,	  fold	  change.	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To	  validate	  the	  microarray	  findings	  VEGF-­‐A	  dependent	  regulation	  of	  selected	  genes	  
in	   LSEC	   and	   HUVEC	   was	   confirmed	   from	   2	   additional	   donors	   (Fig.	   5-­‐2).	   	   These	  
experiments	  showed	  consistent	  regulation	  of	  genes	  as	  predicted	  by	  the	  microarray.	  	  
Importantly	   however,	   since	   none	   of	   the	   genes	   that	   had	   been	   identified	   as	   likely	  
soluble	   signals	   had	   previously	   been	   implicated	   in	   HCV	   infection	   I	   sought	   to	  
characterise	   the	   conditioned	   media	   biochemically	   to	   guide	   identification	   of	   the	  
putative	  proviral	  factor.	  







Figure	  5-­‐2.	  	  Validation	  of	  VEGF-­‐A	  regulated	  transcripts.	  	  	  
Expression	  of	   predicted	  VEGF-­‐A	   regulated	   transcripts	  was	  determined	   in	   LSEC	   and	  
HUVEC	   from	   two	   independent	   donors.	   	   Endothelial	   cells	   were	   starved	   of	   VEGF-­‐A	  
overnight	   and	   stimulated	   with	   VEGF-­‐A	   for	   18	   hours	   as	   indicated.	   	   Expression	   of	  
predicted	  up-­‐regulated	  genes	  (A),	  and	  down-­‐regulated	  genes	  (B)	  was	  determined	  by	  
quantitative	  RT-­‐PCR.	   	   Expression	   is	   shown	   relative	   to	  untreated	   control	   cells	   using	  
the	  2-­‐ΔΔCt	  method.	  
	  






















































































5.2	   Biochemical	  characterisation	  of	  LSEC	  expressed	  proviral	  factor(s)	  
	  
The	   hypothesis	   that	   LSEC	   express	   a	   soluble	   pro-­‐viral	   factor	   that	   is	   negatively	  
regulated	  by	  VEGF-­‐A	  is	  based	  on	  data	  showing	  that	  pre-­‐treating	  hepatoma	  cells	  with	  
endothelial	   cell	   conditioned	   media	   increased	   their	   permissivity	   to	   HCV	   infection.	  
Initial	   experiments	   confirmed	   that	   conditioned	  media	   collected	   from	  LSEC	   isolated	  
from	   6	   independent	   donors,	   in	   the	   presence	   or	   absence	   of	   VEGF-­‐A,	   had	   similar	  
effect(s)	   on	   HCV	   infectivity.	   	   I	   observed	   a	   consistent	   increase	   in	   HCV	   infection	   of	  
hepatocytes	  treated	  with	  LSEC	  conditioned	  media	  that	  was	  ablated	  by	  VEGF-­‐A	  (Fig.	  
5-­‐3A).	   Importantly,	   the	   proviral	   activity	   of	   un-­‐stimulated	   media	   showed	   a	   dose-­‐
dependent	  relationship	  following	  serial	  dilution	  of	  that	  media	  (Fig.	  5-­‐3B).	  
	  	  
	  






Figure	  5-­‐3.	  	  LSEC	  express	  proviral	  factors	  in	  the	  absence	  of	  VEGF-­‐A	  stimulation.	  
Conditioned	  media	  collected	  from	  LSEC	  isolated	  from	  6	  independent	  donors	  seeded	  
at	  4x104/cm2	  either	  untreated,	  or	  stimulated	  with	  VEGF-­‐A	   (10ng/mL)	   for	  24	  hours.	  
The	  media	  were	  diluted	  1:2	  with	  fresh	  media	  and	  used	  to	  treat	  Huh-­‐7.5	  cells	  for	  18	  
hours	  before,	  and	  for	  48	  hours	  following	  infection	  with	  HCV	  JFH-­‐1	  (A).	  Infectivity	  was	  
assessed	  48	  hours	  post-­‐infection	  by	  staining	  for	  NS5A	  and	  enumerating	  positive	  foci.	  	  
Conditioned	   media	   were	   also	   diluted	   in	   fresh	   media	   as	   indicated	   before	   treating	  	  
Huh-­‐7.5	   cells	   and	   infectivity	   assessed	   as	   above	   (B).	   	   Statistical	   comparisons	   were	  
made	  with	  the	  Kruskal-­‐Wallis	  test	  with	  Dunn’s	  correction	  and	  where	  ***	  P<0.001	  vs.	  
mock	  conditioned	  media	  (n=6	  donor	  LSEC	  conditioned	  media).	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Secondly	   the	   conditioned	   media	   were	   size-­‐fractionated	   to	   identify	   the	   molecular	  
weight	  of	  the	  putative	  pro-­‐viral	  soluble	  factor(s)	  (Fig.	  5-­‐4).	   	  Using	  columns	  with	  10,	  
30,	   50,	   and	   100	   kDa	   size	   exclusion	  membranes	   I	   tested	   the	   ability	   of	   fractions	   to	  
modulate	   HCV	   infection	   of	   Huh-­‐7.5	   cells.	   Molecular	   weight	   partitioning	   of	   non-­‐
stimulated	  conditioned	  media	  showed	  that	   the	   larger	   than	  50	  kDa	   fraction	  had	  no	  
effect	  on	  HCV	   infection,	  whereas	  the	  fraction	  of	  at	   least	  30	  kDa	   in	  size	  was	  active,	  
suggesting	  the	  pro-­‐viral	  factor(s)	  were	  between	  30	  and	  50	  kDa	  in	  molecular	  weight	  
(Fig.	   5-­‐4A).	   	   As	   expected,	   size	   fractionating	   the	   VEGF-­‐A	   stimulated	   conditioned	  
media	  had	  no	  effect	   of	   viral	   infectivity,	   suggesting	   that	  VEGF-­‐A	   acts	   to	   suppress	   a	  
proviral	  factor	  (Fig.	  5-­‐4B).	  







Figure	  5-­‐4.	  	  Molecular	  weight	  screening	  of	  LSEC	  proviral	  soluble	  factor(s).	  
Conditioned	  media	  (CM)	  was	  collected	  from	  LSEC	  in	  the	  absence	  (A)	  or	  presence	  of	  
VEGF-­‐A	   (10ng/mL)	   (B).	   Media	   was	   fractionated	   using	   molecular	   weight	   cut-­‐off	  
(MWCO)	  exclusion	  membranes.	   	  The	  media	  were	  diluted	  1:2	  with	  fresh	  media	  and	  
used	  to	  treat	  Huh-­‐7.5	  cells	  for	  18	  hours	  before,	  and	  for	  48	  hours	  following	  infection	  
with	  HCV	   JFH-­‐1.	   Infectivity	   is	  presented	   relative	   to	  Huh-­‐7.5	  cells	   treated	  with	  non-­‐
conditioned	  media	  (black	  bars).	  Statistical	  comparisons	  were	  made	  with	  the	  Kruskal-­‐
Wallis	   test	   with	   Dunn’s	   correction	   where	   *	   P<0.05,	   and	   **	   P<0.01,	   vs.	   mock	  
conditioned	  media	  (n=3	  donor	  LSEC	  conditioned	  media).	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5.3	   Identification	  of	  BMP4	  as	  a	  proviral	  factor	  in	  HCV	  infection	  
	  
Using	  the	  data	  generated	   in	  the	  preceding	  experiments	   I	   reviewed	  the	   	  microarray	  
data	  to	  identify	  soluble	  factor(s)	  of	  the	  defined	  molecular	  weight.	  	  Four	  genes	  (CCL2,	  
CXCL1,	   BMP4,	   and	   CXCL2)	   were	   identified	   in	   the	   microarray	   that	   were	   down-­‐
regulated	  by	  VEGF-­‐A.	  	  Of	  these	  only	  BMP4	  has	  a	  molecular	  weight	  that	  is	  compatible	  
with	   the	   size-­‐fractionation	   experiments	   (36	   kDa).	   	   The	   other	   molecules	   are	  
chemokines	  with	  molecular	  weights	  of	  11	  kDa.	   	   Initial	  experiments	  confirmed	   that	  
VEGF-­‐A	   regulates	   LSEC	  expression	  of	  BMP4.	   	   Since	   LSEC	  are	  maintained	   in	  VEGF-­‐A	  
during	   routine	   culture	   to	   aid	   their	   proliferation	   BMP4	   gene	   expression	   following	  
VEGF-­‐A	   withdrawal	   was	   monitored	   (Fig.	   5-­‐5A).	   	   A	   significant	   increase	   in	   BMP4	  
expression	   following	  24	  hours	  VEGF-­‐A	  withdrawal	  was	  noted.	   	   I	   then	   treated	  LSEC	  
starved	  of	  VEGF-­‐A	  with	  recombinant	  growth	  factor	  and	  observed	  a	  dose	  dependent	  
decrease	   in	   BMP4	   messenger	   RNA	   levels	   (Fig.	   5-­‐5B)	   that	   paralleled	   the	   effect	   of	  
VEGF-­‐A	   on	   pro-­‐viral	   activity	   of	   LSEC	   conditioned	  media.	   In	   replicate	   experiments,	  
LSEC	   were	   stimulated	   with	   VEGF-­‐A	   and	   BMP4	   protein	   expression	   determined	   by	  
immunoblotting.	  	  Reduced	  BMP4	  expression	  was	  noted	  consistent	  with	  results	  from	  
the	  transcript	  analyses	  (Fig.	  5-­‐5C).	  	  	  
	  
Finally	  I	  explored	  the	  pathway	  regulating	  the	  VEGF-­‐A	  response	  in	  LSEC.	  	  Using	  VEGF	  
receptor	   specific	   ligands	   I	   noted	   that	   VEGFR-­‐2	   activation	   suppresses	   BMP4	  
expression	   (Fig.	   5-­‐5D).	   	   Furthermore	   since	   a	   role	   for	   the	   p38	   MAPK	   signalling	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pathway	   had	   been	   observed	   in	   LSEC	   pro-­‐viral	   activity	   (Fig.	   4-­‐7),	   this	   pathway	  was	  
manipulated	  with	  a	  chemical	  inhibitor	  and	  monitored	  the	  effect	  on	  BMP4	  messenger	  
RNA	   expression.	   	   Chemical	   inhibition	   of	   p38	  MAPK	   dose	   dependently	   blocked	   the	  
effect	   of	   VEGF-­‐A	   stimulation	   on	   BMP4	   expression	   (Fig.	   5-­‐5E).	   	   In	   summary,	   these	  
studies	   show	   that	   LSEC	  expression	  of	  BMP4	   is	   regulated	  by	  VEGF-­‐A	   via	   a	  VEGFR-­‐2	  
p38	  MAPK	  dependent	  pathway.	  




Figure	  5-­‐5.	  	  BMP4	  is	  regulated	  by	  VEGF-­‐A	  in	  LSEC.	  	  	  
LSEC	   were	   starved	   of	   VEGF-­‐A	   stimulation	   for	   the	   time	   indicated	   and	   BMP4	  
expression	   assessed	   by	   quantitative	   RT-­‐PCR	   (A).	   	   Following	   overnight	   VEGF-­‐A	  
starvation	  LSEC	  were	  stimulated	  with	  VEGF-­‐A	  (at	  the	  doses	   indicated)	   for	  18	  hours	  
and	   BMP4	   expression	   assessed	   (B).	   	   BMP4	   expression	   is	   expressed	   relative	   to	  
untreated	  control	  using	  the	  2-­‐ΔΔCt	  method.	   	   In	  replicate	  experiments	  after	  24	  hours	  
of	  VEGF-­‐A	  (10ng/mL)	  stimulation	  LSEC	  were	   lysed	  to	  analyse	  protein	  expression	  by	  
immunoblotting	   (C).	   	   LSEC	  were	   starved	   of	   VEGF-­‐A	   overnight	   and	   stimulated	  with	  
VEGF-­‐A	  (10ng/mL),	  PlGF	  (10ng/mL),	  or	  VEGF-­‐E	  (10ng/mL)	  as	   indicated	  for	  18	  hours	  
before	   lysis	   and	   quantitative	   RT-­‐PCR	   (D).	   	   Following	   VEGF-­‐A	   starvation	   LSEC	  were	  
treated	   with	   p38	   MAPK	   inhibitor	   (SB203580)	   at	   the	   doses	   indicated	   for	   1	   hour	  
before	   cells	   were	   washed	   and	   stimulated	   with	   VEGF-­‐A	   (10ng/mL)	   for	   18	   hours.	  	  
Expression	  of	  BMP4	  was	  assessed	  by	  quantitative	  RT-­‐PCR	  (E).	  Statistical	  comparisons	  
were	  made	  with	  the	  Kruskal-­‐Wallis	  test	  with	  Dunn’s	  correction	  where	  *	  P<0.05,	  **	  
P<0.01,	   and	   ***	   P<0.001,	   vs.	   untreated	   control	   or	   mock	   conditioned	   media	   as	  
indicated	  (n=6	  donor	  LSEC	  for	  panel	  A-­‐D,	  and	  n=3	  donor	  LSEC	  for	  panel	  E).	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To	  establish	  a	   role	   for	  BMP4	   in	  HCV	   infection	   I	  used	  recombinant	  protein	   to	  study	  
multiple	   aspects	   of	   the	  HCV	   lifecycle.	   	   Firstly	   I	   screened	   for	   an	   effect	   of	   BMP4	  on	  
HCVcc	  infection	  that	  recapitulates	  the	  entire	  lifecycle.	  	  A	  dose-­‐dependent	  increase	  in	  
HCV	   infection	   was	   noted	   in	   keeping	   with	   the	   hypothesis	   that	   BMP4	   is	   a	   proviral	  
factor	  (Fig.	  5-­‐6A).	  	  Importantly,	  the	  BMP4-­‐dependent	  increase	  in	  HCV	  infectivity	  was	  
also	  observed	  with	  primary	  human	  hepatocytes	  as	  the	  target	  cell	  for	  viral	   infection	  
(Fig.	  5-­‐6B).	  	  I	  confirmed	  that	  BMP4	  promotes	  HCV	  RNA	  replication	  in	  hepatoma	  cells	  
supporting	   sub-­‐genomic	   and	   full-­‐length	   replicons	   (Fig.	   5-­‐6C).	   	   Finally	   the	   HCVpp	  
system	  was	  used	   to	   screen	   for	  an	  effect	  of	  BMP4	  on	  HCV	  glycoprotein-­‐dependent	  
entry.	   	   In	   these	   studies	  no	  effect	   of	  BMP4	  on	  HCVpp	  entry	   into	  Huh-­‐7.5	   cells	  was	  
noted	  confirming	   that	   the	  effect	  of	  BMP4	   is	   to	   stimulate	  HCV	  replication	  and	   thus	  
increase	   overall	   infectivity.	   These	   findings	   recapitulated	   the	   earlier	   observations	  
with	  LSEC	  conditioned	  media,	  supporting	  a	  role	  for	  BMP4	  in	  HCV	  replication.	  	  





Figure	  5-­‐6.	  	  BMP4	  increases	  HCV	  replication.	  	  	  
Huh-­‐7.5	   cells	  were	   treated	  with	   increasing	   doses	   of	   BMP4	   and	   infected	  with	   HCV	  
JFH-­‐1.	   	  48	  hours	  post	   infection	  cells	  were	  stained	  for	  NS5A	  and	  infectivity	  assessed	  
by	  enumerating	  NS5A	  positive	   foci	   (A).	   	   Primary	  human	  hepatocytes	  were	   treated	  
with	  BMP4	  (100ng/mL)	  and	   infected	  with	  HCV	  JFH-­‐1.	   	  72	  hours	  post	   infection	  cells	  
were	   lysed	   for	   quantification	   of	   HCV	   RNA	   abundance	   by	   quantitative	   RT-­‐PCR	   (B).	  	  
Huh-­‐7.5	   cells	   harbouring	   HCV	   subgenomic	   replicons	   were	   treated	   with	   increasing	  
doses	  of	  BMP4	  and	  72	  hours	   later	  were	   lysed	   for	  quantitative	  RT-­‐PCR	  analysis	   (C).	  	  
HCV	  RNA	  abundance	  is	  expressed	  relative	  to	  untreated	  control.	  	  Increasing	  doses	  of	  
BMP4	  were	  used	   to	   stimulated	  Huh-­‐7.5	   cells	   undergoing	   infection	  with	  HCVpp,	   or	  
control	  VSVpp.	  	  After	  72	  hours	  cells	  were	  lysed	  for	  quantification	  of	  luciferase	  signal	  
that	   is	   expressed	   relative	   to	   untreated	   control	   (D).	   	   Statistical	   comparisons	   were	  
made	   with	   the	   Mann-­‐Witney	   U	   test,	   or	   the	   Kruskal-­‐Wallis	   test	   with	   Dunn’s	  
correction	  as	  appropriate	  where	  *	  P<0.05,	  and	  **	  P<0.01,	  vs.	  untreated	  control	  (n=4	  
independent	  experiments).	   	  






















































































































Finally	   to	   confirm	   a	   role	   for	   BMP4	   in	   LSEC	   conditioned	  media	   on	  HCV	   infectivity	   I	  
studied	   the	   effect	   of	   neutralising	   antibodies	   targeting	  BMP4	   (Fig.	   5-­‐7).	   To	   confirm	  
antibody	   specificity	   Huh-­‐7.5	   cells	   were	   treated	   with	   BMP4	   in	   the	   presence	   or	  
absence	   of	   anti-­‐BMP4	   neutralising	   antibody	   (Fig.	   5-­‐7A).	   	   These	   studies	   confirmed	  
that	  anti-­‐BMP4	  blocked	  the	  effect	  of	  recombinant	  BMP4	  on	  viral	   infectivity.	   	  These	  
experiments	   also	   indicated	   that	   there	  was	   no	   contribution	   from	  BMP4	   in	  Huh-­‐7.5	  
monocultures,	   suggesting	   that	   the	   hepatoma	   cells	   do	   not	   express	   BMP4.	  	  
Neutralising	  BMP4	  abrogated	   the	  proviral	   effect	  of	  unstimulated	   LSEC	  conditioned	  
media	  (Fig.	  5.7B),	  confirming	  the	  role	  of	  BMP4	  as	  the	  pro-­‐viral	  factor	  expressed	  by	  
LSEC	  that	  stimulates	  HCV	  infectivity	  in	  the	  absence	  of	  VEGF-­‐A	  stimulation.	  







Figure	  5-­‐7.	  	  LSEC	  expressed	  BMP4	  increases	  HCV	  infectivity.	  	  	  
Huh-­‐7.5	   cells	  were	   treated	  with	  BMP4	   as	   indicated	   in	   the	   presence	  or	   absence	  of	  
neutralising	   anti-­‐BMP4	   antibody	   (10μg/mL)	   (A).	   	   LSEC	   conditioned	   media	   were	  
generated	   from	   cells	   treated	   with	   VEGF-­‐A	   (10ng/mL)	   as	   previously	   described	   and	  
were	   treated	  with	   neutralising	   anti-­‐BMP4	  antibody	   as	   indicated.	   	   The	  media	  were	  
diluted	  1:2	  with	  fresh	  media	  and	  used	  to	  treat	  Huh-­‐7.5	  cells	  for	  18	  hours	  before,	  and	  
for	   48	   hours	   following	   infection	   with	   HCV	   JFH-­‐1	   (B).	   	   Infectivity	   was	   assessed	   by	  
enumerating	   NS5A	   positive	   foci.	   	   Statistical	   comparisons	   were	   made	   with	   the	  
Kruskal-­‐Wallis	  test	  with	  Dunn’s	  correction	  where	  *	  P<0.05,	  vs.	  untreated	  control,	  or	  
mock	  conditioned	  media	  as	  indicated	  (panel	  A,	  n=3	  experiments;	  panel	  B,	  n=4	  donor	  
LSEC	  conditioned	  media).	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5.4	   BMP4	  and	  VEGFR-­‐2	  expression	  in	  human	  liver	  
	  
There	  are	  limited	  reports	  on	  the	  role	  of	  BMP4	  in	  adult	  liver	  and	  these	  relate	  largely	  
to	   involvement	   in	   pathological	   processes	   including	   fibrosis	   (Fan	   et	   al.,	   2006)	   and	  
carcinogenesis	   (Chiu	   et	   al.,	   2012,	   Maegdefrau	   et	   al.,	   2009,	   Maegdefrau	   and	  
Bosserhoff,	  2012).	  	  I	  therefore	  sought	  to	  investigate	  BMP4	  and	  VEGFR-­‐2	  expression	  
in	  normal	  and	  diseased	  liver.	  	  
	  
VEGFR-­‐2	   expression	   localised	   to	   the	   liver	   sinusoidal	   endothelium	   (Fig.	   5-­‐8A),	  
consistent	   with	   the	   quantitative	   RT-­‐PCR	   detection	   of	   VEGFR-­‐2	   messenger	   RNA	   in	  
LSEC	   (Fig.	   5-­‐8B).	   	   It	  was	   not	   possible	   to	   confidently	   identify	   cell	   types	   in	   the	   liver	  
expressing	  BMP4	  by	  immunohistochemical	  methods	  however	  BMP4	  messenger	  RNA	  
was	   largely	   restricted	   to	  LSEC	  ex	  vivo	   (Fig.	   5-­‐8C),	   suggesting	   that	   this	   cell	   type	   is	  a	  
major	  site	  for	  expression	  in	  the	  liver.	  	  









Figure	  5-­‐8.	  	  VEGFR-­‐2	  and	  BMP4	  expression	  is	  largely	  restricted	  to	  LSEC.	  	  	  
Sections	  of	  normal	  human	  liver	  were	  stained	  with	  antibody	  specific	  for	  VEGFR-­‐2	  (A).	  	  
Constituent	  cell	  types	  (LSEC;	  PHH,	  primary	  human	  hepatocytes;	  BEC,	  biliary	  epithelial	  
cells;	   aLMF,	   activated	   liver	   myofibroblasts)	   were	   isolated	   from	   diseased	   liver	   and	  
expression	  of	  VEGFR-­‐2	  (B),	  and	  BMP4	  (C)	  was	  determined	  using	  quantitative	  RT-­‐PCR.	  	  
Gene	  expression	   is	  expressed	  relative	   to	  LSEC	  using	   the	  2-­‐ΔΔCt	  method	   (n=3	  donors	  
for	  each	  cell	  type).	  
	   	  










































Finally	   before	   embarking	   on	   studies	   of	   HCV	   infected	   whole	   liver	   it	   was	   critical	   to	  
determine	  whether	  HCV	   infection	  per	   se	   regulates	  expression	  of	  BMP4	   in	   infected	  
hepatocytes.	   	  Using	  Huh-­‐7.5	   cells	   infected	  with	  high	   titre	  HCVcc	  BMP4	  messenger	  
RNA	  was	  quantified	  at	  72	  hours	  post	  infection	  and	  compared	  to	  uninfected	  cells.	  	  In	  
cultures	  where	  approximately	  80%	  of	  Huh-­‐7.5	  cells	  were	  infected	  I	  did	  not	  observe	  
any	   increase	   in	  BMP4	   expression	   suggesting	   that	   HCV	   infection	   does	   not	   regulate	  
BMP4	   directly	   (Fig.	   5-­‐9A).	   	   Importantly	   VEGF-­‐A	   messenger	   RNA	   expression	   was	  
increased	   following	   HCV	   infection	   as	   previously	   reported	   (Fig.	   5-­‐9B).	   In	   summary,	  
these	  studies	  highlight	  a	  role	  for	  LSEC	  as	  the	  major	  cell	  type	  in	  the	  liver	  expressing	  
BMP4.	  	  






Figure	  5-­‐9.	  	  HCV	  infection	  does	  not	  regulate	  BMP4	  messenger	  RNA	  expression.	  
	  Huh-­‐7.5	  cells	  were	  infected	  with	  high	  titre	  HCVcc	  JFH-­‐1.	  	  72	  hours	  post	  infection	  the	  
cells	  were	  lysed	  for	  analysis	  of	  gene	  expression	  by	  quantitative	  RT-­‐PCR.	  	  Expression	  
of	   BMP4	   (A),	   and	   VEGF-­‐A	   (B)	   were	   quantified	   and	   expressed	   relative	   to	   the	  
untreated	  control	  using	  the	  2-­‐ΔΔCt	  method.	  	  Statistical	  comparisons	  were	  made	  with	  
the	   Mann-­‐Witney	   U	   test	   where	   *	   P<0.05,	   vs.	   mock	   untreated	   control	   (n=4	  
independent	  experiments).	  
	  












































5.5	   Regulation	  of	  BMP4	  expression	  in	  HCV-­‐associated	  liver	  disease	  
	  
The	  role	  of	  BMP4	  in	   liver	  disease	  is	  poorly	  defined	  and	  to	  determine	  the	  effects	  of	  
HCV	   in	   the	   liver	   I	   studied	   human	   liver	   from	   patients	   with	   end-­‐stage	   liver	   disease	  
from	   either	   HCV	   related	   liver	   disease,	   or	   from	   alcohol	   related	   liver	   disease	   (ALD).	  	  
These	  specimens	  were	  compared	  to	  normal	   liver	  that	  was	  surplus	  to	  requirements	  
for	  transplantation	  purposes.	  
	  
Using	   these	   samples	   I	   first	   looked	   at	   expression	   of	   BMP4	   messenger	   RNA	   and	  
protein	   across	   the	   disease	   states.	   	   In	   these	   studies	   low	   expression	   of	   BMP4	   in	  
healthy	   liver	   and	   increased	   expression	   in	   the	   diseased	   tissue	  was	   noted.	   	   Notably	  
expression	   was	   greatest	   in	   patients	   with	   ALD	   rather	   than	   in	   patients	   with	   HCV	  
infection	  (Fig.	  5-­‐10).	  






Figure	  5-­‐10.	  	  BMP4	  expression	  is	  increased	  in	  chronic	  liver	  disease.	  	  	  
Samples	  from	  normal	  liver,	  and	  diseased	  liver	  as	  a	  consequence	  of	  HCV	  infection	  or	  
alcohol	   related	   liver	   disease	   (ALD)	   were	   analysed	   for	   BMP4	   protein	   (A)	   and	  
messenger	   RNA	   expression	   (B).	   	   Representative	   blots	   from	   3	   donors	   are	   shown.	  	  
BMP4	   expression	   is	   expressed	   relative	   to	   normal	   liver	   control	   using	   the	   2-­‐ΔΔCt	  
method.	  	  Statistical	  comparisons	  were	  made	  with	  the	  Kruskal-­‐Wallis	  test	  with	  Dunn’s	  
correction	  where	  *	  P<0.05,	  and	  ***	  P<0.001,	  vs.	  normal	  liver	  control	  (n=6	  for	  each	  
disease	  type).	  
	  

























We,	   and	   others,	   have	   previously	   reported	   that	   HCV	   infection	   increases	   VEGF	  
expression	   and	   the	   finding	   that	   BMP4	   expression	   was	   increased	   in	   disease	   was	  
surprising	   given	   that	   the	   in	   vitro	   studies	   would	   predict	   an	   inverse	   association	  
between	  VEGF-­‐A	  and	  BMP4	  expression.	  	  I	  therefore	  studied	  the	  expression	  of	  VEGF-­‐
A	  and	  its	  cognate	  receptors	  VEGFR-­‐1	  and	  VEGFR-­‐2	  in	  the	  normal	  and	  diseased	  liver	  
tissue	  samples	   (Fig.	   5-­‐11).	   	  Both	  VEGF-­‐A	  and	  VEGFR-­‐2	  messenger	  RNA	  and	  protein	  
were	   increased	   in	   HCV	   and	   ALD	   related	   liver	   disease	   (Fig.	   5-­‐11).	   	   Since	   a	   clear	  
dependence	   of	   VEGFR-­‐2	   activation	   to	   suppress	   BMP4	   mRNA	   levels	   had	   been	  
observed,	  I	  studied	  VEGFR-­‐2	  phosphorylation	  as	  a	  marker	  of	  receptor	  activation	  (Fig.	  
5-­‐11D-­‐E).	   	   Interestingly	   VEGFR-­‐2	   expression	   was	   increased	   in	   liver	   disease	   where	  
angiogenesis	   and	   increases	   in	   endothelial	   cell	   number	   are	   well	   recognised	  
(Fernandez	  et	  al.,	  2009).	  	  However,	  there	  was	  little	  change	  in	  the	  levels	  of	  VEGFR-­‐2	  
phosphorylation	   observed	   between	   normal	   and	   diseased	   liver	   samples.	   	   The	  
resulting	   outcome	   is	   a	   reduction	   in	   the	   ratio	   of	   phosphorylated	   VEGFR-­‐2	   to	   total	  
VEGFR-­‐2	   in	  diseased	  liver,	  and,	  by	   inference,	  a	  reduction	   in	  the	  VEGFR-­‐2	  activation	  
on	  a	  per	  endothelial	   cell	  basis.	   	   Thus	   in	  HCV	  and	  ALD	  diseased	   liver,	   I	  hypothesise	  
that	  BMP4	  expression	  is	  elevated	  due	  to	  decreased	  per	  cell	  VEGFR-­‐2	  activation	  and	  
that	  this	  may	  contribute	  to	  pathological	  processes	  including	  liver	  fibrosis	  (Fan	  et	  al.,	  
2006),	   carcinogenesis	   (Chiu	  et	  al.,	  2012,	  Maegdefrau	  et	  al.,	  2009,	  Maegdefrau	  and	  
Bosserhoff,	  2012)	  and	  HCV	  replication.	  






Figure	  5-­‐11.	  	  VEGFR-­‐2	  activation	  is	  reduced	  in	  chronic	  liver	  disease.	  	  	  
VEGF-­‐A	  and	  VEGFR-­‐2	  expression	  was	  analysed	  in	  samples	  of	  liver	  tissue	  from	  normal	  
liver,	  and	  diseased	   liver	  as	  a	  consequence	  of	  HCV	   infection	  or	  alcohol	   related	   liver	  
disease	   (ALD).	   	   Expression	  of	  VEGF-­‐A	   (A),	   and	  VEGFR-­‐2	   (B)	   is	   expressed	   relative	   to	  
normal	   liver	   control	   using	   the	   2-­‐ΔΔCt	   method.	   	   Phosphorylation	   of	   VEGFR-­‐2	   is	  
identified	   in	   whole	   liver	   (C)	   and	   relative	   activation	   is	   determined	   by	   the	   ratio	   of	  
phospho-­‐VEGFR-­‐2	  to	  total	  VEGFR-­‐2	  (D).	  	  Statistical	  comparisons	  were	  made	  with	  the	  
Kruskal-­‐Wallis	   test	   with	   Dunn’s	   correction	   where	   *	   P<0.05,	   **	   P<0.01,	   and	   ***	  
P<0.001,	  vs.	  normal	  liver	  control	  (n=6	  for	  each	  liver	  disease	  type).	  
	  





































































Finally	  since	  VEGFR-­‐1	  has	  been	  reported	  to	  act	  as	  a	  decoy	  receptor	  to	  limit	  VEGFR-­‐2	  
activation	  (Fischer	  et	  al.,	  2008)	  I	  sought	  to	  determine	  expression	  of	  VEGFR-­‐1	  in	  liver	  
disease.	   	   Indeed	   VEGFR-­‐1	   expression	   was	   induced	   in	   liver	   disease	   at	   comparable	  
levels	  to	  VEGFR-­‐2	  (Fig	  5-­‐12A).	  	  Furthermore	  I	  was	  interested	  to	  understand	  whether	  
VEGFR-­‐1	   was	   regulated	   in	   LSEC	   by	   VEGF-­‐A	   stimulation.	   	   VEGF-­‐A	   expression	   was	  
increased	   in	   liver	   disease	   and	   in	   cultured	   LSEC	   VEGF-­‐A	   stimulation	   significantly	  
increased	  expression	  of	  VEGFR-­‐1	   (Fig.	  5-­‐12B).	   	  These	  findings	  support	  a	  hypothesis	  
where	   VEGFR-­‐2	   signals	   in	   endothelial	   cells	   in	   diseased	   liver	   may	   be	   limited	   by	  
increased	  expression	  of	  VEGFR-­‐1.	  	  






Figure	  5-­‐12.	   	  VEGFR-­‐1	  expression	   is	   regulated	  by	  VEGF-­‐A	  and	   is	   increased	   in	   liver	  
disease.	  	  	  
Whole	   liver	   samples	   (normal	   liver,	  HCV	   infected,	   and	  alcohol	   related	   liver	  disease,	  
each	   n=6)	   were	   assessed	   for	   VEGFR-­‐1	   expression	   by	   quantitative	   RT-­‐PCR	   and	   is	  
expressed	   relative	   to	   normal	   liver	   control	   using	   the	   2-­‐ΔΔCt	  method	   (A).	   	   LSEC	  were	  
starved	  of	  VEGF-­‐A	  overnight	  and	  then	  stimulated	  with	  increasing	  doses	  of	  VEGF-­‐A	  as	  
indicated	  for	  18	  hours.	  	  VEGFR-­‐1	  expression	  was	  analysed	  by	  quantitative	  RT-­‐PCR	  as	  
above	   (B).	   	   Statistical	   comparisons	   were	   made	   with	   the	   Kruskal-­‐Wallis	   test	   with	  
Dunn’s	   correction	   where	   *	   P<0.05,	   and	   **	   P<0.01,	   vs.	   untreated,	   or	   normal	   liver	  
control	  as	  indicated	  (n=6	  for	  each	  liver	  disease	  type).	  
	  
	   	  













































5.6	   Discussion	  
	  
BMP4	  is	  a	  proviral	  factor	  in	  HCV	  infection	  that	  is	  regulated	  by	  VEGF-­‐A	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
These	  studies	   identify	  two	  novel	  aspects	  of	   liver	  pathophysiology	  with	   implications	  
for	  HCV	  pathogenesis	  and	  liver	  disease	  in	  general.	  	  Firstly,	  I	  have	  identified	  BMP4	  as	  
a	  proviral	  molecule	  that	  is	  expressed	  in	  the	  chronically	  infected	  liver,	  and	  secondly	  I	  
have	  described	  a	  role	   for	  VEGF-­‐A	   in	  regulating	  endothelial	  BMP4	  expression	   in	   the	  
liver.	  	  The	  pathway	  defining	  VEGF-­‐A	  regulated	  BMP4	  expression	  in	  LSEC	  is	  illustrated	  
in	  Fig.	  5-­‐13.	  	  
	  
BMP4	   is	   a	  member	   of	   a	   large	   group	   of	   related	   growth	   factors	   that	   constitute	   the	  
largest	  subgroup	  of	  the	  TGFβ	  superfamily	  (Lavery	  et	  al.,	  2008).	  	  These	  growth	  factors	  
were	   initially	   identified	   for	   their	   ability	   to	   induce	   ectopic	   bone	   formation	   but	   it	   is	  
increasingly	   recognised	   that	  many	   play	   substantial	   roles	   in	   development.	   	   Several	  
members	   of	   the	   family	   are	   critical	   for	   early	   development	   since	   genetic	   deletion	   is	  
embryonically	   lethal	   (Winnier	   et	   al.,	   1995,	   Bragdon	   et	   al.,	   2011).	   	   Indeed	   genetic	  
deletion	   of	   BMP4	   results	   in	  multiple	   defects	   during	   embyogenesis	   including	   failed	  
gastrulation,	   mesoderm	   formation,	   and	   primitive	   haematopoiesis	   (Sadlon	   et	   al.,	  
2004).	  	  BMP4	  is	  also	  involved	  in	  liver	  development	  where	  expression	  in	  the	  septum	  
transversum	  mesenchyme	  is	  responsible	  for	  specification	  of	  the	  endoderm	  to	  a	  liver	  




Similar	   to	  other	  members	  of	   the	  TGFβ	   family	   the	  BMPs	  have	  a	   common	   structure	  
and	   signalling	   pathway	   (Bragdon	   et	   al.,	   2011).	   	   Mature	   BMP	   dimers	   bind	   to	  
transmembrane	   type	   I,	   and	   type	   II	   serine	   threonine	   kinase	   receptors	   (reviewed	   in	  
(Derynck	   and	   Zhang,	   2003,	   Wharton	   and	   Derynck,	   2009).	   	   BMPs	   can	   bind	   three	  
different	   type	   I,	   and	  3	  different	   type	   II	   receptors.	   	  BMP4	  binds	   to	   type	   I	   receptors	  
BMPR-­‐IA,	  BMPR-­‐IB,	  and	  ALK-­‐2,	  and	  to	  type	  II	  receptors	  BMPR-­‐II,	  ActR-­‐II,	  and	  ActR-­‐IIB.	  	  
Signals	   transduced	   by	   these	   receptors	   result	   in	   the	   phosphorylation	   of	   receptor-­‐
regulated	  R-­‐SMAD	  proteins	  (SMAD1,	  SMAD5,	  and	  SMAD8).	  	  These	  activated	  SMADs	  
form	   a	   complex	   with	   the	   co-­‐SMAD	   (SMAD4)	   that	   translocates	   to	   the	   nucleus	   to	  
stimulate	   the	   transcription	   of	   an	   array	   of	   target	   genes.	   	   Signals	   may	   also	   be	  
transduced	   through	   non-­‐SMAD	   pathways	   including	   p38	   and	   ERK	   MAPKs.	   	   Thus	  
signalling	   by	   the	  BMP	   family	   is	   complex	   and	   requires	   regulation	   to	   ensure	   correct	  
transmission	   of	   signals.	   	   Regulation	   is	   managed	   in	   part	   by	   receptor	   specificity	  
however,	  a	  number	  of	  BMP	  antagonists	  exist	  to	  regulate	  extracellular	  BMP	  activities.	  	  
Noggin	  is	  the	  best	  characterised	  BMP	  antagonist	  and	  is	  known	  to	  antagonise	  BMP4,	  
as	  well	  as	  BMP2,	   -­‐5,	   -­‐6,	   -­‐7,	   -­‐13,	  and	  -­‐14	   (Smith	  and	  Harland,	  1992,	  Gazzerro	  et	  al.,	  
1998,	  Bachiller	  et	  al.,	  2000).	   	  Lastly	   inhibitory	  SMADs,	  and	  SMURF	  ubiquitin	   ligases	  
modulate	  intracellular	  signals	  (Massague	  et	  al.,	  2005)	  highlighting	  the	  multiple	  levels	  
for	  regulating	  BMP	  signalling,	  as	  might	  be	  expected	  for	  processes	  that	  are	  critical	  for	  




Additional	   function(s)	  of	  BMP4	   in	   the	   liver	  have	  not	  been	   investigated	   in	  detail.	   In	  
the	  normal	  adult	   liver	  were	  observed	  very	   low	   levels	  of	  BMP4	  were	  observed	  and	  
expression	   was	   increased	   during	   liver	   injury.	   These	   findings	   suggest	   that	   BMP4	  
expression	  may	  be	  activated	  as	  part	  of	   reparative	  processes.	  The	  observation	   that	  
BMP4	   stimulates	   HCV	   replication	   is	   supported	   by	   two	   independent	   publications.	  
Firstly,	  BMP4	  is	  a	  member	  of	  the	  TGFβ	  superfamily	  and	  recent	  reports	  demonstrate	  
that	   TGFβ	   can	   promote	   HCV	   replication	   (Lin	   et	   al.,	   2008).	   	   Secondly,	   in	   a	   siRNA	  
screen	   of	   host	   cell	   factors	   implicated	   in	   HCV	   replication,	   Smad5	   knockdown	   was	  
shown	  to	  limit	  HCV	  replication	  further	  highlighting	  a	  role	  for	  these	  molecules	  in	  the	  
viral	   lifecycle	   (Li	  et	  al.,	  2009).	  Thus	   factors	  expressed	   in	   the	   injured	   liver,	   including	  
TGFβ	  and	  BMP4,	  facilitate	  viral	  replication	  suggesting	  that	  this	  may	  be	  an	  adaptive	  
response	  by	  HCV.	  	  Furthermore	  since	  BMP4	  is	  expressed	  at	  low	  levels	  in	  the	  normal	  
liver	  BMP4	  represents	  a	  novel	  target	  for	  therapeutic	  intervention.	  	  
	  







Figure	  5-­‐13.	  	  LSEC	  paracrine	  signals	  regulate	  HCV	  replication.	  	  	  
In	   the	   normal	   liver	   BMP4	   expression	   is	   suppressed	   through	   VEGFR-­‐2/p38	   MAPK	  
signalling	   (A).	   	   Following	   HCV	   infection	   VEGF-­‐A	   expression	   is	   increased.	   	   In	   the	  
hepatocyte	   this	   stimulates	  depolarisation	  and	   increases	  permissivity	   to	  HCV	  entry.	  	  
VEGFR-­‐2	   signalling	   in	   LSEC	   is	   reduced	   (perhaps	   through	   increased	   expression	   of	  
VEGFR-­‐1)	   thus	   permitting	   BMP4	   expression.	   	   BMP4	   stimulation	   of	   hepatocytes	  
increases	  HCV	  replication	  (B).	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The	  role	  of	  BMP4	  in	  the	  pathogenesis	  of	  chronic	  liver	  disease	  
The	  observation	  that	  BMP4	  is	   increased	  in	  the	  liver	  of	  patients	  with	  advanced	  liver	  
disease	  from	  different	  aetiologies	  is	  interesting.	  	  BMP4	  was	  previously	  implicated	  in	  
the	   development	   of	   liver	   fibrosis	   in	   a	   small	   animal	  model	   (Fan	   et	   al.,	   2006).	   	   The	  
authors	   concluded	   that	   autocrine	   BMP4	   activation	   of	   hepatic	   stellate	   cells	   (HSC)	  
stimulated	   the	   development	   of	   liver	   fibrosis.	   	   However,	   my	   findings	   suggest	   that	  
LSEC	  are	  a	   greater	   contributor	   to	   the	  expression	  of	  BMP4	   than	  HSC.	   	   Indeed	   LSEC	  
expression	  of	  BMP4	  was	  >20	  fold	  that	  in	  activated	  liver	  myofibroblasts	  (aLMF)	  that	  
are	  representative	  of	  the	  activated	  HSC	   in	  the	  diseased	   liver.	   	  The	  findings	  suggest	  
that	  a	  failure	  of	  VEGF-­‐A	  signalling	  in	  the	  endothelium	  will	  drive	  expression	  of	  BMP4	  
and	   this	   in	   turn	   will	   activate	   HSC	   and	   promote	   liver	   fibrosis.	   	   A	   similar	   paracrine	  
circuit	   involving	   VEGF-­‐A	   has	   been	   described	   where	   VEGF	   stimulated	   nitric	   oxide	  
maintains	  HSC	  in	  a	  quiescent	  phenotype	  (Deleve	  et	  al.,	  2008).	  	  Interruptions	  to	  this	  
circuit	  were	  shown	  to	  accelerate	  HSC	  activation	  in	  vitro.	  Thus	  the	  paracrine	  signalling	  
system	   described	   between	   hepatocytes	   and	   endothelial	   cells	   likely	   has	   further	  
effects	  on	  additional	  cell	  types	  in	  the	  liver	  including	  HSC	  that,	  when	  perturbed,	  will	  
accelerate	  liver	  fibrosis.	  
	  
BMP4	  has	  been	  implicated	  in	  the	  development	  and	  progression	  of	  multiple	  cancers,	  
including	  HCC	  (Quante	  et	  al.,	  2011,	  McLean	  et	  al.,	  2011,	  Chiu	  et	  al.,	  2012).	  	  HCC	  is	  a	  
major	  cause	  of	  mortality	  in	  patients	  with	  cirrhosis,	  particularly	  in	  patients	  with	  HCV	  
infection	   (El-­‐Serag,	   2011).	   	   Strategies	   to	   prevent	   the	   development	   of	   HCC	   in	   the	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injured	  liver	  remain	  one	  of	  the	  greatest	  unmet	  needs	  for	  patients	  with	  liver	  disease.	  	  
Endothelial	   cells	   can	  maintain	   stem	   cell	   phenotype	   in	   the	   liver	   (Ding	   et	   al.,	   2010),	  
and	  in	  other	  organs	  by	  expressing	  so-­‐called	  “angiocrine”	  factors	  (Butler	  et	  al.,	  2010,	  
Ding	  et	  al.,	  2010,	  Ding	  et	  al.,	  2011)	  that	  include	  BMP4	  (Mathieu	  et	  al.,	  2008).	  	  These	  
signals	  are	  implicated	  in	  the	  proliferation	  of	  epithelial	  cells	  after	  injury	  and	  it	  is	  likely	  
that	   such	   factors	  are	   involved	   in	   tumorigenesis	   (Butler	  et	  al.,	   2010).	   	  Angiogenesis	  
plays	  a	  critical	  role	  in	  providing	  oxygenated	  blood	  for	  tumour	  growth	  (Carmeliet	  and	  
Jain,	  2011).	  Interestingly,	  exogenous	  administration	  of	  BMP4	  has	  been	  suggested	  as	  
a	  therapeutic	  option	  for	  several	  malignancies	  notably	  glioblastoma	  (Piccirillo	  et	  al.,	  
2006)	   and	   colon	   cancer	   (Lombardo	   et	   al.,	   2011).	   	   This	   option	   has	   recently	   been	  
investigated	   in	  HCC	   (Zhang	  et	  al.,	  2012).	   Interestingly,	  whilst	  high	  concentration	  of	  
exogenous	   BMP4	   suppressed	   tumour	   growth,	   endogenous	   BMP4	   maintained	   the	  
cancer	  stem	  cell	  phenotype.	  This	  evidence,	  and	  my	  findings	  suggest	  that	  endothelial	  
cells	  and	  BMP4	  in	  particular	  may	  have	  a	  key	  role	  in	  driving	  the	  development	  of	  HCC	  
in	  diverse	  forms	  of	  liver	  disease	  including	  HCV	  and	  ALD.	  
	  
VEGF-­‐A	  regulates	  expression	  of	  BMP4	  in	  endothelial	  cells	  
A	  role	   for	  VEGF-­‐A	  to	  regulate	  BMP4	  expression	  has	  not	  previously	  been	   identified.	  	  
This	   is	   a	   potentially	   important	   aspect	   of	   endothelial	   cell	   function	   since	   BMP4	   has	  
multiple,	   and	  pleiotropic	   effects	   in	  different	   tissues	   and	  organs.	   	   In	   the	   adult	   liver	  
BMP4	  is	  likely	  involved	  in	  the	  reparative	  processes	  following	  liver	  injury	  and	  may	  be	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involved	   in	   the	   pathophysiological	   processes	   (i.e.	   fibrosis	   and	   carcinogenesis)	   that	  
often	  accompany	  this	  response.	  	  	  
	  
VEGF-­‐A	   expression	   is	   increased	   in	   chronic	   liver	   disease	   (Fernandez	   et	   al.,	   2009)	  
where	  it	  is	  associated	  with	  the	  inflammatory	  and	  fibrotic	  components	  of	  the	  injury.	  	  
In	  these	  studies	  I	  noted	  an	  increase	  in	  both	  VEGF-­‐A,	  and	  VEGF	  receptor	  expression.	  	  
Stimulation	   of	   VEGFR-­‐2	   is	   characterised	   as	   pro-­‐angiogenic	   (Quinn	   et	   al.,	   1993,	  
Shalaby	   et	   al.,	   1995,	   Olsson	   et	   al.,	   2006),	   whereas	   VEGFR-­‐1	   acts	   to	   control	   the	  
angiogenic	  response	  to	  VEGF-­‐A	  (Fong	  et	  al.,	  1995,	  Hiratsuka	  et	  al.,	  1998,	  Fischer	  et	  
al.,	  2008).	  	  I	  noted	  in	  the	  previous	  chapter	  that	  LSEC	  express	  low	  levels	  of	  VEGFR-­‐1,	  
suggesting	  that	  VEGFR-­‐2	  responses	  were	  critical	  for	  endothelial	   function.	   	   In	  whole	  
liver	   VEGFR-­‐2	   activation	   was	   largely	   unchanged	   despite	   increased	   VEGF-­‐A	   and	  
VEGFR-­‐2	   expression.	   	   These	   changes	   resulted	   in	   an	   overall	   reduction	   in	   VEGFR-­‐2	  
activation	   levels,	   and	   likely	  a	   reduction	   in	  VEGFR-­‐2	  activation	  on	  a	  per	  endothelial	  
cell	  basis.	  	  Reduced	  VEGFR-­‐2	  activation	  was	  associated	  with	  an	  increase	  in	  VEGFR-­‐1	  
expression.	   	   This	   increase	   may	   limit	   the	   activation	   of	   VEGFR-­‐2	   and	   permit	   the	  
expression	   of	   BMP4	   by	   endothelial	   cells	   in	   the	   liver.	   	   Notably	   increased	   VEGFR-­‐1	  
expression	   promotes	   liver	   injury	   in	   a	  murine	  model	   (Mahasreshti	   et	   al.,	   2003).	   	   A	  
relevant	  clinical	  correlate	  of	  this	  is	  the	  pre-­‐eclampsia	  syndrome	  that	  is	  characterised	  
by	  elevated	  soluble	  VEGFR-­‐1	  levels,	  and	  this	  too	  has	  a	  liver	  phenotype	  (Levine	  et	  al.,	  
2004,	   Joshi	   et	   al.,	   2010).	   	   These	   observations	   support	   a	   role	   for	   VEGFR-­‐1	   in	   liver	  




Whilst	  there	  are	  clear	  implications	  of	  increased	  BMP4	  expression	  in	  liver	  disease	  it	  is	  
interesting	   to	   speculate	   on	   the	   role	   of	   this	   signalling	   system	   in	   other	   systems.	  	  
Foremost	   amongst	   those	   with	   similar	   paracrine	   interactions	   is	   the	   kidney.	   	   Here	  
there	  is	  intimate	  cross-­‐talk	  between	  the	  renal	  epithelial	  cell,	  the	  podocyte,	  and	  the	  
glomerular	  endothelial	  cell.	  	  The	  elegant	  work	  from	  the	  Quaggin	  group	  has	  identified	  
the	   consequences	   of	   failed	   VEGFR-­‐2	   signalling	   in	   glomerular	   endothelial	   cells	   for	  
glomerular	   function	  (Eremina	  et	  al.,	  2006,	  Eremina	  et	  al.,	  2008)	  and	  recent	  studies	  
suggest	   that	   conditional	   deletion	   of	   VEGFR-­‐2	   has	   significant	   effects	   on	   sinusoidal	  
endothelial	  biology	  (Sison	  et	  al.,	  2010).	  	  It	  is	  noteworthy	  that	  BMP4	  signalling	  in	  the	  
glomerulus	  has	  also	  been	  recently	  implicated	  in	  glomerular	  disease	  (Tominaga	  et	  al.,	  
2011,	  Kishi	  et	  al.,	  2011)	  and	  understanding	  whether	  BMP4	  is	  regulated	  by	  VEGF-­‐A	  in	  
glomerular	  endothelial	  cells	  would	  permit	  the	  evaluation	  of	  additional	  strategies	  to	  
prevent	  the	  morbidity	  and	  mortality	  from	  these	  prevalent	  diseases.	  
	  
In	  summary	  I	  have	  identified	  a	  role	  for	  BMP4	  in	  the	  HCV	  lifecycle	  that	  may	  represent	  
an	   adaptation	   to	   the	   reparative	   environment	   in	   the	   liver.	   	   Furthermore	   I	   have	  
identified	   a	   critical	   role	   for	   VEGF-­‐A	   in	   regulating	   the	   expression	   of	   BMP4	   by	  
endothelial	   cells	   in	   the	   liver.	   	   This	  paracrine	   signalling	   system	  has	   implications	  not	  
only	   in	  the	  pathogenesis	  of	  HCV	  related	   liver	   injury	  but	   in	   liver	   injury	  of	  all	  causes.	  
For	   this	   reason	   BMP4	   is	   an	   attractive	   therapeutic	   target	   particularly	   since	   it	   is	  
expressed	  at	  only	  very	  low	  levels	  in	  the	  normal	  liver.	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Chapter	  6	   General	  Discussion	  
	  
6.1	   Perspective	  
	  
The	  study	  of	  HCV	  has	  been	  accelerated	  by	  the	  discovery	  of	  first	  the	  replicon	  system,	  
and	  subsequently	  HCVcc	  (Lindenbach	  et	  al.,	  2005,	  Wakita	  et	  al.,	  2005,	  Zhong	  et	  al.,	  
2005).	  	  The	  aim	  of	  these	  systems	  has	  been	  to	  understand	  HCV	  biology	  to	  permit	  the	  
development	   of	   rational	   drug	   therapies	   that	  will	   improve	   the	   outlook	   for	   patients	  
with	  HCV	  infection.	  
	  
Over	  the	   last	  decade	  there	  has	  been	  rapid	  progress	   in	  the	  development	  of	  directly	  
acting	  antiviral	  (DAA)	  agents,	  particularly	  for	  genotype	  1	  HCV	  infection.	  	  Indeed	  the	  
first	   of	   these	   agents	   that	   target	   the	   viral	  NS3	  protease,	   telaprevir	   and	  boceprevir,	  
have	  recently	  been	  licensed	  for	  use	  in	  this	  population	  (Zeuzem	  et	  al.,	  2011,	  Jacobson	  
et	   al.,	   2011,	   Bacon	   et	   al.,	   2011,	   Poordad	   et	   al.,	   2011).	   	   These	   agents	   have	   the	  
potential	   to	   reduce	  mortality	   from	  end-­‐stage	   liver	  disease	   (Rowe	  et	  al.,	  2012),	  but	  
this	   is	   associated	   with	   increased	   rates	   of	   adverse	   effects,	   and	   the	   risk	   of	   viral	  
resistance	  (Rowe	  and	  Mutimer,	  2011,	  Halfon	  and	  Locarnini,	  2011,	  Pawlotsky,	  2011).	  	  
Further	  DAA	   agents	   are	   in	   development	   and	   these	   used	   in	   combination	  will	   likely	  
reduce	  the	  frequency	  of	  adverse	  effects	  and	  increase	  the	  chance	  of	  viral	  eradication	  




Many	   patients	   however	   have	   longstanding	   HCV	   infection	   leading	   to	   the	  
development	  of	  significant	  fibrosis,	  and	  often	  cirrhosis,	   in	  the	  liver.	   	  These	  patients	  
are	   at	   risk	   of	   complications	   of	   that	   scarring,	   including	   the	   development	   of	   portal	  
hypertension,	   liver	   failure,	   and	   the	   development	   of	   primary	   liver	   cancer	   (HCC).	  	  
Whilst	   the	   probability	   of	   these	   events	   occurring	   after	   successful	   treatment	   in	  
patients	  with	   cirrhosis	   is	   reduced,	   it	   is	   not	   zero	   (Singal	   et	   al.,	   2010b,	   Singal	   et	   al.,	  
2010a).	   	   Thus	   there	   remains	   a	   significant	   unmet	   need	   for	   patients	  with	  HCV	  even	  
after	  viral	  eradication.	  
	  
Identification	  of	  host	  pathways	  that	  are	  implicated	  in	  the	  progression	  of	  liver	  fibrosis	  
during	   liver	   injury,	  and	   in	   the	  development	  of	  HCC	   is	  paramount	   to	   try	   to	  address	  
this	  need	  and	  improve	  outcomes	  for	  these	  patients.	  	  Following	  viral	  eradication	  it	  is	  
likely	  that	  similar	  pathways	  that	  drive	  hepatocellular	  carcinogenesis	  will	  be	  active	  in	  
both	   patients	   previously	   infected	   with	   HCV,	   and	   those	   with	   other	   liver	   diseases.	  	  
Therefore	   identification	   of	   such	   pathways	   may	   have	   benefits	   to	   all	   patients	   with	  
advanced	  liver	  disease.	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6.2	   LSEC	  are	  protective	  HCV	  infection	  
	  
Hitherto	   the	   literature	   supports	   a	   role	   for	   LSEC	   in	   the	   capture	   and	   probable	  
transcytosis	   of	   infectious	   virus	   particles	   to	   permissive	   hepatocytes	   (Protzer	   et	   al.,	  
2012).	   	  However	   the	  data	  presented	  here	   suggest	   that	   LSEC	  are	  protective	   in	  HCV	  
infection	   rather	   than	   acting	   to	   potentiate	   HCV	   as	   had	   been	   previously	   suggested.	  	  
Recent	   data	   from	   a	   mouse	   model	   of	   adenoviral	   infection	   indicates	   that	   LSEC	   are	  
responsible	   for	   scavenging	   the	   vast	   majority	   of	   circulating	   virions	   rapidly	   after	  
inoculation	  (Ganesan	  et	  al.,	  2011).	  	  The	  in	  vivo	  studies	  of	  HCV	  kinetics	  at	  the	  time	  of	  
liver	   transplantation	   support	   these	   conclusions	   and	   although	   the	   fate	   of	   these	  
scavenged	  particles	  is	  not	  clear	  the	  in	  vitro	  data	  suggest	  that	  trans-­‐infection	  is	  a	  rare	  
event	  in	  HCV	  infection.	  	  Thus	  the	  majority	  of	  particles	  bound	  by	  LSEC	  as	  they	  enter	  
the	  liver	  are	  likely	  processed	  for	  destruction	  (or	  antigen	  presentation)	  depleting	  the	  
plasma	  pool	  of	  circulating	  virus	  and	  protecting	  underlying	  hepatocytes.	  
	  
Recently	   available	   mathematical	   models	   of	   steady	   state	   viral	   kinetics	   supports	   a	  
model	   where	   infected	   hepatocytes	   are	   long-­‐lived,	   and	   new	   infection	   events	   are	  
relatively	   rare	   (Ribeiro	   et	   al.,	   2012,	   Dahari	   et	   al.,	   2005).	   	   Since	   the	   number	   of	  
particles	   produced	   per	   day,	   and	   the	   number	   of	   hepatocytes	   in	   the	   liver	   is	  
comparable	   (approximately	   1011)	   (Neumann	   et	   al.,	   1998,	   Dahari	   et	   al.,	   2005)	   and	  
survival	   of	   infected	   and	   non-­‐infected	   hepatocytes	   is	   in	   the	   region	   of	   months	   the	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majority	  of	  HCV	  particles	  are	  either	  non-­‐infectious,	  or	  more	   likely	  destroyed	   in	  the	  
periphery,	  or	  by	  scavenging	  LSEC	  during	  chronic	  infection.	  
	  
The	  function	  in	  HCV	  infection	  of	  non-­‐permissive,	  non-­‐immune,	  cell	  types	  in	  the	  liver	  
is	  a	  neglected	  area	  of	  study.	  	  Hepatocytes	  are	  protected	  to	  a	  large	  extent	  from	  toxic	  
enteric	  products	  in	  portal	  blood	  by	  the	  scavenging	  properties	  of	  LSEC	  and	  the	  finding	  
that	  LSEC	  are	  protective	  in	  HCV	  infection	  should	  not	  therefore	  come	  as	  a	  surprise.	  	  It	  
is	  interesting	  however	  that	  LSEC	  act	  to	  reduce	  hepatocyte	  permissivity	  through	  cell	  
contacts	   when	   these	   have	   been	   previously	   investigated	   for	   other	   indications.	  	  
Studying	  these	  complex	  interactions	  is	  challenging	  however	  it	  would	  be	  informative	  
to	   understand	   the	   changes	   in	   hepatocyte	   phenotype	   that	   are	   mediated	   by	   LSEC	  
during	  HCV	  infection.	  	  Similar	  studies	  have	  been	  done,	  largely	  with	  rat	  heaptocytes,	  
to	   dissect	   the	   mechanisms	   through	   which	   LSEC	   and	   hepatocyte	   phenotypes	   are	  
maintained	  by	  this	  crosstalk	  (Bhatia	  et	  al.,	  1999,	  Khetani	  et	  al.,	  2004,	  Hui	  and	  Bhatia,	  
2007,	   March	   et	   al.,	   2009).	   	   Further	   studies	   employing	   human	   cells	   may	   identify	  
further	  host	  pathways	  implicated	  in	  the	  development	  of	  liver	  injury	  in	  HCV	  infection.	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6.3	   The	  role	  of	  BMP4	  in	  HCV	  infection	  
	  
The	   hepatic	   lobule	   is	   a	   complex	  microenvironment	   and	   the	   role	   of	   (non-­‐immune)	  
cells	   other	   than	   hepatocytes	   in	   HCV	   infection	   has	   been	   well	   studied.	   	   I	   have	  
exploited	   the	   endothelial	   cell	   hepatocyte	   co-­‐culture	   system	   to	   identify	   BMP4	   as	   a	  
novel	  proviral	  factor	  that	  is	  expressed	  in	  the	  liver	  of	  patients	  with	  HCV	  infection.	  
	  
The	  role	  of	  host	  factors	  that	  are	  upregulated	  in	  the	  injured	  liver	  in	  HCV	  infection	  has	  
been	   limited	   to	   immune	   responses.	   	   Targeted	   analyses	   of	   gene	   expression	   in	  
infected	   liver	   have	   identified	   possible	   contributory	   factors	   (Asselah	   et	   al.,	   2005,	  
Asselah	  et	  al.,	  2009)	  but	  it	  may	  be	  difficult	  to	  discern	  the	  true	  effects	  of	  these	  factors	  
in	   the	   cell	   culture	  models	   employed.	   	   Indeed	   these	   reductionist	   systems	  may	   give	  
misleading	  results	  when	  other	  cell	  types	  in	  the	  liver	  are	  considered.	  
	  
A	  prime	  example	  of	   this	   is	  VEGF-­‐A.	   	  We	  have	  previously	   reported	  that	   this	  growth	  
factor	   is	   capable	   of	   inducing	   hepatocyte	   depolarisation	   and	   increasing	   hepatocyte	  
permissivity	  for	  HCV	  entry	  and	  infection.	  	  It	  was	  suggested	  that	  anti-­‐VEGF	  therapies	  
might	   have	   a	   role	   as	   an	   adjunctive	   treatment	   for	   patients	   with	   HCV	   infection	  
(Himmelsbach	   et	   al.,	   2009,	  Mee	   et	   al.,	   2010).	   	   The	  work	   presented	   here	   suggests	  
that	   treatment	   with	   anti-­‐VEGF	   strategies	  may	   in	   fact	   be	   deleterious	   by	   activating	  
BMP4	  expression	  and	   thus	  accelerating	  viral	   replication.	   	   To	   further	   support	   these	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observations	  in	  co-­‐culture	  of	  LSEC	  and	  HepG2	  cells	  we	  noted	  that	  polarised	  HepG2	  
cells	   were	   protected	   from	   VEGF-­‐A	   treatment	   in	   the	   presence	   of	   LSEC	   (IAR	   &	  
Christopher	  Mee,	  unpublished	  observation).	   	   It	   is	   true	   that	   the	  balance	  of	  VEGF-­‐A	  
signalling	   in	   the	   liver	   in	   HCV	   infection	   is	   still	   not	   completely	   understood.	   	   In	   the	  
absence	   of	   a	   faithful	   small	   model	   of	   disease	   where	   normal	   architectural	  
relationships	  are	  maintained	  and	  paracrine	  signalling	   is	   intact	   the	  community	  does	  
not	  have	  the	  tools	  to	  dissect	  this	  further.	  
	  
The	   identification	   of	   BMP4	   as	   a	   proviral	   factor	   in	   HCV	   infection	   is	   intriguing	   and	  
examining	  the	  functions	  of	  BMP4	  in	  the	  developing	  liver	  (Rossi	  et	  al.,	  2001,	  Lemaigre,	  
2009,	  Si-­‐Tayeb	  et	  al.,	  2010)	  suggests	  a	  role	  for	  BMP4	  in	  the	  reparative	  processes	  that	  
are	  established	  after	  infection.	  	  I	  therefore	  speculate	  that	  HCV	  has	  evolved	  to	  exploit	  
BMP4	   signalling	   as	   a	   primer	   for	   replication.	   	   This	   hypothesis	   is	   supported	   by	   the	  
report	  that	  TGFβ	  also	  increases	  HCV	  replication	  (Lin	  et	  al.,	  2008)	  suggesting	  that	  this	  




	   	  
	  	  
186	  
6.4	   A	  role	  for	  BMP4	  in	  liver	  injury	  and	  carcinogenesis	  
	  
As	  a	  member	  of	   the	  TGFβ	  superfamily	  BMP4	  has	  been	  described	  to	  be	   involved	   in	  
liver	  fibrosis	  (Fan	  et	  al.,	  2006,	  Zhong	  et	  al.,	  2009),	  and	  in	  carcinogenesis	  (Chiu	  et	  al.,	  
2012,	  Maegdefrau	  et	  al.,	  2009,	  Maegdefrau	  and	  Bosserhoff,	  2012).	  	  A	  central	  role	  for	  
endothelial	   cell	   regulation	   of	   these	   processes	   has	   been	   proposed	   by	   several	  
investigators	   (Deleve	   et	   al.,	   2008,	   Butler	   et	   al.,	   2010),	   and	   endothelial	   cells	   are	  
critically	  involved	  in	  organ	  regeneration	  (Ding	  et	  al.,	  2011),	  including	  the	  liver	  (Ding	  
et	   al.,	   2010,	   LeCouter	   et	   al.,	   2003).	   	   There	   are	   therefore	   several	   potential	  
implications	  of	  VEGF-­‐A	  regulation	  of	  BMP4	  in	  endothelial	  cells.	  
	  
	  
BMP4	  in	  liver	  fibrosis	  
LSEC	   have	   been	   described	   to	   regulate	   activation	   of	   hepatic	   stellate	   cells	   (HSC)	  
through	  a	  VEGF-­‐A	  and	  nitric	  oxide	  mediated	  mechanism	  (Deleve	  et	  al.,	  2008).	   	  This	  
report	   highlights	   the	   importance	   of	   both	   LSEC	   and	   VEGF-­‐A	   in	   the	  maintenance	   of	  
normal	  liver	  architecture	  and	  also	  in	  the	  response	  to	  liver	  injury.	  	  A	  putative	  role	  of	  
BMP4	  in	  liver	  fibrosis	  has	  been	  suggested	  by	  studies	  in	  small	  animal	  models	  of	  liver	  
fibrosis	  (Fan	  et	  al.,	  2006,	  Zhong	  et	  al.,	  2009).	  	  In	  the	  only	  direct	  evidence	  to	  date	  of	  
the	   involvement	   of	   BMP4	   in	   fibrosis	   an	   autocrine	   activation	   loop	   in	   HSC	   was	  
proposed	   (Fan	   et	   al.,	   2006).	   	   I	   have	   shown	   that	   LSEC	   rather	   than	   cells	   of	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mesenchymal	  origin	  are	  responsible	   for	  the	  majority	  contribution	  to	  hepatic	  BMP4	  
expression	  and	  these	  data	  suggest	  that	  LSEC	  may	  further	  regulate	  HSC	  function	  by	  
suppressing	  profibrotic	  BMP4	  in	  response	  to	  VEGF-­‐A	  stimulation	  in	  the	  normal	  liver.	  	  
Indeed	   I	   detected	   no	   change	   in	   endothelial	   nitric	   oxide	   synthetase	   activation	   by	  
immunoblotting	   for	   phosphorylated	   protein	   in	   diseased	   liver	   (IAR,	   unpublished	  
observation)	   suggesting	   a	   more	   prominent	   role	   for	   BMP4	   in	   endothelial	   cell	  
regulation	  of	  HSC	  phenotype.	  
	  
	  
BMP4	  in	  carcinogenesis	  
A	  role	  for	  BMP4	  in	  the	  development	  of	  HCC	  has	  recently	  been	  proposed	  (Chiu	  et	  al.,	  
2012,	  Maegdefrau	  et	   al.,	   2009,	  Maegdefrau	   and	  Bosserhoff,	   2012).	   	   These	   studies	  
indicate	  that	  BMP4	  is	  overexpressed	  in	  HCC,	  that	  BMP4	  may	  be	  regulated	  by	  hypoxia,	  
and	  that	  BMP4	  will	  both	  stimulate	  hepatocellular	  proliferation	  and	  migration.	   	  The	  
data	   highlighting	   increased	   BMP4	   expression	   in	   advanced	   liver	   disease	   from	   both	  
HCV	   related,	   and	   alcohol	   related	   liver	   injury	   suggest	   a	   novel	   mechanism	   through	  
which	  chronic	  liver	  injury	  is	  associated	  with	  the	  development	  of	  HCC.	  
	  
The	  increasing	  understanding	  of	  carcinogenesis	  supports	  a	  role	  for	  cancer	  stem	  cells	  
in	   the	   initiation	   and	   persistence	   of	   cancer	   (Hanahan	   and	   Weinberg,	   2011).	  	  
Endothelial	   cells	   are	   required	   for	  maintaniance	  of	   the	   stem	   cell	   niche	   in	   the	  bone	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marrow	  (Goldman	  et	  al.,	  2009,	  Hooper	  et	  al.,	  2009)	  and	  the	  endothelial	  cells	  of	  the	  
liver	   exhibit	   similar	   phenotypic	   characteristics	   to	   those	   of	   the	   bone	  marrow.	   	   It	   is	  
therefore	   likely	   that	   LSEC	   have	   similar	   functions	   and	   the	   regulation	   of	   BMP4	   by	  
VEGF-­‐A	  supports	  this	  hypothesis	  (Butler	  et	  al.,	  2010).	  	  BMP4	  has	  been	  described	  as	  
an	  “angiocrine”	  signal	  from	  endothelium	  to	  neural	  stem	  cells	  (Mathieu	  et	  al.,	  2008)	  
and	  dysregulation	  of	  these	  signalling	  systems	  may	  provide	  one	  mechanism	  through	  
which	  cancer	  progression	  may	  be	  accelerated.	  
	  
Another	   intriguing	  possibility	   is	   the	   role	  of	  BMP4	   in	  driving	   tumour	  progression	   in	  
the	   presence	   of	   anti-­‐VEGF	   treatment.	   	   Therapeutic	   targeting	   of	   angiogenesis	   was	  
once	   seen	   as	   a	   “magic	   bullet”	   for	   the	   treatment	   of	   cancer	   but	   results	   have	   been	  
disappointing	  (Bergers	  and	  Hanahan,	  2008).	  	  In	  most	  cases	  there	  is	  a	  brief	  period	  of	  
tumour	  control	  followed	  by	  inevitable	  progression.	  	  Indeed	  in	  HCC	  targeting	  VEGF-­‐A	  
through	  tyrosine	  kinase	  inhibition	  with	  the	  drug	  sorafenib	  only	  prolonged	  survival	  by	  
a	  median	  of	  2-­‐3	  months	  (Llovet	  et	  al.,	  2008,	  Cheng	  et	  al.,	  2009).	  There	  are	  multiple	  
mechanisms	  described	  to	  explain	  these	  findings	  including	  a	  pre-­‐existing	  non-­‐reliance	  
on	   VEGF-­‐A	   signalling,	   and	   tumour	   evasion	   of	   the	   anti-­‐angiogenic	   therapy	   (Bergers	  
and	  Hanahan,	  2008).	  	  Importantly	  in	  small	  animal	  models	  priming	  endothelium	  with	  
anti-­‐VEGF	   treatment	   before	   inoculation	   with	   cancer	   cells	   accelerates	   disease	  
progression	  and	  the	  occurrence	  of	  metastatic	   spread	  highlighting	  a	  critical	   role	   for	  





The	   observation	   that	   VEGF-­‐A	   regulates	   BMP4	   expression	   suggests	   two	   additional	  
mechanisms	   through	   which	   tumour	   progression	   might	   be	   accelerated	   in	   these	  
circumstances.	  	  Firstly,	  BMP4	  has	  been	  described	  to	  accelerate	  tumour	  progression	  
in	   several	  models	  of	   carcinogenesis	   (Butler	  et	   al.,	   2010)	  and	   inhibiting	  VEGF-­‐A	  will	  
promote	   endothelial	   BMP4	   expression.	   	   Secondly,	   BMP4	   has	   been	   described	   to	  
stimulate	   endothelial	   to	   mesenchymal	   transition	   and	   acquisition	   of	   stem	   cell-­‐like	  
phenotype	   (Medici	   et	   al.,	   2010).	   	   Such	  mesenchymal	   cells	   expressing	   BMP4	   have	  
been	  implicated	  in	  the	  progression	  of	  ovarian	  cancer	  (McLean	  et	  al.,	  2011,	  Quante	  et	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6.5	   Conclusions	  
	  
These	  studies	  have	  highlighted	  a	  role	  for	  LSEC	  in	  the	  protection	  of	  the	  liver	  against	  
HCV	  infection	  and	  have	  implicated	  BMP4	  in	  HCV	  replication	  and	  persistence.	  	  Most	  
importantly	   however	   I	   have	   identified	   a	   novel	   paracrine	   signalling	   system	   where	  
hepatocyte	  derived	  VEGF-­‐A	  suppresses	  endothelial	  expression	  of	  BMP4.	  	  This	  system	  
is	  dysregulated	  in	   liver	  disease	  perhaps	  as	  a	  reparative	  response	  to	   liver	   injury	  and	  
this	  aspect	  of	  endothelial	  cell	  biology	  warrants	  further	  study.	  
	  
The	   potentially	   diverse	   roles	   of	   endothelial	   cell	   BMP4	   expression	   in	   the	   liver	  
suggests	   therapeutic	   manipulation	   of	   this	   pathway	   that	   may	   yield	   significant	  
benefits	   arresting	   in	   the	  progression	  of	   liver	  disease	  and	   the	  development	  of	   liver	  
cancer.	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